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ABSTRACT 
 
BURDEN OF ILLNESS AND PHARMACOECONOMIC EVALUATION OF 
LUMACAFTOR/IVACAFTOR IN CYSTIC FIBROSIS 
 
 
 
By 
Pratyusha Vadagam 
December 2017 
 
Thesis supervised by Dr. Khalid M. Kamal 
Objectives: (1) To estimate the burden of illness in cystic fibrosis (CF) using 2010-2014 
Medical Expenditure Panel Survey (MEPS) data, and (2) to conduct a pharmacoeconomic 
evaluation of lumacaftor/ivacaftor in the treatment of CF.  
Methods: The study was conducted in two parts. Part 1 involved a retrospective analysis 
using individuals in MEPS database with an International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis code of 277.00 for a 
principal diagnosis of CF. Dependent variables were cumulative and out-of-pocket 
(OOP) expenditures and independent variables included patient demographics and 
clinical characteristics. Unweighted and weighted estimates of expenditure in CF group, 
and an incremental cost burden in CF group compared to non-CF group was estimated. In 
Part 2, static decision models were developed using MS Excel® to evaluate the cost 
 v 
effectiveness and budget impact of lumacaftor/ivacaftor over a 1-year time frame from a 
payer perspective. Model inputs included drug costs (wholesale acquisition costs from 
2015 Redbook), drug administration/monitoring costs from package inserts, Centers for 
Medicare and Medicaid 2016 Physician Fee Schedule and published literature, 
percentage predicted forced expiratory volume (FEV1% predicted) and pulmonary 
exacerbation values from TRAFFIC and TRANSPORT clinical trials and cost to treat 
pulmonary exacerbations from published literature. The outcomes in the CEA included 
total cost of therapy, average cost effectiveness ratio (ACER) defined as cost per FEV1% 
predicted and incremental cost effectiveness ratio (ICER) defined as difference in the 
ratio of cost per FEV1% predicted of lumacaftor/ivacaftor and placebo. Outcomes in the 
BIA included total budget impact, cost per member per month (PMPM) defined as total 
budget impact per hypothetical plan population, and cost per treated member per month 
(PTMPM) defined as total budget impact per target CF population. All costs were 
adjusted to 2016 dollars and one-way sensitivity analyses were conducted to test the 
model robustness given uncertainty in model inputs and study assumptions 
Results: The average annual cost of CF care in the US between 2010-2014 was 
approximately $44,600, with prescription medications being the highest cost contributor. 
The mean cumulative expenditure in children with CF was $13,990 compared to 
$3,231.27 non-CF group, whereas in adults with CF it was $16,975.80 compared to 
$8,859.87 in non-CF group. The annual cost of therapy per patient due to 
lumacaftor/ivacaftor was $379,780.11 in 2016. The ACER in patients treated by 
lumacaftor/ivacaftor was $151,912.044 while the ICER compared to a placebo was 
$95,016.28 per FEV1% predicted. The annual total budget impact due to inclusion of 
 vi 
lumacaftor/ivacaftor on the health plan formulary was $266,045.59. The PMPM cost was 
$0.022 and the PTMPM cost was $6.2067. 
Conclusion: The systematic assessment of incremental CF costs and its impact on the 
society is essential in increasing the awareness of decision makers to implement 
intervention strategies that are effective in lowering the disease incidence and the overall 
cost of disease management. In CF patients, lumacaftor/ivacaftor has demonstrated better 
clinical effectiveness compared to placebo alongside an increased drug acquisition cost. 
However, the therapy may be a viable alternative to existing standard therapy over a 
short-time horizon. Healthcare payers, both private and public, need to evaluate the cost 
effectiveness and the financial impact when considering expansion of new drug coverage 
in CF management. 
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CHAPTER ONE: BACKGROUND 
 
INTRODUCTION 
Cystic fibrosis (CF) is a chronic, progressive, genetic disease, which primarily affects the 
respiratory, digestive and reproductive organ systems in both children and adults. 1 In CF, 
cells that produce mucus, sweat and digestive juices are impaired, resulting in secretion 
of thick and sticky mucus leading to breathing difficulty or even fatal lung infections over 
time (Refer Figure 1). 2 Sweat and mucus play an important role in regulating the 
temperature and lubrication of respiratory, digestive, reproductive systems, and in 
protecting the organ systems from infection and drying. In the lungs, the abnormally 
thick mucus clogs airways and traps bacteria leading to extensive lung damage and an 
eventual respiratory failure. In the pancreas, mucus prevents the release of digestive 
enzymes that help in the break down food and absorption vital nutrients, obstructing 
digestion process. 3  
Based on the diagnosis criteria, CF can be categorized into classic and non-classic types. 
In classic CF, the patient demonstrates clinical disease in one or more organ systems such 
as the pancreas, upper and lower respiratory tracts, male reproductive tract and has 
elevated sweat chloride levels (≥60 mmol/L). Non-classic CF is usually seen in 2% of the 
patient population and is characterized by normal or intermediate sweat chloride levels. 
In non-classic CF individuals, the diagnosis depends upon DNA analysis which involves 
identification of two copies of a disease-causing mutation in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene on each parental allele or the 
measurement of nasal potential difference (NPD). 4 
 2 
Figure 1: Healthy lung vs. cystic fibrosis affected lung 
 
Source: Mayoclinic.org, 2016  2 
  
 
 
 
 
 
 
 
 
 
 
 
 3 
The NPD test is used to measure the voltage across the nasal epithelium by measuring 
sodium and chloride transport in secretory epithelial cells through assessment of trans-
epithelial bioelectric properties which reflect CFTR function. 5  
 
Cause 
Genes are located on chromosomes within the cell nucleus and provide instructions for 
the cells to make proteins. Every human being has 46 chromosomes, with 23 inherited 
from each parent. Each of the 23 pairs of chromosomes contains a complete set of genes 
and every individual has two sets (one from each parent) of genes for each function. In 
some individuals, the basic building blocks of a gene (called as base pairs) are mutated. A 
mutation can cause the body to make a defective protein or no protein at all, resulting in 
the loss of essential biological functions and eventually resulting in diseases. CF is one 
such disease which is caused due to defects in CFTR gene. 6 
CFTR gene is present on human chromosome 7 and is made up of 25,000 DNA 
nucleotides. As in every human gene, the DNA sequence is transcribed into a messenger 
molecule called mRNA. The CFTR gene has 27 segments called exons that are spliced 
together to make the complete mRNA message. The mRNA message is then translated 
into a chain of amino acids. This amino acid chain folds up into the correct 3-dimensional 
shape to produce CFTR protein. 7 
The CFTR protein functions as a channel across cell membrane that produces various 
secretary fluids and digestive enzymes and transports negatively charged particles called 
chloride ions into and out of cells. The transport of chloride ions helps in controlling the 
movement of water in tissues, necessary to produce thin, freely flowing mucus. Mucus is 
 4 
a slippery substance that lubricates and protects the lining of the airways, digestive 
system, reproductive system and other organs and tissues. The CFTR protein also 
regulates the function of other channels that transport positively charged sodium ions 
across cell membranes. These channels are necessary for the normal functioning of 
organs such as the lungs and pancreas. 8 
The mutations in CFTR gene affect the composition of mucous layer lining the epithelial 
cells in the lungs and pancreas. The disruption of ion transport affects the amount of 
water and texture of mucus in cell linings of lungs (Refer Figure 2). 
There are more than 1700 mutations that are known to affect CFTR gene and can be 
classified based on their effect on the CFTR protein (Refer Table 1). Some conditions 
caused by two CFTR mutations might lead to only mild lung disease with or without 
affecting the pancreas. These conditions can be described as atypical or non-classic CF. 
Other disease conditions which do not meet the usual diagnostic criteria for classical CF 
are referred to as CF-related disease. For example, congenital bilateral absence of the vas 
deferens can cause sterility in males. 8 The most common CFTR mutation is a deletion of 
three DNA nucleotides, which leads to the deletion of an amino acid (phenylalanine) at 
position 508 of the protein sequence. This is denoted as phe508del mutation (F508), and 
is found in around 90% of patients with CF. 
Classes I, II and III mutations, presented in Table 1, generally lead to complete loss of 
function and cause more severe disease. Classes IV and V cause reduction in function 
and have a milder effect.   
 
 
 5 
Figure 2: Normal lung vs. cystic fibrosis lung airways 
Source: Genetics and nutrition  7 
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Table 1:  Classification of cystic fibrosis transmembrane conductance regulator 
gene mutations 
 
Source: Genetics and nutrition  7 
 
 
 
 
  
 
 
 
 
 
 
 
Class Effect on CFTR protein Example of mutation 
I Shortened protein W1282X. Instead of inserting the amino acid 
tryptophan (W), the protein sequence is 
prematurely stopped (indicated by an X). 
II Protein fails to reach cell 
membrane 
ΔF508. A phenylalanine amino acid (F) is deleted 
III Channel cannot be 
regulated properly 
G551D. A “missense” mutation: instead of a 
glycine amino acid (G), aspartate (D) is added 
IV Reduced chloride 
conductance 
R117H. Missense 
V Reduced due to incorrect 
splicing of gene 
3120+1G>A. Splice-site mutation in gene intron 16 
 7 
The most common CFTR mutation identified was F508del mutation occurring in 
approximately 87% of CF patients reported in 2015 CF Patient Registry Annual Report. 
Of the 87%, homozygous F508del mutation accounted for about 46%. The other 
commonly occurring mutations were G542X mutation (4.6%) and G551D mutation 
(4.4%). All the other mutations account to less than 4%.  
 
Disease inheritance  
CF is an autosomal recessive disorder where children inherit altered genes from one or 
both parents. In CF, each parent carries one abnormal and one normal CF gene but they 
do not show any evidence of the disease because the normal CF gene dominates the 
abnormal CF gene. 1 The disease can be inherited in two ways: 
 i) If two copies of the defective CF gene are inherited (one copy from each parent) they 
are called CF patients. For this, both parents must have at least one copy of the defective 
gene.  
ii) People who inherit only one copy of the defective CF gene are called carriers and they 
do not have the disease. Each time two CF carriers have a child, the chances are: 
 25 percent (1 in 4) the child will have CF 
 50 percent (1 in 2) the child will be a carrier but will not have CF 
 25 percent (1 in 4) the child will not be a carrier and will not have CF (Refer 
Figure 3). 
Most genetic tests only screen for the commonly occurring CF mutations. Hence, the 
tests may sometimes falsely indicate a person as not being a carrier while they are 
carriers for the disease 6 
 8 
Figure 3:  Inheritance of cystic fibrosis 
 
 
 
Source: National Institutes of Health  6  
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Disease progression 
The disease begins with reduced CFTR protein activity at the epithelial cell surface. This 
then leads to a cascade of altered lung physiology including altered inflammatory 
response leading to cell inflammation, obstruction, infection of lungs and airway surface 
liquid (ASL) depletion, leading to defective mucociliary clearance. All these events 
enhance disease progression and eventually lead to death. 9, 10 
 
Risk factors for disease progression 
The only risk factor for getting CF is having parents with abnormal CF genes who pass 
the altered genes to their children. However, beyond genetic control, there are many 
factors that influence the severity of the disease and yet, there is still no clear evidence 
for understanding the influence of genetic and environmental factors on disease 
outcomes.  11 
People with CF need to consume a very large number of calories to maintain weight and 
growth which can be difficult to achieve. Physical activity also helps in keeping lungs 
healthy. People with CF should not smoke or be exposed to second hand smoke, as it will 
worsen lung disease. They should also be careful with alcohol intake and it should be 
completely avoided in case of liver disease. CF also worsens with age. CF patients 
usually experience a small decline in lung function each year. Table 2 shows examples of 
how different pairs of mutations in the CFTR gene affect clinical outcomes.   
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Table 2: Some possible cystic fibrosis transmembrane conductance regulator allele 
genotypes and disease severity 
 
Genotype 
(Combination of 
CFTR alleles) 
Description Possible symptoms (these can vary 
depending on modifier genes and 
environmental factors) 
Wild-type / Wild-type homozygote Unaffected 
 ∆508F / ∆508F homozygote Severe lung disease, pancreatic insufficient 
R117H / R117H homozygote Congenital bilateral absence of the vas 
deferens, No lung or pancreas disease. 
WT / ∆508F heterozygote Unaffected 
WT / 3120+1 G>A heterozygote Unaffected 
∆508F / W1204X compound 
heterozygote 
No lung disease, pancreatic insufficient 
R553X and W1316X compound 
heterozygote 
Mild lung disease, pancreatic insufficient 
591∆18 / E831X compound 
heterozygote 
No lung or pancreas disease, nasal polyps 
 
Source: Genetics and nutrition  7 
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Other risk factors associated with an increased risk of future lung disease progression for 
all age groups include young age, high lung function, female sex, certain CFTR 
genotypes and modifier genes, pancreatic insufficiency, poor nutritional status, lower 
socioeconomic status, respiratory viral infections, infection with Pseudomonas 
aeruginosa or Burkholderia cepacia and diabetes mellitus. Low weight-for-age and 
height-for-age percentiles, presence of crackles, Pseudomonas infection, daily sputum, 
cough and clubbing at age 3 were associated with lower FEV1 values at 6 years of age. 
12 
 
Severity 
Beyond genetic control, all CF patients have individual disease courses of severity and 
symptomology. Severity of pathophysiologic consequences associated with CF is 
influenced by the extent to which CFTR activity is reduced. Individuals carrying a single 
CFTR mutation (CF carriers) have reduced CFTR protein activity on cell surfaces 
(~85%) but are unaffected. People with CF (those carrying two mutant CFTR alleles) 
with one mutation retaining residual (but reduced) CFTR function have less aggressive 
disease phenotypes and better overall survival than those who carry two CFTR mutations 
resulting in little or no CFTR activity. 9   
 
Assessing severity of disease 
Forced expiratory volume in 1 sec (FEV1) and the fraction of FEV1 present in a CF 
patient compared to a reference population (FEV1% predicted or percent predicted FEV1) 
can be used to assess CF lung disease progression and survival. 11 The FEV1 is defined as 
 12 
the volume of air forcefully exhaled in 1 second. FEV1% predicted is defined as FEV1% 
of the patient divided by the average FEV1% in the population for individuals of similar 
age, sex and body composition. 13 The progression of lung disease in CF patients can be 
described by plotting their FEV1% predicted throughout their lifetime but it may not be 
reliable for children under 6 years of age because FEV1% predicted is not reliably 
collected before age 6. 12 As lung disease progresses with age, FEV1% predicted 
decreases. 14,15 
 
Stages of CF disease 
Severity of illness is assessed by the percentage predicted FEV1 (FEV1% predicted), with 
FEV1% predicted >70%, 40%-69% and <40% categorized as mild, moderate and severe 
CF, respectively. 16 Disease severity can also be influenced by age. Patients with a severe 
lung disease phenotype are at greater risk for mortality at a younger age, whereas those 
with a mild disease phenotype are more likely to survive to older ages. 
 
DIAGNOSIS  
CF diagnosis involves multiple steps. A complete diagnostic evaluation for CF involves a 
newborn screening, sweat chloride test, prenatal test, a genetic or carrier test and a 
clinical evaluation. 17 
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New born screening 
Newborn screening (NBS) is a nationwide program used to identify health conditions 
including CF. It is usually done in the first 2 to 3 days after birth and involves a genetic 
test or a blood test. A blood sample is tested for the levels of immunoreactive trypsinogen 
(IRT) released by pancreas. Higher levels of IRT indicate abnormal functioning of 
pancreas. But, a newborn's IRT levels may also be increased due to premature birth or a 
stressful delivery. Hence, other confirmatory tests like genetic tests which report faulty 
CFTR genes in newborn are warranted. 18 
 
Sweat chloride test 
Sweat chloride test is very important to diagnose CF. It measures the amount of salt in 
sweat with the help of an electrode by producing mild electric current. CF diagnosis is 
confirmed by high levels of salt in sweat. 19 
 
Prenatal test 
Prenatal genetic tests are done on pregnant women to check if the fetus has CF. A sample 
of fluid is collected from the uterus and checked for the CFTR genes. 18 
 
Genetic test/Carrier test 
A genetic or carrier test is conducted by testing a sample of blood or saliva for faulty 
CFTR gene. Genetic testing usually detects faulty CF genes in 9 out of 10 cases. 18 
 
 14 
Clinical evaluation 
Clinical evaluation involves a chest x ray to check for the inflammation or air trap in 
lungs, a sinus x ray to check for signs of sinusitis, sputum culture to check for bacterial 
growth and lung function tests to check for FEV1 levels and lung functioning. 
18 
 
SYMPTOMS  
Symptoms of CF vary with disease severity. Even in the same person symptoms may 
worsen or improve with time where as some people may not show any symptoms until 
adulthood (Refer Figure 4). 
 
Respiratory system signs and symptoms 20 
Thick and sticky mucus associated with CF clogs the tubes that carry air in and out of the 
lungs leading to 
• A persistent cough that produces thick mucus (sputum) 
• Wheezing 
• Breathlessness 
• Exercise intolerance 
• Repeated lung infections 
• Inflamed nasal passages or a stuffy nose 19 
 15 
Figure 4: Symptoms of cystic fibrosis individuals at diagnosis reported in Cystic 
Fibrosis Patient Registry  
 
Source: Cystic Fibrosis Foundation Patient Registry, 2015 21 
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Digestive system signs and symptoms 20 
Mucus can also block tubes that carry digestive enzymes from pancreas to small intestine 
hindering the absorption of nutrients leading to 
• Foul-smelling, greasy stools 
• Poor weight gain and growth 
• Intestinal blockage, particularly in newborns (meconium ileus) 
• Severe constipation 19 
 
Reproductive system signs and symptoms 
Men with CF are infertile as they are born without a vas deferens. Women with CF may 
have issues related to pregnancy because of mucus blocking the cervix. 19 
 
COMPLICATIONS  
Respiratory system complications 19, 20 
• Damaged airways (bronchiectasis)  
• Chronic infections  
• Growths in the nose (nasal polyps) 
• Coughing up blood (hemoptysis) 
• Pneumothorax  
• Respiratory failure 
• Acute exacerbations 
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Digestive system complications 19, 20 
• Nutritional deficiencies  
• Diabetes  
• Blocked bile duct  
• Intestinal obstruction  
• Distal intestinal obstruction syndrome (DIOS) 
 
Other complications 19, 20 
• Thinning of the bones (osteoporosis) 
• Electrolyte imbalances and dehydration 
 
TREATMENT  
As there is no definitive cure for CF, the goals of current therapy focus on delaying 
disease progression, reduction of pulmonary exacerbations, relief of chronic symptoms 
and improving the patient’s quality of life. 22 Aggressive and complex treatments 
including a daily administration time that range from 1 to 2.5 hours, is warranted to 
achieve these goals. 22 CF treatment includes air way clearance techniques, oral and 
inhaled medications, exercise and good nutrition. Airway clearance techniques (ACTs) 
loosen thick, sticky mucus and it can then be cleared from the lungs by coughing or 
huffing. Clearance of airways decrease lung infections and improve lung function. Chest 
physiotherapy involving percussion (clapping) or vibration may also be useful to loosen 
mucus from the walls of airways. 
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Medications 
Medications are prescribed as maintenance therapy to clear lungs and to prevent or fight 
infections in CF treatment. Existing maintenance therapy includes inhaled oral and 
intravenous antibiotics (penicillins, cephalosporins, sulfa drugs, aminoglycosides, 
macrolides, tetracyclines, quinolones, vancomycin, linezolid, imipenem and meropenem, 
aztreonam), mucous thinners (hypertonic saline, dornase alpha), bronchodilators 
(albuterol, salmeterol), corticosteroids (fluticasone, prednisone), nonsteroidal anti-
inflammatory drugs (ibuprofen) and other drugs like enzyme replacement therapy 
(Creon® or Pancreaze®) are also used.  
Currently, the newer CFTR modulators are being used as disease modifying therapies. 
The disease modifying therapies correct the function of the defective protein made by the 
CF gene and they target specific mutations of the CFTR gene.23 There are currently two 
US Food and Drug Administration (FDA) approved CFTR modulators: ivacaftor 
(Kalydeco®) and lumacaftor/ivacaftor (Orkambi®). Ivacaftor acts by facilitating chloride 
ion transport and by potentiating the channel-open probability (or gating) of the G551D-
CFTR protein. 24 The F508del mutation of CFTR results in protein misfolding and causes 
a defect in cellular processing and trafficking, thereby reducing the quantity of CFTR at 
the cell surface. Lumacaftor acts by improving the conformational stability of F508del-
CFTR, resulting in increased processing and trafficking of mature protein to the cell 
surface. 25 Both lumacaftor and ivacaftor act directly on the CFTR protein and are called 
CFTR potentiators. (Refer Table 3)
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Table 3: Cystic fibrosis transmembrane conductance regulator modulator therapies, ivacaftor and lumacaftor/ivacaftor  
 
Drug Category Initial US 
approval 
Indication Dose Annual cost 
(WAC) 
Ivacaftor* CFTR potentiator 2012 For patients age 
6 years and older 
who have 
G551D mutation 
in CFTR gene 
One 150 mg tablet Q12 
hours PO with fat-containing 
food 
$311,501.42 
 
Lumacaftor/ivacaftor# CFTR potentiator 2015 For patients age 
6 years and older 
who are 
homozygous for 
the F508del 
mutation in the 
CFTR gene 
Age 12 years and older: two 
tablets (each containing 
lumacaftor 200 mg/ivacaftor 
125 mg) Q12 hours PO12 
hours PO 
$259,588.80 
For patients age 6 years 
through 11 years: Two 
tablets (each containing 
lumacaftor 100 mg/ivacaftor 
125 mg) Q12 hours PO12 
hours PO 
 
Source: Kalydeco Tablets Label-FDA 2012; Vertex-lumacaftor/ivacaftor package insert 2016; Micromedex solutions 2015# and 2016* 
Red book 24-26, WAC: Whole sale acquisition cost ; Q: every; PO: by mouth 
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EPIDEMIOLOGY  
Prevalence 
According to 2013 CF Foundation Patient Registry Annual Report, more than 30,000 
Americans, 3,000 Canadians, and 20,000 Europeans (more than 70,000 worldwide) are 
living with CF. 1, 3 Although the disease affects all races and ethnic groups, it occurs most 
commonly in Caucasian individuals with Northern European ancestry than in African 
Americans, Native Americans and Asian Americans. In the United States (US), the 
prevalence of CF is as follows: 
 Caucasians of Northern European origin: 1 case per 3,200-3,500 population 
 Hispanics: 1 case per 9,200-9,500 population 
 African Americans: 1 case per 15,000-17,000 population 
 Asian Americans: 1 case per 31,000 population. 27  
About 1 in every 20 Americans is an unaffected carrier of an abnormal CF gene. This 
accounts to around 12 million CF carriers who are unaware of it. 1 According to 2015 CF 
Foundation Patient Registry Annual Report, more than half of the CF population was 18 
years or older (Refer Figure 5). 21 CF prevalence was estimated at 28,983 cases in the 
2015 Patient Registry Report. 
Although there are more than 1,700 known mutations causing CF, only 
242 CFTR mutations have been confirmed so far. 28 The prevalence of the gene 
mutations varies with geographic location and are presented in Table 4. Most common 
mutations were taken from the CF patient registries from different regions and mutations 
occurring in more than one percent of patients were included for all regions except 
Canada, as it listed only the five most common mutations, all of which occur on one or  
 21 
Figure 5: Age distribution and prevalence of cystic fibrosis in 2015 
 
 
 
Source: Cystic Fibrosis Foundation Patient Registry, 2015 21 
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Table 4: Most commonly occurring mutations in selected regions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: CFTR sciene.com, 2016 28  
 
 
 
 
 
 
 
 
 
 
 
Mutations United States Canada Europe Australia 
621+1G→T X X 
 
X 
1717-1G→A X 
  
X 
2789+5G→A X 
   
3120+1G→A X 
   
3849+10kbC→T X 
   
A455E 
 
X 
  
F508del X X X X 
G542X X X X X 
G551D X X X X 
N1303K X 
 
X X 
R117H X 
  
X 
R553X X 
   
W1282X X 
 
X 
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both alleles in more than or equal to 2.6 percent of patients. The distribution 
of CFTR mutations also vary based on race of the patients. Table 5 depicts the 
prevalence of CFTR mutations based on ethnicity. 
 
Incidence 
In the US, CF occurs at a rate of 1 in 3,400 births. Approximately 1,000 new cases of CF 
are diagnosed each year and more than 75% individuals are diagnosed by two years of 
age. According to 2015 CF Foundation Patient Registry Annual Report, 853 new cases 
were diagnosed with CF (Refer Figure 6). 21  
 
ECONOMIC BURDEN  
Despite a low prevalence, the costs of illness is substantial and the costs vary widely in 
different countries. In the US, the mean annual total costs of CF medical care in 1996 was 
estimated at $13,300. 29 The costs ranged from $6,200 among patients with mild disease 
to $43,300 among patients with severe disease. Of the total costs, 47% were from 
hospitalization, 18% were from dornase alfa (DNase or Pulmozyme) prescription 
medication, 12% were from clinic visits, and 10% were from outpatient antibiotics. The 
annual national costs of medical care for the entire CF population in the US was 
estimated at $314 million (1996). However, according to CF Foundation, the average 
annual costs of CF care in 1996 was $45,000. 29 A 2006 study reported the average cost 
of care for a person with CF living in the US to be around $48,000 which was 20 times 
higher than someone without CF. 30 
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Table 5: Prevalence of common mutations in cystic fibrosis 
 
Prevalence  Mutations 
1:3500 (United States) F508 del, G542X, G551D, R117H, N1303K 
1:3200 (USA Caucasians) F508 del, G542X, G551D, W1282X 
1:15,000 (African Americans) F508 del, A559T, 3120+1G TO A 
1:10,000 (Latin Americans) F508 del, G542X, 406-1 G TO A, 1811 +1.6 
Kb A TO G 
1:10,500 (Native Americans) F508 del, R1162X, L1093P 
 
Source: CFTR sciene.com, 2016 28 
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Figure 6: Incidence of Cystic Fibrosis from 1991-2015  
 
Source: Cystic Fibrosis Foundation Patient Registry, 2015 21; NBS: New born screening 
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In 2011, the mean annual costs of CF care was about $29,000 per patient, $20,000 for 
prescription medications and $22,102 for inpatient hospital stays. Hospital costs have 
been shown to account for 75% of the total CF-related services costs (excluding 
medications). 31 However, recent study suggested that the annual estimated costs of CF 
care in 2011 were $30,000, $57,000, and $215,000 for patients with mild, moderate, and 
severe disease, respectively. Costs were highest among children with severe disease of 
age group 10-14 years (estimated annual cost of care was $343,900) and decreased in 
adults with mild disease with age increasing up to 45 years (estimated annual cost of care 
was $15,600 for patients aged 40-44 years). 32 
 
PROBLEM STATEMENT 
CF is a rare disease, affecting approximately 0.0089 % of the US population. Even 
though the economic burden due to CF is substantial, there is very little data available to 
understand the different contributors to the economic burden. Very few studies have 
reported burden of illness and CF healthcare resource utilization and majority of those 
studies were done in early 2000’s. 29, 30 CF medications and hospitalizations have been 
shown to account for higher expenditure among total CF care costs. There are no recent 
studies which comprehensively report the economic burden of the disease in terms of 
medical resource utilization such as outpatient visits, emergency visits, office visits, 
home health, prescription medications and hospital inpatient stays over a time frame. 
Hence, burden of illness studies, which provide latest estimates of out-of-pocket (OOP) 
and total economic impact of CF are warranted. These studies not only provide in depth 
estimates of utilization of various medical services, OOP expenditures and cumulative 
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expenditures but also help reflect the economic impact due to CF on the entire US 
population by calculating national weighted estimates. 
With the introduction of novel CFTR modulator therapies into the market, there is a 
paradigm shift in the management of CF. These disease modifying therapies have good 
clinical effectiveness including increase in FEV1% values, improvement in revised cystic 
fibrosis questionnaire (CFQR) scores, improved body mass index (BMI) and reduction in 
pulmonary exacerbation events. These regimens therefore, have the potential to increase 
median life expectancy and delay the occurrence of death. However, the annual cost of 
ivacaftor is estimated to be over $300,000 and lumacaftor/ivacaftor is estimated to be 
around $270,000 as per the dosing regimens. Ivacaftor targets G551D CFTR mutation 
whose prevalence is just around 4% in total CF population whereas lumacaftor/ivacaftor 
targets F508del mutation whose prevalence is nearly around 90% of total CF population 
specifically around 45% with respect to homozygous F508 del mutation. Hence, the 
market as well as coverage for lumacaftor/ivacaftor is more than that for ivacaftor alone 
as a monotherapy. Ivacaftor was initially approved in 2012 and has been shown to be cost 
effective based on published literature 33,  34 whereas, lumacaftor/ivacaftor approved in 
2015 was rejected by Health Technology Assessments like National Institute for Health 
and Care Excellence (NICE) of United Kingdom (UK) and National Centre for 
Pharmacoeconomics (NCPE) of Ireland, stating poor cost effectiveness and significant 
budget impact with an associated opportunity cost. 35, 36 Little is known if 
lumacaftor/ivacaftor is affordable and cost effective in the US healthcare system given 
the lack of published literature supporting its cost effectiveness or affordability in the US. 
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Given its high costs, there is a need to evaluate the overall value of lumacaftor/ivacaftor 
in CF management. 
 
CONCEPTUAL FRAMEWORK 
The study has two parts. The first part of the study involved estimating the economic 
burden on CF patients using a retrospective cross-sectional cohort study stratified into 
two different age groups. This study utilized longitudinal data from 2010-2014 obtained 
from Medical Expenditure Panel Survey (MEPS), which collects data from a sample of 
families drawn from a nationally representative sub sample of households who participate 
in National Health Interview Survey. Patient ID’s with ICD-9-CM diagnosis code of 
277.00 for principal diagnosis of CF (2010-2014) were included in the analyses. Full year 
consolidated files along with appendix and individual medical events including outpatient 
visit, office visit, emergency visit, inpatient stays, home health and prescription 
medication files were analyzed to determine patient demographics, clinical characteristics 
such as comorbidities and resource utilization related to the above-mentioned events in 
different settings. All the analyses were conducted using Statistical Analysis System 9.4 
(SAS Institute; Cary, NC). An a priori significance was set at p ≤0.05 was used for all 
statistical tests. 
The second part of the study involved pharmacoeconomic evaluations including a cost 
effectiveness analysis (CEA) to compare the incremental cost effectiveness ratio of 
lumacaftor/ivacaftor with placebo and a budget impact analysis (BIA) to estimate the 
total budget impact, cost per member per month (PMPM) and cost per treated member 
per month (PTMPM) in comparison to an existing standard therapy for CF.  
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STUDY HYPOTHESES 
 The hypothesis for the first part of the study is that the economic burden of illness due to 
CF is substantial and prescription medications account for the highest expenditure. The 
hypothesis for the second part of the study is that the lumacaftor/ivacaftor has poor cost 
effectiveness and high budget impact based on the rejection of the drug by other Health 
Technology Assessments. 
 
STUDY OBJECTIVES AND RESEARCH QUESTIONS 
The study involved two parts with specific research questions under each part. 
Part 1: Burden of illness in cystic fibrosis 
To estimate the burden of illness of cystic fibrosis using 2010-2014 MEPS data. 
Research questions 
1) To describe the demographics, clinical characteristics and resource utilization of CF 
patients. 
2) To estimate the incremental cost burden of CF group compared to a non-CF group. 
Part 2: Pharmacoeconomic evaluation of lumacaftor/ivacaftor 
To conduct a pharmacoeconomic evaluation of lumacaftor/ivacaftor in the treatment of 
CF. 
Research questions 
1) To conduct cost effectiveness analysis of lumacaftor/ivacaftor to understand the 
overall effectiveness of the drug compared to its costs. 
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2) To conduct a budget impact analysis to understand the potential financial impact of 
introducing a new drug in a health plan. Both analyses were conducted from a payer 
perspective 
 
STUDY SIGNIFICANCE 
As stated earlier, CF poses a significant economic burden on patients and the demand for 
novel CFTR modulator therapies is increasing due to enhanced benefits and improved 
median life expectancy. In the past, very few studies have reported economic burden and 
none of them utilized public databases to comprehensively address a wide range of 
medical events which influence the cost burden on individuals. Lumacaftor/ivacaftor is a 
latest drug approved by US FDA in 2015. Although the drug was rejected by Health 
Technology Agencies of a few countries, little is known about its true cost effectiveness 
value in the US. 
The present study will not only estimate the total cost burden incurred by CF patients due 
to healthcare resource utilization of various medical services but it will compare the 
differences in costs across medical services used by patients. The study also aims to 
estimate the incremental cost burden in CF group compared to a control group. Detailed 
understanding of resource utilization pattern along with common comorbidities reported 
by patients will help healthcare providers to have a better picture of population at risk or 
disease severity groups. Timely management of the disease based on utilization pattern 
can help delay disease progression and improve quality of life in CF patients. 
To our knowledge, the present study is one of the first studies evaluating the cost 
effectiveness of lumacaftor/ivacaftor and the findings are expected to help payers in their 
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decision-making process. If this drug is proved to be cost-effective and if it falls under 
US national threshold, insurance companies should implement programs to ensure patient 
access to these medications as the drug is only covered under Medicare Part D with a 
copay range of $6,014 - $24,057. 37 
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CHAPTER TWO: LITERATURE REVIEW 
 
CF is a chronic, progressive, genetic disease which is difficult to treat. With the 
introduction of novel CFTR modulator therapies, there has been a shift in the 
management of CF resulting in delayed disease progression, increased median life 
expectancy and improved quality of life. A literature review was conducted to provide 
existing evidence to the two major objectives of the study.  
 
PART 1: BURDEN OF ILLNESS IN CYSTIC FIBROSIS  
The newly approved CFTR modulator therapies are very expensive and they have a 
significant economic burden on CF patients. Hence, there is a need to understand the 
economic burden of illness due to CF. The goal was to conduct a systematic literature 
review to estimate the total economic burden of illness, healthcare resource utilization 
costs and to identify gaps in existing literature. 
 
Methods 
Search strategy 
A systematic literature search was conducted in peer-reviewed journals using the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines (Refer Figure 7). 38 The search included all the studies assessing cost of care, 
cost of illness, burden of illness, health resource utilization costs in databases such as 
PubMed and SCOPUS until February 2017. 
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Figure 7: Schematic presentation of methodology used in literature review 
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Records not relevant  
(n=272) 
 
Articles assessed for 
eligibility  
(n=37) 
 
Articles excluded, with 
reasons  
(n=19) 
 
Studies included in 
qualitative synthesis  
(n=18) 
 
Exclusion Criteria 
 
Non-English: 12 
Case report: 1 
Erratum: 1 
User’s guide: 1 
Reviews: 4 
 
 
Duplicate records 
(n=0) 
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Key terms 
Cystic fibrosis, database analysis, retrospective database analysis, secondary database 
analysis, databases analyses, medical expenditure panel survey, MEPS, healthcare cost 
and utilization project, HCUP, patient registry, electronic medical records, EMR, 
pharmacy claims data, insurance claims data, administrative claims data, cost of care, 
burden of illness, resource utilization, cost of healthcare, cost of illness. 
Final search syntax  
 (“Cystic Fibrosis” [mesh] OR “Cystic Fibrosis” [tiab] OR “Cystic Fibrosis” [ot]) AND 
("Database analysis"[tiab] OR "Database analysis"[ot] OR "Database analyses"[tiab] OR 
"Database analyses"[ot] OR “medical expenditure panel survey” [tiab] OR “medical 
expenditure panel survey”[ot] OR “MEPS” [tiab] OR “MEPS” [ot] OR “healthcare cost 
and utilization project” [tiab] OR “healthcare cost and utilization project” [ot] OR 
“HCUP” [tiab] OR  “HCUP” [ot] OR “National inpatient sample”[tiab] OR “National 
inpatient sample”[ot] OR “NIS”[tiab] OR “NIS”[ot] OR “patient registry” [tiab] OR 
“patient registry” [ot] OR “electronic medical records ” [tiab] OR “electronic medical 
records” [ot] OR “EMR” [tiab]  OR “EMR” [ot] OR “pharmacy claims data” [tiab] OR 
“pharmacy claims data” [ot] OR “insurance claims data” [tiab] OR “insurance claims 
data” [ot] OR “administrative claims data” [tiab] OR “administrative claims data” [ot]OR 
“burden of illness” [tiab] OR “burden of illness” [ot] OR “cost of illness” [tiab] OR “cost 
of illness” [ot] OR “cost of care” [tiab] OR “cost of care” [ot] OR “resource utlization” 
[tiab] OR “resource utilization” [ot] OR “cost of healthcare” [tiab] OR “cost of 
healthcare” [ot]) 
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Inclusion/Exclusion criteria 
Journal articles were included if they evaluated burden of illness, cost of care or CF 
healthcare resource utilization costs. Reviews, commentaries, editorials and other reports 
were excluded. Further the search was limited to studies in English language. 
Data extraction 
The following variables were extracted from the identified studies: year in which the 
study was conducted, author, type of setting in which the study was conducted or the 
source of data, patient demographics such as population size, mean age, Gender 
distribution, inclusion/exclusion criteria of study population, factors assessed in the study 
like inpatient stays, hospitalization costs, total medical costs, prescription medication 
costs and important findings from the study. 
 
Results 
Of the 309 articles screened, 272 were identified as not relevant and the remaining 37 
articles were assessed for eligibility based on inclusion/exclusion criteria. Further 19 
articles were excluded and 18 articles were included in the review for qualitative 
synthesis. Of the 18 articles, 9 (50%) were conducted in the US, 8 (44.4%) were 
conducted in Europe and 1 (5.5%) in Australia. The studies utilized a variety of methods 
with 10 (55.5%) studies using retrospective database analysis, 3 (16.6%) studies using 
cross sectional analysis of questionnaires and 5 (27.7%) studies using prospective design 
were conducted in medical care centers. Most commonly used databases were CF Patient 
Registry, administrative, medical claims followed by hospital billing and medical 
records. None of the studies were conducted utilizing publicly available databases like 
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MEPS. Studies assessed the association between costs and health related quality of life 
(HRQoL) in CF, economic burden due to Pseudomonas infection, costs in patients with 
lung impairment, expenditures in privately insured patients and costs in pediatric patients. 
Factors assessed in the studies were patient demographics, costs for office visits, 
hospitalization visits, ER visits, inpatient hospitalizations, prescription medications, total 
medical costs, hospitalization length, and time to next hospitalization, cost of informal 
care, productivity losses, mortality demographics, complications and costs due to 
pulmonary exacerbations.  Though costs due to various medical events like office visits, 
outpatient visits, emergency visits, home health, inpatient stays and prescription 
medications were studied, all of them together were not addressed as a single study. The 
findings from the studies suggested that there is an increase in rate of hospitalizations 
over the years. Prevalence of comorbid conditions like acute kidney injury and chronic 
liver disease have also increased. Patients with prior lung transplantation account for 
more hospitalizations. A study conducted by Kopp et al., assessed the impact of 
geographic location on hospitalization in CF patients and found that the West region was 
associated with risk of longer hospital stays, specifically due to the use of dornase alfa 
drug. 39 Old age and history of bronchopulmonary aspergillosis in the Northeast, use of 
chronic macrolide drugs in the South and Candida albicans infection or Pseudomonas 
aeruginosa in the Midwest were also associated with increased hospitalization length. 
Risk for subsequent hospitalizations was significantly less in the northeast compared to 
other regions. Another study conducted by Wertz et al., evaluated economic impact of 
tobramycin and reported that the total and per member per month costs decreased in 
tobramycin inhalation solution users. 40 In 1996, annual cost of CF-related medical care 
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averaged $13,300 with a range of $6,200 among patients with mild disease to $43,300 
among patients with severe disease. Of total costs, 47% were from hospitalization, 18% 
were from DNase (Pulmozyme), 12% were from clinic visits, and 10% were from 
outpatient antibiotics whereas the national estimate of the annual cost of CF-related 
medical care in the United States was $314 million per year in 1996. 29 A study 
conducted by Ouyang et al., reported annual medical care expenditure for a person with 
CF to be $48,098 in 2006, which was 22 times higher than for a person without CF and 
outpatient medication costs were the highest cost drivers. 30 Analysis of an administrative 
claims data by O'Sullivan et al., reported total annual CF care costs in patients with 
pseudomonas aeruginosa infection to be $29,000 and prescription medication cost to be 
$20,000 in 2006. 31 Another study conducted using claims data from 2005-2008 
estimated the annual per-patient expenditures after a Pseudomonas aeruginosa infection 
to increase to $51,821 from a pre-infection annual per-patient medical expenditure of 
$33,305. 41 Summary of results is presented in Table 6.
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Table 6: Summary of burden of illness in cystic fibrosis 
 
Study year Data source Inclusion 
 
Exclusion criteria 
Patient 
population 
Factors 
evaluated 
Study findings 
Chatterjee K 
et al. 42 2016 
2003-2013, NIS 
data of HCUP  
CF patients with ICD-9-
CM code 277.00 -277.09 
were included 
N= 311,651, mean 
age: 22.3 yrs, age 
≥18 yrs: 63.6%, 
age <18 yrs: 
36.4%, male: 
45.8%, female: 
54.2% 
Inpatient stays, 
co-morbidities 
during 
hospitalizations, 
outcomes and 
discharge 
disposition 
 The annual rate of hospitalizations per 1,000 CF 
patients in the US increased from 994 to 1,072 
from 2003 to 2013 
 In-hospital mortality decreased from 1.9% to 1.2% 
from 2003 to 2013 
 Patients with prior lung transplantation accounted 
for 6.5% of hospitalizations and had a significantly 
higher prevalence of AKI 
Kopp BT et 
al. 39 2016 
2007-2012 CF 
Foundation 
Patient Registry  
Participants with 
information on 
state of residence, new 
births and deaths during 
the study period with at 
least 1 year of data prior 
to death were included 
N = 30,896 Impact of 
geographic 
region on 
recovery from 
hospitalization, 
hospitalization 
length, time to 
next 
hospitalization 
 Post hospitalization lung function and nutritional 
measures were similar among different regions for 
1 year.  
 Dornase alfa use in west region, history of allergic 
bronchopulmonary aspergillosis and adult age in 
the Northeast, chronic macrolide use in the South, 
and infection with Candida albicans and 
Pseudomonas aeruginosa in the Midwest were 
associated with increased hospitalization length.  
 Risk of subsequent hospitalization was low in the 
Northeast compared with other regions.  
 Caucasians in the South had significantly lower 
risk of future hospitalization compared with 
African Americans 
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Wertz DA et 
al. 40 2011 
2004-2009 
administrative 
claims data  
Individuals aged 0-64 
years with at least two 
medical claims for CF 
on different service dates 
in the study period 
between January 1, 2004 
and March 31, 2009 
were included 
N= 832.388 TSI 
users (mean age 
19 years, 48% 
female) and 444 
non-users (mean 
age 30 years, 54% 
female) 
Differences in 
PMPM costs pre-
index to post-
index in 
tobramycin 
solution for 
inhalation users 
and non-users  
 Total and CF-related PMPM costs decreased $959 
(17%) and $113 (3%) respectively after starting 
TSI 
 CF-related inpatient PMPM costs decreased by 
$1,171 (49%; p=0.01), while CF-related 
prescription PMPM costs increased by $992 
(p<0.01) among TSI users  
 CF-related inpatient PMPM costs decreased by 
$381 (38%; p=0.16) for low and $1,425 (50%; 
p=0.21) for medium users and decreased by $1,829 
(51%; p=0.02) for high users 
O’Sullivan 
AK. 31 2011 
2002-2006 
administrative 
claims data  
Patients with at least one 
medical claim of CF 
with pulmonary 
manifestations who were 
at least 6 years of age as 
of February, 2011or 
older as of the year of 
the index 
date with at least 12 
months of continuous 
enrollment following the 
index date were included 
unless there was 
evidence that 
disenrollment was due to 
death 
N= 1,064  Costs for office 
visits, 
hospitalization 
visits, ER visits, 
inpatient 
hospitalizations, 
prescription 
medications, total 
medical costs 
were analyzed 
 80% had at least one CF-related office visit,  
34% had a CF-related hospital stay and 95% 
filled at least one prescription over one year 
 Total annual CF-related healthcare costs averaged 
$29,000 excluding $20,000 for prescription 
medications.  
 In the subgroup analysis, there was a trend 
towards longer lengths of stay and higher 
inpatient costs with fewer numbers of TIS 
prescriptions filled 
Mlčoch T et 
al. 43 2017 
2009-2011 
medical records 
from 39ebul CF 
Registry and 
invoices to 
health insurance 
companies 
 Patients with original 
medical/cost records 
were included 
 
 Children younger than 
4 years of age, without 
cost data, complete 
medical records, died 
after lung 
transplantation and 
N= 242  Medical 
procedures, 
inpatient care, 
cost of drugs and 
devices 
 Mean total healthcare costs were €14,486 per 
patient, majority accounted by medicinal products 
and devices (€10,321).  
 Medical procedures (€2676) and inpatient care 
(€1829) accounted to very small percentage.  
 Patient age and lung disease severity were the most 
important cost drivers 
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died with data 
collection period were 
excluded 
Levy JF et 
al. 44 2016 
1989-2010 
hospital billing 
and medical 
records 
CF children enrolled in 
Wisconsin newborn 
screening trial with 
hospital billing and 
medical records 
available from 1989 to 
2010 were included 
N= 73 children 
with CF 
Treatments, 
hospitalizations, 
and nutritional 
and pulmonary 
outcomes. 
 Average annual total cost of CF care was $24,768  
 Outpatient drug costs (53%) and hospitalizations 
(32%) represented most of costs 
 Drug costs were 48% for pulmonary indications 
and 52% for non-pulmonary 
 Pulmonary drug costs for children taking dornase 
alfa were 54% of their drug costs while 
pulmonary drug costs were only 31% for children 
not taking dornase alfa 
 Significant differences in frequency of inpatient 
stays existed for children with pancreatic 
insufficiency  
Angelis A et 
al. 45 2015 
Questionnaires 
given to 
patients and 
caregivers 
identified from 
CFT Registry 
Non-institutionalized CF 
patients receiving 
outpatient care were 
included 
N= 74 (39 male 
and 35 female), 
mean age: 18.3 
years, 
  
Demographic 
characteristics, 
health resource 
utilization, 
informal care, 
productivity 
losses and 
HRQOL 
In 2012, average annual cost for a CF patient was 
€48,603, with direct healthcare costs amounting to 
42.9%, direct non-healthcare costs accounting to 
44.3% and indirect costs attributable to productivity 
losses accounting to 12.8%.  
Chevreul K 
et al. 46 2015 
Questionnaires 
given to 
patients  
Patients recruited 
on a voluntary basis 
through the CF reference 
center of 
Nantes–Roscoff, the 
French CF Society and 
the patient association 
Adults, N= 82, 
Children, N= 158 
Socio-
demographic 
characteristics, 
healthcare 
consumption and 
presence of a 
carer. 
 The total average annual cost of CF care was 
€29,746 per patient 
 Total costs were higher in adults than in children 
and increased with disease duration 
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Vaincre la 
Mucoviscidose between 
September 2012 and 
May 2013 were included 
Iskrov GG 
et al. 47 2015 
Questionnaires 
given to 
patients or 
caregivers 
CF patients who 
received outpatient care 
with the given 
community were 
included 
Patients: N= 33 
(<18 years: N = 
17), mean age:  16 
years,  
Carers: N= 17, 
mean age: 34 yrs, 
Socio-
demographic 
characteristics, 
health resource 
utilization, 
informal care, 
labor 
productivity 
losses 
 Median annual cost of CF in Bulgaria was € 
24,152 per patient in 2012 
 Median annual costs for children were found to be 
significantly higher than those for adults. 
 Drugs had biggest monetary impact 
Van Gool K 
et al. 48 2013 
2003-2005 
Cystic Fibrosis 
Australian 
Registry data 
De-identified patient 
data from Registry 
N= 2,255 (male: 
52%), mean age: 
15.43 yrs 
Clinical 
measures, 
mortality, 
demographics, 
complications, 
and healthcare 
resource use 
 The mean annual healthcare cost for treating CF 
was US $15,571 in 2013 
 Costs for patients with mild, moderate, and severe 
disease were US $10,151, US $25,647, and US 
$33,691, respectively  
 Lifetime healthcare costs were approximately US 
$306,332 (3.5% discount rate) 
 Most of costs were accounted by hospital inpatients 
(58%), followed by pharmaceuticals (29%), medical 
services (10%), complications (2%), and diagnostic 
tests (1%) 
Colombo C 
et al. 49 2013 
Prospective 
observational 
study in 
Lombardia 
regional 
CFRRC, Milan, 
Italy 
Patients seen during an 
outpatient visit or who 
were hospitalized 
between March and July 
2009 were included 
Children: N= 55 
(male ≤5 yrs: N= 
25), mean age: 3 
yrs  
Adults: N= 106 
(male >5 yrs: N= 
58, mean age: 17 
yrs  
Direct medical 
costs including 
hospitalizations, 
outpatient 
interventions, 
drugs, devices, 
dietetic products 
The mean annual cost of care per patient increased 
with age and lung disease severity from €4,164 in 
children aged ≤5 years to €30,123 in patients aged >5 
years with severe lung disease. 
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Heimeshoff 
M et al. 50 
2012 
Observational 
study at CF 
treatment center 
Patients admitted to an 
inpatient unit at a CF 
treatment center during 
the first 6 months of 
2004 and patients who 
visited the center’s CF 
outpatient unit during 
the entire year were 
included 
N= 266 (inpatient: 
N= 87,  
Outpatient: N= 
125,  
inpatient and 
outpatient: N= 54) 
Resource 
utilization data 
 Mean total cost per patient per year was €41,468 in 
2004 
 Direct medical costs accounted for more than 90% 
of total costs and averaged €38,869 (€3,876 to 
€88,096), whereas direct non-medical costs were 
minimal  
 Indirect costs amounted to €2,491 (6% of total 
costs) 
 Important cost driving factors were outpatient 
pharmacy, disease severity 
Sansgiry SS 
et al. 41 2012 
MarketScan 
claims database 
 Cases continuously 
enrolled in a managed 
care plan for 12 
months before and 
after the index date 
were included 
 
 Individuals with a 
prior PA infection, 
enrolled in capitated 
plans, without 
prescription 
medication coverage 
or not 
continuously enrolled 
with complete medical 
coverage were 
excluded 
N= 358 (female: 
48%), mean age: 
20.1 yrs,  
Healthcare 
utilization, 
medical and 
pharmacy costs 
Average annual cost per patient following initial 
Pseudomonas aeruginosa infection increased by an 
estimated $18,516 of $3,113 was accounted by 
outpatient costs, $10,123 was accounted by inpatient 
costs and $4,943 was accounted by pharmacy costs 
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Dewitt EM 
et al. 51 2012 
RCT, study case 
report forms, 
Medicare 
physician fee 
schedule, the 
NIS and the 
Red Book 
 Participants aged 5 
years or older with a 
confirmed diagnosis 
of CF and mild 
impairment in lung 
function with FEV1% 
predicted of 75% with 
clinical stability for 4 
weeks before 
screening were 
included  
 
 Exclusion criteria 
included abnormal 
renal or liver 
function, history of 
liver or lung 
transplant, 
Burkholderia cepia 
infection, change in 
medications within 28 
days of screening, use 
of inhaled hypertonic 
saline within 2 weeks 
of screening, and use 
of oral corticosteroids 
exceeding 10 mg 
once daily or 20 mg 
every other day 
N= 352, mean 
age: 14.6 yrs 
Medications, 
outpatient, 
emergency visits, 
hospital 
admissions, tests, 
procedures and 
home nursing  
 Mean total costs (excluding denufosol) were 
$39,673 (SD $26,842) in 2007 of which 85% 
were attributable to medications  
 Female sex and P. aeruginosa infection were 
associated with higher costs 
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Ouyang L et 
al. 30 2009 
2004-2006 
insurance 
claims data 
 Subjects enrolled in 
fee for-service 
plans, having a CF 
diagnosis from 
either inpatient or 
outpatient visit claims 
in each year between 
2004-2006 with only 
one year or multiple 
years of data available 
if they had at least one 
CF diagnosis recorded 
in those claims were 
included 
 
 Individuals without 
complete insurance 
coverage for 12 
months in each year, 
enrolled in capitated 
plans, without 
prescription 
medication coverage in 
their insurance plans 
were excluded  
  Medical care 
expenditures, 
including both 
insurance 
reimbursements 
and patient OOP 
expenses 
 The annual medical care expenditure for a person 
with actively managed CF averaged $48,098 in 
2006, which was 22 times higher than for a person 
without CF  
 Outpatient medication costs were the highest cost 
drivers 
Huot L et al. 
52 2008 
Questionnaire 
given to 
patients 
enrolled in a CF 
reference center 
Patients covered by local 
French NHI system in 
2000 and 2003 who 
filled out a questionnaire 
in 2000 and existing 
patients in the NHI 
claims database in 2003 
were included  
 
 
Newborns with the 
illness detected at birth 
in 2003 and patients who 
had a lung transplant 
were excluded 
N= 65 in 2000, 
N= 64 in 2003 
Direct medical 
costs in 2000 and 
2003 
 Average cost of care was €16474/patient/year in 
2000 and €22,725 in 2003 
 Hospital care increased from 15% of the total cost 
in 2000 to 22% in 2003 
 Medications accounted for 45% of the total cost 
for the two periods, with an average cost of 
€7,229/patient/year in 2000 and €10,336 in 2003 
 Home intravenous antibiotic therapy accounted for 
20% of the total cost for the two periods  
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Baumann U 
et al. 53 2003 
Databases of 
hospital 
administration, 
diagnostic 
departments, 
clinical 
database of CF 
unit and patient 
records. 
 Pediatric CF 
population from 
Hanover Medical 
School over a period 
of 1 year regularly 
attending the CF center 
were included  
 
 Population with 
additional diseases 
unrelated to CF or with 
a shared care from 
other CF-centers were 
excluded 
N= 138 (male: 
54%)  
Clinical 
parameters and 
healthcare 
utilization  
 Total annual expenditure per patient amounted to 
€23,989 between 1996-1997 with home drug 
treatment representing the most important single 
cost factor (47% of total costs).  
 Costs increased with age and doubled in the first 
18 years and they correlated with P. aeruginosa 
airway colonization status and FEV1.  
 Costs of patients with chronic P. aeruginosa 
infection were more than three times higher than 
for uninfected patients. 
Lieu TA ey 
al. 29 1999 
Computerized 
cost database 
(medical 
records) and 
CFF annual 
survey 
Those who had 
continuous health plan 
membership with Kaiser 
Permanente Medical 
Care Plan via 
commercial insurance 
during 1996. 
N= 136 (male: 
52%, whites: 
93%), age: 9 
months to 56 yrs 
(mean: 16.6 yrs, 
median: 13 yrs), 
age ≥18 years: 
N=44, all had 
graduated from 
high school or had 
attended college 
and 50% were 
employed 
Demographics, 
severity of 
illness, and other 
clinical 
information  
 Annual cost of medical care in 1996 averaged 
$13,300 ranging from $6,200 among patients with 
mild disease to $43,300 among patients with 
severe disease 
 Of total costs, 47% were from hospitalization, 18% 
were from Dnase (Pulmozyme®), 12% were from 
clinic visits, and 10% were from outpatient 
antibiotics 
 Costs of medical care for the entire population of 
CF patients in the US were estimated to be $314 
million per year in 1996 
 
NIS: National Inpatient Sample; HCUP: HealthCare Cost and Utilization Project; N: sample size; yrs: years; AKI: acute kidney 
injury; TSI/TIS: tobramycin solution for inhalation; PMPM: per member per month; ER: emergency; CFT: cystic fibrosis trust; 
HRQOL: health related quality of life; PA: Pseudomonas aeruginosa; RCT: randomized clinical trial; FEV1% predicted: percent 
predicted FEV1; FEV1: forced expiratory volume in one second; NHI: national health insurance; CFF: Cystic Fibrosis Foundation; 
CFRRC: cystic fibrosis  reference center; OOP: out-of-pocket 
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PART 2: PHARMACOECONOMIC EVALUATIONS IN CYSTIC 
FIBROSIS 
 
High medication acquisition costs associated with novel CFTR modulator therapies have 
warranted the need for cost effectiveness analyses of these drugs. However, it is also 
necessary to understand the economic impact of the disease and the economic evaluations 
of existing drugs in CF treatment to assess the need for novel therapies. The goal was to 
conduct a systematic review of pharmacoeconomic evaluation studies in CF to assess the 
impact of disease on patients and to identify existing literature on costs effectiveness of 
lumacaftor/ivacaftor. 
 
Methods 
Search strategy 
A systematic literature search was conducted in peer-reviewed journals using the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines (Refer Figure 8). 38 The search included all the economic evaluation studies 
assessing cost of illness, cost effectiveness, budget impact, cost utility, cost benefit, 
decision analysis of existing and novel therapies using databases such as PubMed and 
SCOPUS until February 2017. 
Key terms 
Cystic fibrosis, ivacaftor, Kalydeco, lumacaftor/ivacaftor, Orkambi, pharmacoeconomic 
evaluation, pharmacoeconomic analysis, economic evaluation, costs, cost effectiveness 
analysis, CEA, cost of illness COI, cost minimization analysis, CMA, cost benefit  
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Figure 8: Schematic presentation of methodology used in literature review 
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(n=413) 
 
Records not relevant  
(n=352) 
 
Articles assessed for 
eligibility  
(n=61) 
 
Articles excluded, with 
reasons  
(n=47) 
 
Studies included in 
qualitative synthesis  
(n=14) 
 
Exclusion Criteria 
Reviews: 21 
Non-English: 15 
Case studies, RCT: 3 
Other reports, updates, 
monographs, editorials: 8 
 
 
 
 
Duplicate records 
(n=38) 
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analysis, CBA, budget impact analysis BIA, cost utility analysis, CUI, decision analysis, 
decision tree, Markov model, simulations model. 
Final search syntax  
(“Cystic Fibrosis” [mesh] OR “Cystic Fibrosis” [tiab] OR “Cystic Fibrosis” [ot] OR 
“Ivacaftor” [tiab] OR “Ivacaftor” [ot] OR “Kalydeco“ [tiab] OR “Kalydeco” [ot] OR 
“Orkambi” [tiab] OR “Orkambi” [ot] OR “Lumacaftor/Ivacaftor” [tiab] OR “Lumacaftor/ 
Ivacaftor” [ot]) AND (“Economics, Pharmaceutical”[Mesh] OR “pharmaceutical 
economics”[tiab] OR “pharmaceutical economics”[ot] OR “pharmacoeconomics”[tiab] 
OR “pharmacoeconomics”[ot] OR “pharmacoeconomic”[tiab] OR 
“pharmacoeconomic”[ot] OR“Economic evaluation”[tiab] OR “Economic 
evaluation”[ot] OR “costs” [tiab] OR “costs” [ot] OR “Cost effectiveness analysis” [tiab] 
OR “Cost effectiveness analysis” [ot] OR “CEA” [tiab] OR “CEA ” [ot] OR “Cost of 
illness”[tiab] OR “Cost of illness”[ot] OR “COI” [tiab] OR “COI” [ot] OR “Cost 
minimization analysis” [tiab] OR “Cost minimization analysis” [ot] OR “CMA” [tiab] 
OR “CMA” [ot] OR “Cost benefit analysis” [tiab] OR “Cost benefit analysis” [ot] OR 
“CBA” [tiab] OR “CBA” [ot] OR “Budget impact analysis” [tiab] OR “Budget impact 
analysis” [ot] OR “BIA” [tiab] OR “BIA” [ot] OR “Cost utility analysis” [tiab] OR “Cost 
utility analysis” [ot] OR “CUI” [tiab] OR “CUI” [ot] OR “Decision analysis” [tiab] OR 
“Decision analysis” [ot] OR “Decision tree” [tiab] OR “Decision tree” [ot] OR “Markov 
model” [tiab] OR “Markov model” [ot] OR “Simulations model” [tiab] OR “Simulations 
model” [ot]) 
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Inclusion/Exclusion criteria 
Journal articles were included if they evaluated cost of illness or cost effectiveness, 
budget impact, cost utility, cost benefit, decision analysis of therapies used in CF 
treatment. Reviews, commentaries, editorials and other clinical trials reports were 
excluded. Further the search was limited to studies published in English and after January 
1st, 2000. 
Data extraction 
The following variables were extracted from the identified studies: year in which the 
study was conducted, type of economic evaluation, model used, perspective of the study, 
time horizon considered for evaluation, source of data for model inputs, comparators used 
in the evaluation, outcomes of the study, type of sensitivity analysis, year in which costs 
were calculated (price year), discount rate used, results including the ICERs, and 
sponsors of the study, if any. 
 
Results 
Of the total 451 articles identified using the search syntax, 38 duplicate records were 
eliminated and 352 articles were identified to be irrelevant. 61 articles were assessed for 
eligibility based on inclusion/exclusion criteria. 47 articles were excluded with reasons 
and 14 articles were included for qualitative synthesis. Of the 14 articles included, 5 
(35.7%) studies were conducted in the US, 7 (50%) in Europe and 2 (14.2%) in Australia. 
5 studies conducted in the US included 2 (40%) cost effectiveness analyses, 2 (40%) cost 
benefit analyses and 1 (20%) budget impact model. Cost effectiveness analyses and 
budget impact models were conducted from a US third party payer perspective. 
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Medications evaluated for overall costs effectiveness and affordability included ivacaftor, 
inhaled aztreonam lysine and tobramycin inhalation solution whereas cost benefit 
analyses were conducted for diagnostic tests including carrier screening and genetic tests. 
The outcomes assessed in a cost effectiveness analyses included cost per QALY and 
incremental life time costs. Total increase in the budget and per member per month cost 
were the primary outcomes of the budget impact model whereas cost benefit analysis 
assessed net benefit due to screening tests and average annual, lifetime direct medical 
costs per CF patient avoided. All the five economic evaluations used Markov models and 
involved one way, probabilistic sensitivity analysis. All costs were discounted at rate of 
3%. A study conducted by Dilokthornsakul et al., 34 to evaluate the cost effectiveness of 
ivacaftor reported that ivacaftor was associated with 18.25 additional life-years and 15.03 
additional quality-adjusted life-years. Ivacaftor has also been shown to improve 
morbidity and mortality similar to that of non-CF patients. A comparative CEA of 
aztreonam vs. tobramycin reported aztreonam lysine inhalation to be associated with an 
average cost saving of $41,947 per patient over 3 years along with greater quality-
adjusted life-years and total life-years in 2013-2014. 54 A cost benefit analysis suggested 
that the cumulative net saving of a genetic test for all carrier-couples was $33.3 billion in 
2006. 55 
Other studies conducted outside the US included 3 cost effectiveness analyses of dry 
powder antibiotics, ivacaftor and carrier screening, 2 cost of illness studies, 3 cost 
analyses and 1 cost consequence analysis. Most of the studies were sponsored by 
pharmaceutical companies or a health research organization and the inputs for cost 
effectiveness analyses were provided by the manufacturing companies. There was no 
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evidence of a CEA conducted for lumacaftor/ivacaftor in the literature with in the United 
States as well as outside the country although the drug was approved in 2015. The 
economic evaluations included antibiotics, screening techniques and overall cost of 
illness. There was only a single study which was identified to evaluate the cost 
effectiveness of a novel CFTR therapy called ivacaftor. The literature review clearly 
demonstrated the need for establishing the overall cost effectiveness as well as 
affordability of the drug lumacaftor/ivacaftor in the United States as well as outside the 
country. Summary of results presented in Table 7. 
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Table 7: Summary of pharmacoeconomic evaluations in cystic fibrosis 
 
Study 
Year 
Type of 
economic 
evaluation 
 
Model 
Study perspective 
 
Time horizon 
 
Data source 
Treatment 
 
Comparator 
Outcomes Sensitivity 
analysis 
 
Price year 
 
Discount rate 
Findings Sponsor 
Dilokthor
nsakul P 
et al. 33,34 
2016 
 Cost 
effectiveness 
analysis and 
budget 
impact 
model 
 
 Markov 
model 
 US Payer 
 
 Life time  
 
 Published 
literature 
 Ivacaftor plus 
usual care                      
 
 Usual care 
alone 
Cost/QALY, 
incremental 
life time cost, 
PMPM 
budget 
impact 
 One way, 
probabilistic 
sensitivity 
analysis 
 
 2013 
 
 3% 
 Incremental lifetime cost 
was $3,374, 584  
 The budget impact was 
$0.087 PMPM 
 Ivacaftor increased life-
years and QALY’s in CF 
patients with the G551D 
mutation and moved 
morbidity and mortality 
closer to that of non-CF 
population  
None 
Schechter 
MS et al. 
54 2015 
 Cost 
effectiveness 
analysis 
 
 Markov 
model 
 US Payer 
 
 3 years  
 
 Comparator trial 
data including 
clinical outcomes, 
QOL. Costs from 
published 
literature and 
proprietary 
databases. 
 Inhaled 
aztreonam 
lysine 
 
 Inhaled 
tobramycin       
Over all costs 
for two 
treatments, 
QALY, total 
life years 
 Extensive 
scenario and 
probabilistic 
sensitivity 
analysis 
 
 2013-2014 
 
 3% 
Use of aztreonam lysine 
for inhalation was 
associated with an average 
cost saving of $41,947 per 
patient over 3 years as 
well as greater QALY and 
total life-years. 
Abacus 
Internatio
nal, 
Gilead 
Sciences 
  
5
3
 
Whiting 
P et al. 33 
2014 
 Cost 
effectiveness 
analysis 
 
 Markov 
model 
 NHS perspective 
 
 Life time  
 
 Inputs from 
manufacturers 
model with 
modifications 
specific to UK 
 Ivacaftor plus 
standard care  
 
 Standard care  
ICER, cost / 
QALY 
gained. 
 Probabilistic 
sensitivity 
analysis 
 
 2010 
 
 3.5 %  
 The ICER varied between 
£335,000 and £1,274,000 
per QALY gained.  
 The total additional 
lifetime costs for all 
eligible CF patients in 
England ranged from 
£438M to £479M.  
 The lifetime cost for 
standard care alone was 
£72M. 
Vertex 
Pharmac
euticals 
Tappende
n P et al. 
56 2014 
 Cost 
effectiveness 
analysis 
 
 State 
transition 
model  
 NHS and PSS 
 
 1 year 
 
 Patient level and 
aggregate data 
from RCT’s and 
literature. 
Resource use and 
costs associated 
with drug 
acquisition, 
management of 
exacerbations and 
reduced 
53ebulized 
maintenance from 
reference sources 
and expert 
opinion. 
 Colistimethate 
sodium DPI, 
tobramycin 
DPI  
 
 Nebulised 
tobramycin  
ICER, cost / 
QALY 
gained. 
 Simple and 
probabilistic 
sensitivity 
analysis 
 
 2011/2012  
 
 3.5 % 
 Colistimethate sodium 
DPI produced fewer 
QALY’s than nebulized 
tobramycin and the ICER 
was approximately 
£288,600 saved per QALY 
lost.  
 The ICER for tobramycin 
DPI versus nebulized 
tobramycin was £124,000 
per QALY gained.  
NIHR 
HTA 
Heimesh
off M et 
al. 50 
2012 
Cost of 
illness  
 Societal 
perspective 
 
 1 year  
 
 Direct medical 
costs from 
outpatient 
NA Average total 
costs of CF 
per patient 
and per year 
 Monte Carlo 
simulation 
 
 2004 
 
 Not reported 
 Mean total cost per patient 
per year was €41,468 
 Direct medical costs 
accounted for more than 
90% of total costs and 
averaged €38,869 (€3,876 
to €88,096), whereas 
direct non-medical costs 
were minimal 
None 
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pharmacy, direct 
non-medical and 
indirect costs 
collected from 
patients 
 Indirect costs amounted to 
€2,491 (6% of total costs) 
 There was a 90% 
probability that annual 
costs will be lower than 
€37,300 
Norman 
R et al. 57 
2012 
 Cost 
effectiveness 
analysis 
 
 
 Decision tree 
model 
 Healthcare system 
perspective 
 
 Life time 
 
 Australian DRG 
data, screening 
costs from Human 
Genetics 
Society of 
Australia CF 
carrier screening 
position statement, 
lifetime costs of 
management of a 
CF patient 
were estimated 
using Australian 
Registry data of 
CF patients 
 Carrier 
screening  
 
 No screening 
Effectiveness 
was 
expressed in 
terms of CF 
births 
averted, 
incremental 
cost per CF 
birth 
 Univariate 
sensitivity 
analysis  
 
 2010 
 
 5 %  
 Screening reduced the 
annual incidence of CF 
births from 34 to 
14/100,000 births  
 In initial pregnancies, 
costs in the screening arm 
exceeded those in the non-
screening arm  
 Pre-collected information 
reduced the incidence of 
CF in subsequent 
pregnancies at low 
additional costs  
 
Cystic 
Fibrosis 
Australia 
and a 
National 
Health 
and 
Medical 
Research 
Council 
Health 
Services 
Research 
Woodwar
d TC et 
al. 58 
2010 
 Budget 
impact 
analysis 
 
 Population 
based MS 
Excel model 
 US MCO 
perspective 
 
 4 years  
 
 RCT’s, model 
assumptions by 
KOL, CFF Patient 
Registry Annual 
Data, costs from 
published 
 Tobramycin 
inhalation 
solution plus 
standard care  
 
 Standard care 
alone 
Total 
increase in 
budget, 
PMPM 
budget  
 One-way 
sensitivity 
analysis 
 
 2008 
 
 Not reported 
 Assuming an increase in 
TIS use from 20% to 25%, 
the 1-year budget 
increased $231,251 or 
from $0.049 to $0.053 
PMPM 
 The net drug budget 
increase was $243,919  
 Increasing utilization of 
TIS, from 20% to 40% 
over 4 years resulted in an 
Novartis 
Pharmac
euticals 
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literature based on 
Medicare 
reimbursements 
 
incremental overall budget 
increase of $925,002 
Tur-
Kaspa I 
et al. 59 
2010 
 Cost benefit 
analysis 
 
 Markov 
model 
 Perspective of 
RGI 
 
 Life time 
 
 Administrative 
records, specialty 
pharmacy bills 
 PGD test cost 
 
 Average 
annual and 
lifetime direct 
medical costs 
per CF patient 
avoided. 
Cumulated 
net saving of 
an IVF-PGD 
program,  
 Not reported 
 
 2006  
 
 Not reported 
 Net savings of IVF-PGD 
program would be $2.3 
million per patient and a 
$2.2 billion for all new CF 
patients annually in life 
time treatment costs 
 A total of 618,714 
cumulative years of 
patients suffering because 
of CF and thousands of 
abortions could be 
prevented 
Partial 
funding 
by 
Institute 
for 
Human 
Reproduc
tion 
Chicago. 
Maxwell 
S et al. 60 
2010 
 Cost 
consequence 
analysis 
 
 Decision tree 
model 
 Public health 
sector perspective  
 
 Life time 
 
 Probability and 
cost estimates for 
the analysis from 
published 
literature, current 
prenatal screening 
program data, 
specialist clinical 
input and national 
health data. 
 
 Carrier 
screening  
 
 No screening 
Total costs 
for screening, 
net savings 
due to no 
screening 
 One-way 
sensitivity 
analysis 
 
 2008  
 
 3.5%  
 Annual cost to provide a 
prenatal CF carrier-
screening program is 
Au$5.32 million, Au$3.35 
million and $2.93 million 
for one-step, two-step 
simultaneous and two-step 
sequential screening 
respectively 
 No screening model 
provided a net saving over 
a lifetime horizon 
None 
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Davis LB 
et al. 55 
2010 
 Cost benefit 
analysis  
 
 Markov 
model 
 Outpatient 
reproductive 
health practices 
 
 Life time 
 
 
 Data from RCT’S 
case series, case 
control, 
observational 
studies and 
databases 
 PGD for carrier 
couples CF  
 
 Natural 
conception 
(NC) 
 Net benefit 
of giving 
birth to a 
child as the 
present value 
of lifetime 
earnings 
minus 
lifetime 
medical costs 
(Net benefit 
in) 
 One-way 
sensitivity 
analysis 
 
 2007 
 
 3% 
 For women, younger than 
35 years of age, the net 
benefit of PGD over NC 
was $182,000 ($715,000 
vs. $532,000, 
respectively).  
 For women aged 35 – 40 
years, the net benefit of 
PGD over NC was 
$114,000 ($634,000 vs. 
$520,000, respectively).  
 For women, older than 40 
years, the net benefit of 
PGD over NC was 
$148,000 ($302,000 vs. 
$450,000 respectively). 
None 
Huot L et 
al. 52 
2008 
Cost of 
illness 
 Perspective of 
French national 
healthcare 
insurance  
 
 1 year 
 
 Information on 
sociodemographic 
data and CF 
characteristics 
were collected 
from the patients’ 
medical records 
NA Annual total 
costs of CF 
 Not reported 
 
 2003  
 
 Costs were not 
discounted 
 Average annual cost of 
CF was €16,474 per 
patient in 2000, and 
€22,725 in 2003 (based on 
the 2003€ value).  
Vaincre 
la 
Mucovis
cidose 
associati
on and 
the Lilly 
Institute 
funds for 
medico-
economic 
evaluatio
n 
Horvais 
V et al. 61 
2006 
Cost analysis 
of inpatient 
and 
outpatient 
costs 
 Perspective of the 
French healthcare 
system. 
 
 1 year  
 
 Data were 
obtained from 
medical records, 
NA Annual total 
costs of CF 
care 
 Not reported  
 
 2000-2001 
 
 Not reported 
 The total annual cost of 
CF care totaled €16,189 
per patient 
 Outpatient costs accounted 
for 88% of the total cost 
versus 12% for inpatient 
costs 
 Medication costs were the 
highest with 21% of the 
French 
Cystic 
Fibrosis 
Associati
on 
“Vaincre 
la 
Mucovis
cidose” 
and from 
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and questionnaires 
filled out by the 
patients.  
total cost for home 
intravenous antibiotic 
treatments and 49% of the 
total cost for chronic 
medications. 
the 
Program
me 
Hospitali
er de 
Recherch
e 
Clinique 
(PHRC
—Health 
ministry)
. 
Elliott 
RA et al. 
62 2005 
Cost analysis   UK NHS hospital 
trust 
 
 1 year 
 
 Data from clinical 
records 
 Home care  
 
 Hospital care 
Annual cost 
of care  
 Not reported 
 
 2002 
 
 Not reported 
Patients who had >60 % of 
courses at home over 1 
year had a mean cost of 
£13,528, compared with 
22,609 pounds for patients 
who had > 60 % of 
courses in the hospital and 
a mean cost of £19,927 for 
patients who had an equal 
mix of home and hospital 
care 
School of 
Pharmac
y 
and 
Pharmac
eutical 
Sciences, 
Universit
y of 
Manchest
er 
Weijers-
Poppelaar
s FA et 
al. 63 
2005 
Cost analysis  Societal 
perspective 
 
 Life time  
 
 
 Published 
literature 
 Single-entry 
two-step 
(SETS)  
 
 Double-entry 
two-step 
(DETS) 
Net costs of 
carrier 
screening 
techniques 
 Univariate and 
multivariate 
sensitivity 
analysis  
 
 2002 
 
 4% 
SETS screening during GP 
consultations was the least 
expensive (net cost of US 
$1,111,354 per year) 
Netherla
nds 
Organisat
ion for 
Health 
Research 
and 
Develop
ment 
 
QALY: quality adjusted life years; QOL: quality of life; NHS: National Health Service; ICER: incremental cost effectiveness ratio; M: 
million; PSS: personal social services; DPI: dry powder for inhalation; NIHR: National Institute for Health Research; HTA: Health 
Technology Assessment; NA: not applicable; DRG: diagnosis related group; A$: Australian dollar; MCO: managed-care organization; KOL: key 
opinion leaders, CFF: Cystic Fibrosis Foundation; RGI: Reproductive Genetics Institute; IVF: in-vitro fertilization; PGD: pre implantation 
genetic diagnosis; GP: general physician
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CHAPTER THREE: METHODS 
 
The study comprises of two parts. The objective of Part 1 was to estimate the economic burden 
of illness due to healthcare resource utilization in patients with CF. Cumulative and OOP 
expenditures due to various medical events were calculated using 2010-2014 MEPS data. The 
objective of Part 2 was to evaluate the cost effectiveness and budget impact of 
lumacaftor/ivacaftor in the treatment of CF. Economic models were developed using drug costs 
taken from the 2015 Red Book, clinical effectiveness from clinical trials, monitoring and adverse 
event costs from published literature and physician fee schedule. This chapter includes a 
description of data sources and the methodologies for both parts of the study. 
 
PART 1: BURDEN OF ILLNESS IN CYSTIC FIBROSIS 
MEPS is a publicly-available healthcare database which is collected and maintained by the 
Agency for Healthcare Research and Quality (AHRQ).  The national data is a set of large-scale 
surveys of families and individuals, their medical providers (doctors, hospitals, pharmacies) and 
employers. MEPS collects data on specific health services such as frequency of healthcare 
resource use, cost of services, mode of payment (public/private insurance) as well as data on the 
cost, scope and extent of health insurance availability. 64 
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Components of MEPS data 
Two major components of MEPS include the household and the insurance component. In the 
household component (HC), data is collected from a sample of families and individuals drawn 
from a nationally representative subsample of households who participated in the previous year’s 
National Health Interview Survey, which is conducted by the National Center for Health 
Statistics. Information collected in the HC include demographic characteristics, health 
conditions, health status, medical services use, charges and source of payments, health insurance 
coverage, income, and employment.  
The Insurance component (IC) collects data on health insurance plans offered by a sample of 
private and public-sector employers to their employees. It consists of information on number and 
types of private insurance plans offered (if any), premiums, contributions by employers and 
employees, eligibility requirements, benefits associated with these plans and employer 
characteristics.  
MEPS also includes a medical provider component (MPC) which covers hospitals, physicians, 
home healthcare providers and pharmacies identified by HC respondents. This component is 
used to supplement or replace information received from the HC respondents, if needed. 65 
 
Data collection  
MEPS collects data using an overlapping panel design. A new panel of households is selected 
every year and data for each panel is collected for two calendar years in five rounds of interviews 
conducted over two years. This design provides continuous and current estimates of healthcare 
expenditures at both the person and household level for two panels for each calendar years. The 
timing and relationship between panels, rounds, and calendar years are depicted in Figure 9. 65 
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Figure 9: MEPS panel design: Data reference periods 
 
 
 
Source: MEPS, panel design; 66 N: number of persons with positive person weight on the file; 
For example, panels 18 and 19 consist of five rounds of interviews with rounds 3-5 (of panel 18) 
and rounds 1-3 (of panel 19) providing data for 2014. Data for the year 2015 consists of data 
collected from rounds 3-5 (of panel 19) and rounds 1-3 (of panel 20)    
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Household component of MEPS 
Data files in HC include full year and medical events like prescribed medicines, dental visits, 
hospital inpatient stays, emergency room visits, outpatient visits, office-based medical provider 
visits, home health, appendix to MEPS events and other medical expenses files.  
 
Description of HC data files  
Full year consolidated file 
Full year consolidated file consists of demographics, patient identifiers, health status, variables 
related to disability days, access to care, employment, quality of care, patient satisfaction, health 
insurance and use variables, income variables and expenditure variables. 67 
Medical conditions file 
This file provides information on the household-reported medical conditions based on 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9) and 
clinical classification codes. 68 
Prescribed medicines file 
Each record in the prescribed medicines file represents one prescribed medicine purchased or 
obtained by the household respondent during a given calendar year. Each prescription record 
includes an identifier for a unique prescribed medicine, characteristics associated with the event 
(for example, National Drug Code [NDC], medicine name etc.), conditions associated with the 
medicine, the date on which the person first used the medicine, total expenditure and sources of 
payment, types of pharmacies that filled the household’s prescriptions and a full year person-
level weight. 69 
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Hospital inpatient stays file 
Each record in the hospital inpatient stays file represents one inpatient hospital stay reported by a 
household during a given calendar year. The data in the file includes the date of the hospital 
inpatient stay, reason for the stay, types of services received, conditions and procedures 
associated with the hospital inpatient stay, medicines prescribed and imputed expenditure data. 70 
Emergency room visits file 
Each record in the emergency room visits file represents one emergency room visit reported 
during a given calendar year. The data includes the date of the visit, types of care and services 
received, types of medicine prescribed during the visit, condition codes, expenditures and 
sources of payment associated with the visit. 71 
Outpatient visits file 
Each record in the outpatient visits file represents one outpatient visit reported during a given 
calendar year. The data includes the date of visit, whether a doctor was seen, type of care 
received, type of services provided, expenditures and sources of payment. 72 
Office-based medical provider visits file 
Each record in the office-based medical provider visits file represents one office-based medical 
provider visit reported during a given calendar year. As the data includes the date of visit, time 
spent with the provider, types of treatment and services received, types of medicine prescribed, 
condition codes, expenditures and sources of payment associated with the visit. 73 
Home health file 
Each record in the home health file represents one home health event reported during a given 
calendar year. The data includes the type of provider, type of services received, length of visit, 
reason for the visit, expenditures and sources of payment. 74 
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Appendix to event files 
Appendix consists of files which are used to link medical condition file and prescribed medicines 
file with other event files and. 75 
 
Description of study variables  
Dependent variables 
Cumulative and OOP expenditure  
Cumulative expenditure was defined as the sum of direct payment for care provided during the 
year, including OOP and payments by private insurance, Medicaid, Medicare, and other sources. 
Payments for over-the-counter drugs were not collected in MEPS. Indirect payments not related 
to specific medical events such as Medicaid Disproportionate Share and Medicare Direct 
Medical Education subsidies, were also not included. Each year, cumulative and OOP 
expenditure information was captured for different medical events like home health, office visits, 
outpatient visits, emergency visits, inpatient stays and prescription medications. In addition, 
cumulative and OOP expenditures for doctor and for facility were captured separately for 
inpatient stays, outpatient and emergency visits. 
Independent variables 
Age 
 Age was included as a continuous variable and calculated as the difference in years between the 
date of birth and the date of the interview. For the present study, age was categorized into two 
groups- ≥18 years (adults) and <18 years (children), to study the differences in demographics, 
clinical characteristics and expenditures. 
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Gender 
Gender was categorized as male and female. 
Race 
Race was represented as a categorical variable with five categories - White, Black, Hispanic, 
Asian and Other. 
Household income 
Household income was defined as the family’s total income in US dollars and was included as a 
continuous variable. 
Marital status 
Respondents reported their current marital status during the interview. The original variable 
consisted of six categories - married, widowed, divorced, separated, never married and under 16 
years, which was collapsed into three categories for the study - married, not married and under 
16 years. The ‘not married’ category comprised of never married, widowed, divorced and 
separated. 
Insurance coverage 
The insurance coverage variable had three different categories - private (insurance provided 
through employment, TRICARE), public (Medicaid, Medicare) and uninsured.  
Comorbidities 
MEPS captured information about comorbid conditions such as high blood pressure, coronary 
heart disease, angina, heart attack, stroke, other heart diseases, emphysema, high cholesterol, 
cancer, diabetes, arthritis, asthma among adults (age ≥18 years) whereas in children (age <18 
years) the only comorbid condition captured was asthma. 
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Sample selection 
Selection of cases 
From the medical conditions file, individuals with CF were identified using the ICD-9-CM code 
277.00. Because MEPS uses a panel survey design where an individual could be interviewed for 
five rounds over two calendar years, it was possible that an individual might have appeared in 
the sample more than once. Thus, unique records which reported using at least one CF-related 
medical service were identified, creating the final sample utilized for all the study analyses.  
As per the 2015 CF Foundation Patient Registry Report, the prevalence of CF was different in 
adults and children. 21 Previous studies have reported higher annual CF care costs in children 
than in adults. In addition, differences exist in the number of comorbidities in children and adults 
with CF, which may have further impacted the costs and resource utilization in CF care. 31 
Hence, cases were stratified into children (age <18 years) and adults (age ≥ 18 years) (Refer 
Figure 10). 
Selection of controls 
From the medical conditions file, those patients without an ICD-9-CM code listed for 277.0 were 
identified as a control group and stratified into children (age <18 years) and adults (age ≥18 
years) (Refer Figure 11). 
 
Data Analysis 
Demographics and clinical characteristics in cases and controls 
Descriptive analyses were conducted to describe the demographics and clinical characteristics in 
cases and controls followed by an independent sample t-test or a chi-square test depending on the 
type of variable to compare significant mean differences between both the groups. 
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Figure 10: Criteria for selection of cases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records in medical conditions file of MEPS data with ICD-9-CM code 277.0  
(N=179) 
Number of unique records reported 
without any usage of medical service 
(N=21) 
Number of unique records which reported 
usage of at least a single medical service 
(N=109) 
Adults 
(N=78) 
Children 
(N=31) 
Number of unique records 
(N=130) 
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Figure 11: Criteria for selection of controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records in medical conditions file of MEPS data with ICD-9-CM code not 
equal to 277.00 
(N=570,150) 
Adults 
(N=476,181) 
Children 
(N=93,969) 
Unique adults 
(N=60,871) 
Unique children 
(N=24,650) 
Unique records 
(N=85,521) 
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Resource utilization in cases 
Resource utilization among cases was assessed by calculating expenditure for various medical 
events like office visits, home health, prescription medications, inpatient stays, outpatient visits 
and emergency visits from 2010 to 2014. Weighted and unweighted OOP and cumulative mean 
and total direct payments for care provided during the year for all the observations of a medical 
event were calculated. OOP expenditure was defined as the expenditure paid directly by an 
individual. Cumulative expenditure was defined as expenditure paid by an individual and 
payments by private insurance, Medicare, Medicaid and other sources. For office visits, home 
health and prescription medications, cost of care was reported as OOP and cumulative 
expenditure whereas for other medical events, OOP and cumulative expenditures were further 
classified into payment for facility and payment for doctor. For each of the five years, medical 
conditions file was linked with appendix file using unique condition ID. The resulting file was 
then merged with each event file using unique a medical event ID. Six such files were created for 
six types of medical events. Each file was later merged with a full year consolidated file using a 
unique person ID. The resulting files represented those observations which had ICD-9-CM code 
of 277.0 and records related to a medical event. The observations extracted from 2010-2014 are 
presented in Table 8. 
For every record, a total cumulative expenditure variable was created for every medical event, by 
adding up the expenditure on every occasion of the associated medical event. Similarly, a total 
OOP expenditure variable was created by adding the OOP expenditure incurred on every 
instance of a medical event. A person-level weight was used to compute national estimates of 
expenditures. 
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Table 8: Number of observations in each medical event file from 2010-2014 
 
Event  Observations Total Unique 
observations 
 2010 2011 2012 2013 2014 2010-2014 
Home health  7 0 0 2 7 16 4 
Inpatient stays  1 2 3 5 5 16 11 
Office-based 
medical office visits  
34 37 93 66 53 283 85 
Outpatient visits  4 30 47 9 3 93 22 
Emergency room 
visits  
0 3 2 3 7 15 12 
Prescription 
medications  
57 67 182 129 119 554 62 
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Resource utilization in controls 
For each of the five years, medical conditions file was linked with full year consolidated file 
using unique person ID (DUPERSID). The resulting files represented those observations that did 
not have CF (patients without an ICD-9-CM code for 277.00) and records related to a medical 
event. Similar to cases, total expenditure variable was created for each unique individual in the 
control sample. 
Incremental cost burden in cases over controls 
The incremental cost approach estimates the excess expenditures associated with the disease and 
is the difference in expenditures between the cases and the controls. 76-82  The incremental 
expenditure methodology captures expenditures solely attributable to a disease, as it adjusts for 
differences in variables considered to have an impact on expenditures. 77, 83 Multivariate 
modeling is difficult to use for healthcare expenditure data because of its peculiar distribution 
which includes restricted range (non-negative observations), excessive zero values and skewness. 
84 It is challenging to select an appropriate multivariate model specification to assess the 
incremental expenditure associated with a disease. Generalized linear model (GLM) is now 
considered efficient to model expenditure data. 85 Based on published literature, GLM with log 
function was selected to estimate the incremental expenditure as it resulted in a best-fitting 
model. 85-87 
Incremental total expenditure for various categories of medical events associated with CF cases 
were estimated separately in children (age <18 years) and in adults (age ≥18 years) using GLM 
models with log function. The dependent variable was mean cumulative expenditure and the 
independent variable was CF (yes/no). Among children, covariates included gender 
(male/female), race (White, Black, Hispanic, Asian and others), insurance coverage (private, 
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public and uninsured) and asthma as it was the only comorbidity information captured in 
children below 18 years. Among adults, covariates included gender (male/female), race (Whites, 
Blacks, Hispanics, Asian and others), insurance coverage (private, public and uninsured) and a 
comorbidity index score (high blood pressure, multiple diagnosis of high blood pressure, 
coronary heart disease, angina, heart attack, other heart disease, stroke, emphysema, high 
cholesterol, cancer, diabetes, arthritis, asthma). A comorbidity index score was created by 
summing all the comorbid conditions (if present) and categorizing them into three different 
groups: comorbidity index score 1-3, comorbidity index score 4-6 and comorbidity index score 7 
and above. 
 
PART 2: PHARMACOECONOMIC EVALUATION OF LUMACAFTOR/ 
IVACAFTOR IN CYSTIC FIBROSIS 
 
Although lumacaftor/ivacaftor has demonstrated higher efficacy, lower side effects, and most 
importantly, has offered a new treatment option to patients with CF with F508del mutation, the 
estimated drug cost of $270,172.77 in 2016 dollars has become a source of concern for 
healthcare stakeholders. Despite the clinical benefits, the high cost of therapy necessitates an 
assessment of the overall value of the drug in terms of its cost effectiveness and the financial 
impact on health plans. 
Economic evaluations are of two types- full and partial. A full economic evaluation compares 
both the costs and consequences (effectiveness, benefits) of two or more interventions. These 
types of evaluations require the identification, measurement and valuation of both costs and 
consequences. There are four full economic evaluations including cost-minimization, cost-
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effectiveness, cost-utility and cost-benefit analyses. These analyses differ in the way in which 
the outcomes are measured and reported. 88 
Evaluations which address only costs or outcomes are considered to be partial economic 
evaluations. 89 These evaluations do not involve a comparison between alternative interventions 
or do not relate costs to benefits but these analyses are also useful as they provide elements of 
information for a full evaluation. Cost analysis, cost consequence analysis and cost of illness 
analysis are few examples of partial economic evaluations. 90 
 
Outcomes 
The outcomes of interest in economic evaluations include the average cost-effectiveness ratio, 
marginal cost effectiveness ratio and incremental cost-effective a cost-effectiveness ratio. Cost 
effectiveness ratio (CER) is a way of calculating the cost per unit of benefit of a drug or an 
intervention.  
Average CER (ACER) 
A CER when calculated relative to no treatment is referred to as an average CER  
Average CER = Cost A/Effect A 
Marginal CER  
A marginal CER refers to the change in costs and health benefits from a one-unit expansion or 
contraction of service from a healthcare intervention 
Marginal CER = (Cost n*A – Cost (n-1) * A)/Effect n*A – Effect (n-1) *A 
In most scenarios, new interventions must be compared to existing therapies through an 
incremental cost effectiveness analysis (CEA). 
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Incremental CER (ICER) 
An incremental CER can be expressed as change in costs and health benefits when one 
healthcare intervention is compared to an existing one 
Incremental CER= CostA– CostB/EffectA – EffectB 
Where effect = natural outcome such as FEV1% predicted values or QALY 
A, B are alternative interventions. 91 
 
Components of a cost effectiveness analysis 
Patient population and comparator 
The first step in an economic evaluation is the identification of a target intervention and a target 
patient population. Then appropriate comparator drugs need to be identified. The target 
population can be identified from characteristics of patient population used in clinical trials. Ideal 
comparator drugs include medications belonging to same therapeutic class of the target 
intervention, no drug or an existing standard therapy.  
Perspective 
Identification of perspective is very important while conceptualizing economic analyses. 
Perspective focuses on the viewpoint of stakeholders and dictates what costs are included in the 
analysis. Some perspectives include government, provider, third party payer, society, and patient.  
• Government perspective includes all the costs incurred by the government, including 
employment costs.  
• Provider perspective includes all inpatient and outpatient costs, including hospital 
stay, outpatient visit, medical equipment, costs of medical testing, medications. 
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• Third party payer perspective includes all costs that are reimbursed to providers for 
provision of care. 
• Societal perspective is the broadest perspective and includes both direct medical, 
nonmedical costs and indirect costs (work productivity loss, caregiver costs). 
Time horizon and discounting 
The analysis should state clearly the time horizon of the CEA which will cover the time over 
which the costs and outcomes will occur. When cost and outcomes occur for an extended period, 
discounting should be used to represent the values to current day. Typical discount rates range 
from 3 to 6%.  
Costs 
Costs can be determined in three steps: identification, measurement and valuation. The 
perspective of study used in the analysis will determine the type of costs to be included in the 
study. Studies conducted from a societal perspective include all costs - including direct, indirect, 
and intangible costs whereas studies conducted from a payer perspective includes only direct 
medical costs. Direct medical costs include all costs that are attributable to the treatment such as 
hospitalization, medication costs, and diagnostic testing. Direct non-medical costs include 
transportation costs to and from the hospital/healthcare centers. Indirect costs include loss of 
income due to work productivity loss. Intangible costs include costs associated with pain and 
suffering.  
Sensitivity Analysis (SA) 
It is very essential to determine the sensitivity of estimates to variations in costs and outcomes. 
Sensitivity analysis is a process of checking the robustness of the results and conclusions of 
economic evaluations. It is conducted by varying the underlying assumptions and inputs over a 
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range of possible values. The model is considered to be robust if the sensitivity analysis results 
are found to be stable over a wide range of input parameters. Different types of sensitivity 
analysis used are one-way SA, two-way SA, multi-way SA, tornado analysis and probabilistic 
SA. 91 
 
Model design 
Two static decision models were developed using Microsoft Excel ® to evaluate the cost 
effectiveness and budget impact of lumacaftor/ivacaftor in a hypothetical CF population. Static 
models were utilized since the evaluations involved shorter time horizon. Dynamic Markov 
models require time dependent transition probabilities and are not available in the literature, 
because the drug was approved by the US FDA in 2015 and long-term effectiveness data of the 
drug was not available at the time of the study. A shorter time horizon was chosen for the model 
to reflect the outcomes and duration of published clinical trials. 
 
Comparators  
Lumacaftor/ivacaftor is a CFTR modulator therapy indicated in patients aged 6 years and older 
with homozygous F508 del mutation of CFTR gene. Lumacaftor/ivacaftor does not replace any 
existing therapy because the drug targets a specific gene mutation. The CEA, therefore, 
compared lumacaftor/ivacaftor against placebo and the BIA calculated the pre- and post-
inclusion of the drug on the formulary along with standard pulmonary therapy that included 
bronchodilators, inhaled antibiotics, dornase alfa, inhaled hypertonic saline and inhaled 
corticosteroids. 92 
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Patient population 
The hypothetical patient population in both CEA and BIA analyses was CF patients aged 12 
years and older with homozygous F508 del mutation of CFTR gene who were on standard 
therapy at baseline and treated by lumacaftor/ivacaftor. The demographics and clinical 
characteristics of the study population were based on clinical trial data of lumacaftor/ivacaftor 
(Refer Table 9). 92  
For BIA, the assumption was that patients continued to receive existing standard pulmonary 
therapy consisting of bronchodilators, inhaled antibiotics, dornase alfa, inhaled hypertonic saline 
and inhaled corticosteroids even after the introduction of lumacaftor/ivacaftor.  
The target population for BIA was calculated based on a total US population of 322,762,018 and 
a population of 274,062,018 aged 12 years and above. 93, 94 The prevalence of CF in the entire US 
population was estimated as 0.008976%.  Using this data, the estimates of CF prevalence in 
population 12 years or above was calculated as 24,609 (0.008976%). Similarly, the prevalence of 
CF in a hypothetical plan population of one million was estimated at 8,970. Out of 8,970, 7,750 
(86.4%) were estimated to have F508 del mutation with 46.1% of those qualifying with 
homozygous F508 del mutation, leading to the target population estimation of 3,572. The target 
population for BIA is presented in Figure 12. 
 
Perspective 
Both models were analyzed from a US third party payer perspective. Direct costs such as drug 
acquisition costs, monitoring costs and costs to treat adverse events were included in the 
analyses.  
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Table 9: Demographics and baseline characteristics of study population 
 
Characteristics Placebo 
(N=371) 
Lumacaftor/ivacaftor 
(N=369) 
Female: n (%) 181 (48.8) 182 (49.3) 
Age in years: mean (range) 25.4 (12-64) 25.3 (12-57) 
Subgroup: n (%)  
12 to <18 years 96 (25.9) 98 (26.6) 
≥18 years 275 (74.1) 271 (73.4) 
FEV1% predicted at baseline:  
mean (range) 
60.4 (33.9-99.8) 60.5 (31.3-96.5) 
Subgroup: n (%) 
FEV1% predicted <40 28 (7.5) 29 (7.9) 
FEV1% predicted ≥40 to <70 238 (64.2) 233 (63.1) 
FEV1% predicted ≥70 to ≤90 97 (26.1) 100 (27.1) 
FEV1% predicted >90 3 (0.8) 3 (0.8) 
 
Source: Wainwright et al., 2016 92 
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Figure 12: Target population for budget impact analysis of lumacaftor/ivacaftor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Total US population  
322,762,018  
Prevalence of CF in the entire US 
28,983 (0.008970%) 
 
US population 12 years and above  
274,062,018  
 
Prevalence of CF in US population 12 
years and above 
24,609 (0.008970%) 
 
Hypothetical plan population 
1,000,000 
 
Prevalence of CF in plan population 
8,970 (0.008970%) 
 
CF population with F508 del mutation 
7,750 (86.4%) 
 
CF population with homozygous F508 
del mutation 
3,572 (46.10%) 
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Analytical time frame 
Both models were analyzed over a one-year time frame. The shorter time frame was chosen to be 
consistent with the length of phase 3 clinical trials and the outcomes data extracted from the 
trials. 92 As discussed earlier, long-term clinical efficacy of the drug was not available at the time 
of the study. 
 
Efficacy/safety inputs 
The FEV1% predicted value was utilized as an efficacy input in the CEA model as it was the 
most commonly reported primary outcome in the phase 3 clinical trials of lumacaftor/ivacaftor. 
Mean absolute change in FEV1% predicted reported at week 24 in the clinical trials, was utilized 
in the analyses. 92 The safety data of the drug included the most common adverse events reported 
by subjects in the phase 3 clinical trials. The most common adverse events were defined as those 
that occurred in at least 10% of the patients in any treatment group (Refer Table 10). 92  
 
Cost inputs 
Drug acquisition costs 
The drug acquisition costs were WAC taken from 2015 Redbook®, inflated to 2016 value, using 
inflation data from the Bureau of Labor Statistics. Dosage information was taken from published 
FDA package inserts and number of doses per package were identified from the Redbook®. The 
dosage information was then utilized to calculate the number of packages per year per patient.
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Table 10: Safety/efficacy of lumacaftor/ivacaftor from phase 3 and published clinical trials 
 
 TRAFFIC  TRANSPORT  Pooled analysis  
Placebo 
(n=184) 
Lumacaftor/ 
ivacaftor 
(n=182) 
Placebo 
(n=187) 
Lumacaftor/ 
ivacaftor  
(n=187) 
Placebo 
(n=371) 
Lumacaftor/ 
ivacaftor  
(n=369) 
Efficacy at week 24 
Absolute change in percent 
predicted FEV1 from baseline Mean 
(SE) 
-0.44(0.524) 2.16 (0.530) -0.15 (0.539) 2.85 (0.540) -0.29 
(0.531) 
2.50 (0.534) 
Percent difference vs. placebo in 
absolute change, mean (95% CI) 
- 2.6 (1.2-4.0) - 3.0 (1.6-4.4) - 2.8 (1.8-3.8) 
Safety at week 48 
Participants affected/at risk for 
pulmonary exacerbations, n (%) 
112/184 
(60.86%) 25 
73/182 
(40.10%) 25 
139/187 
(74.33%) 25 
79/187 
(42.24%) 25 
182 
(49.2%) ^ 
132  
(35.8%) ^ 
Participants discontinued because of 
an adverse event, n (%) 
- - - - 6  
(1.6%) ^ 
17  
(4.6%) ^ 
 
Source: TRAFFIC: NCT01807923 95; TRANSPORT: NCT01807949 96; CI: confidence interval; SE: standard error 
all the values reported from phase 3 TRAFFIC and TRANSPORT trials unless specified; ^ values reported from published clinical 
trial, Wainwright et al., 2016  92; the reported adverse events were those that either developed or increased in severity at or after the 
time patients received the initial dose of the study drug (placebo or lumacaftor/ivacaftor), up to 28 days after receipt of the last dose; 
FEV1% predicted: percent predicted forced expiratory volume in 1 second
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For both analyses, the drug acquisition costs were calculated as the product of package cost and 
the number of packages required per year over the respective time horizon. Any product rebates, 
discounts, patient co-pay or co-insurance were not considered in the analyses. Drug acquisition 
costs of lumacaftor/ivacaftor and standard therapy are presented in Table 11. 
Monitoring costs 
The monitoring schedules utilized in both analyses were taken from the package insert of 
lumacaftor/ivacaftor and CF Care Guidelines reported by the 2013 CF Foundation Patient 
Registry. 25, 97 Monitoring test schedules associated with lumacaftor/ivacaftor included aspartate 
aminotransferase test (AST), alanine aminotransferase test (ALT) and bilirubin which were taken 
from package insert. All other laboratory tests were taken from guidelines published by CF 
Foundation. 25, 97 Frequency of clinic visits, outpatient visits and inpatient stays were taken from 
published literature. 25, 97 The costs for laboratory and monitoring tests were obtained from the 
2016 Physician Fee Schedules of Centers for Medicare and Medicaid (CMS) using the Current 
Procedural Terminology (CPT) codes for each test, healthcare blue book (2016), and from 
published literature. 98, 99 The monitoring test schedules and annual costs are presented in Table 
12 and the probabilities of medical and adverse events are presented in Table 13 
 
Outcome measures 
The outcomes of interest for CEA included cost of therapy per patient, ACER presented as cost 
per FEV1% predicted per patient, and ICER presented as additional cost per one-unit increase in 
FEV1% predicted per patient.  
 Total cost of therapy: sum of all the costs involved in treatment by placebo or 
lumacaftor/ivacaftor. 
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Table 11: Dosing and acquisition costs of medications 
 
Source: Wainwright et al., 2016 92; PO = by mouth; Q: every  
 
 
Drug  Dose, 
frequency, 
route 
Doses 
per pack 
Whole sale acquisition 
price per package ($) 
Packages 
needed per 
year 
Whole sale 
acquisition price per 
year 2016 ($) 
Lumacaftor/ivacaftor 
Orkambi®  
400 mg 
lumacaftor/250 
mg ivacaftor, 
Q12 hours PO12 
hours  
112 19,923.08 13.03 270,172.77 
Bronchodilator  
Albuterol (Proventil HFA®) 100 
0.18 mg 
Q6 hours 
inhalation 
74,444 75.36  0.039 2.93 
Inhaled antibiotic 
Tobramycin  
(TOBI®) 101 
300 mg 
Q12 hours 
inhalation 
56 3,604 13 46,852 
Mucolytic agent 
Dornase alfa (Pulmozyme®) 102 
2.5 mg 
Q daily 
inhalation 
30 3,283.41 12.16 39,926.26 
Mucolytic agent 
Hypertonic saline 
(Nebusal®) 103 
10 ml of 6% 
solution 
Q12 hours 
inhalation 
24 40.00 30.4 1,216.00 
Inhaled corticosteroid 
Fluticasone (Flonase®) 104 
200 mcg 
Q daily 
inhalation 
9.9 11.84 147.4 1,745.21 
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Table 12: Monitoring costs 
 
 Probability CPT code Frequency Unit cost 
2016 ($) 
Annual 
cost 2016 
($) 
Drug monitoring 
AST 
 
84450 105 4  14 106 56 
ALT 
 
84460 107 4  14 108 56 
Bilirubin 
 
82247 109 4  13 110 52 
Sputum/throat cultures 
 
87070, 87205 111 4 158.40 112 633.6 
Lung function tests /PFT 
 
94010 113 2  36.52 114 73.04 
Influenza Vaccine (flu shot) 
 
90656 115 1  24 116 24 
Fat soluble vitamins blood levels  
 
A: 84590 117 
D: 82306 118 
E: 84446 119 
K: 84597 120 
2  A: 31 121 
D: 100 122 
E: 37 123 
K: 36 124 
408 
Oral glucose tolerance test 
 
82951, 82952 125 1  34 126 34 
Clinic visits  0.56^ 99205 (initial),  
99215 (subsequent) 
127 
4.39 31 
562.5* 
1,382.85 
Outpatient visits 0.55^  6.26 31 291.18* 1,002.53 
Inpatient stays 0.28^  0.64 127 7,377.05* 1,321.96 
Adverse events 
Pulmonary exacerbations in placebo 
group 
0.39#  
 
3.6 128 13,612.65 129 19,112.14 
Pulmonary exacerbations in 
lumacaftor/ivacaftor group 
0.31#  3.6 128 13,612.65 129 15,191.71 
 
^Calculated using rate of medical events from O'Sullivan et al., 2011 31; * calculated as a part of objective 1 using MEPS 2014 data 
and inflated to 2016; #: calculated using rate of pulmonary exacerbations in placebo group and lumacaftor/ivacaftor group reported 
in phase 3 clinical trial
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Table 13: Probabilities of medical events and adverse events 
 
Variable Number 
considered 
for 
analysis 
Disc Number with 
the event 
Group 
followed 
until 
Patient 
years 
Rate of 
event 
Probability 
Medical events 
Clinic visits 1,064 0 862 (81.01%) 1 year 1,064 0.810 1-0.444= 0.555 
Outpatient visits 1,064 0 860 (80.8%) 1 year 1,064 0.808 1-0.445= 0.554 
Inpatient stays 1,064 0 359 (33.76%) 1 year 1,064 0.337 1-0.713= 0.286 
Adverse events 
PE in 
lumacaftor/ivacaftor 
group 
371 6  182 0.9 years 334 185/334= 
0.55 
1-0.609 = 0.391 
PE in placebo group 369 17  132 0.9 years 332 140.5/332= 
0.42 
1-0.685= 0.314 
 
Source: O'Sullivan et al., 2011 31; Wainwright et al., 2016 92 disc: discontinued; PE: pulmonary exacerbation;* half considered to be 
followed until 24 weeks; patient years: number considered for analysis * time followed; rate of event: number with event/ patient 
years; probability: 1-e –r* t, where r: rate of medical event, t: time horizon (1 year) 
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 ACER: total cost of therapy/ FEV1% predicted at week 24 from pooled analysis of phase 
3 clinical trials.  
 ICER: (cost lumacaftor/ivacaftor - cost placebo)/ (outcome lumacaftor/ivacaftor - outcome placebo)  
Where outcome = FEV1% predicted at week 24 from pooled analysis of phase 3 clinical trials 
The outcomes of interest for BIA included total budget impact, PMPM cost and PTMPM cost. 
 Total budget impact: difference in budget pre-and post-inclusion of 
lumacaftor/ivacaftor to the health plan formulary with existing standard therapy.  
 PMPM cost: total budget impact/ total hypothetical plan population 
 PTMPM cost: total budget impact/ total target population 
 
Sensitivity analysis 
Univariate sensitivity analyses were conducted to test the model assumptions and uncertainty in 
certain model variables, to determine the impact of varying the model inputs on the CEA and 
BIA of lumacaftor/ivacaftor. Drug acquisition costs, monitoring costs and cost to treat 
pulmonary exacerbations were varied over a range of estimates (±25 %) to test the robustness of 
the results based on the ranges used in the literature. 130-132 However, costs due to medical events 
including clinic visits, outpatient visits and inpatient stays were assumed to decline by 10% in 
lumacaftor/ivacaftor group and hence, sensitivity analyses for these variables was conducted at -
10% and -25%. 
 
Model assumptions 
Several assumptions were made in the study. First, a recently published study reported the mean 
weighted medication possession ratio (MPR) of the CF population on lumacaftor/ivacaftor to 
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range from 87% to 99.5% with a mean MPR of 92.28%. 133 To provide a fair comparison and to 
avoid preference to lumacaftor/ivacaftor therapy, adherence to lumacaftor/ivacaftor, placebo 
(CEA), and standard therapy (BIA) were all assumed to be 100%. Second, the prevalence of CF 
was based on the latest estimates available from 2015 CF Foundation Patient Registry Annual 
Report and it was assumed to be same in 2016 as well. Third, patients were assumed to be 
maintained on the assigned therapy throughout the duration of the model. Fourth, clinical inputs 
such as FEV1% predicted values and pulmonary exacerbation rates taken from published phase 3 
clinical trials were assumed to be highly reliable and valid. Fifth, because the analyses had a 
short analytic frame, it was assumed that the disease condition of the patient remained the same 
and the patient did not transition to a higher level of disease severity. Sixth, in CEA, subjects 
were assumed to be on standard therapy at baseline which included pulmonary maintenance 
medications. Finally, for both analyses, costs due to medical events including clinic visits, 
outpatient visits and inpatient stays were assumed to decline by 10% after the initiation of 
lumacaftor/ivacaftor therapy. The cost of pulmonary exacerbations was adjusted based on the 
probabilities obtained from published clinical trials. 
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CHAPTER FOUR: RESULTS 
 
Although CF results in the use of more healthcare resources, recent estimates of the economic 
burden of CF is lacking. Novel CFTR therapies like ivacaftor and lumacaftor/ivacaftor have 
shown a tremendous improvement in FEV1% predicted rates from baseline in phase 3 clinical 
trials but the cost effectiveness of the lumacaftor/ivacaftor therapy has not been reported in the 
US. Thus, the overall objective of this study was to estimate the burden of illness in CF patients 
and to understand the overall effectiveness and affordability of lumacaftor/ivacaftor therapy. 
Results from the study are reported in this section 
 
PART 1: BURDEN OF ILLNESS IN CYSTIC FIBROSIS 
 
Demographics and clinical characteristics of adult CF cases and controls 
A descriptive analysis was conducted on 2010-2014 MEPS data to understand the demographics 
and clinical characteristics of CF cases and controls. The number of records identified with a 
diagnosis code of CF were 22, 24, 49, 46 and 38 for the years 2010, 2011, 2012, 2013 and 2014, 
respectively. Unique records of 130 (72.6%) unique individuals were identified from the total 
179 records. Further, only 109 (83.8%) of the 130 records reported using at least one CF-related 
medical service.  
Of the 109 records, 78 (71.5%) were identified as adults (age ≥18 years). The number of records 
identified for control sample in 2010, 2011, 2012, 2013 and 2014 were 102,284, 108,595, 
118,801, 123,829 and 116,641 respectively. A total of 570,150 discharge records of controls 
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were identified, of which 85,521 (14.9%) were identified as being unique. Further, 60,871 
(71.1%) were identified as adults. 
Demographic and clinical characteristics of adult CF cases and controls are presented in Table 
14. Ages of cases ranged from 18-82 years with an average of 50.55 ±17.04 years and the ages of 
control group ranged from 18-85 years with a mean of 46.85 ± 18.03 years. There was no 
significant difference in the mean age between CF cases and controls (t statistic: -1.81, 
p=0.0703). The average household income was also similar with $61,872.46 among cases and 
$61,182.67 among controls (t statistic: -0.11, p=0.9148). 
Both cases (67.95%) and controls (55.99%) were predominantly female and majority were 
Whites (65.14%, 28.64%, respectively). Descriptive analysis on marital status showed that 
52.38% of cases were married and 47.62% were unmarried whereas among control group, 
48.24% were married and 36.79% was unmarried. It was also observed that only 1 (1.28%) out 
of 78 CF cases was uninsured, but the uninsured proportion was comparatively higher among 
controls (15.77%). MEPS captured information related to fewer comorbidities including 
cardiovascular diseases, respiratory diseases like asthma and emphysema, diabetes, high 
cholesterol, arthritis, and cancer. The most commonly reported comorbidities among cases and 
controls were hypertension (50%, 30.46%, respectively), high cholesterol (46.15%, 33.09%, 
respectively) and arthritis (41.03%, 27.85%, respectively). Results of the chi-square analyses 
reported significant association between gender (chi-square value: 4.5235, p=0.0334*), race 
(chi-square value: 18.3170, p=0.0011*), insurance coverage (chi-square value: 13.7497, 
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Table 14: Demographic and clinical characteristics of adult cystic fibrosis cases and controls  
 
Individual 
characteristics 
Cases (N=78) 
 
Controls (N=60,871) 
 
Test 
statistic 
P value 
Age  Mean: 50.55 ±17.04 years 
 
Mean: 46.85 ± 18.03 years 
 
-1.81  0.0703 
Gender Male: 25 (32.05%) 
Female: 53 (67.95%)  
Male: 26,791(44.01%) 
Female: 34,080 (55.99%) 
4.5235  0.0334* 
Race White: 40 (51.28%) 
Black: 10 (12.82%) 
Hispanic: 4 (5.12%) 
Asian: 1 (1.28%) 
Others: 1 (1.28%) 
Missing: 22 (28.20%) 
White: 19,223 (31.57%) 
Black: 8,693 (14.28%) 
Hispanic: 10,764 (17.68%) 
Asian: 2,919 (4.79%) 
Others: 1,114 (1.83%) 
Missing: 18,158 (29.83%) 
18.3170 
0.0011* 
Household 
income 
Mean: $61,872.46 ± 55,240.25 
(95% CI: $49,417.71, $74,327.21) 
 
Mean: $61,182.67 ± 56,904.26 
(95% CI: $56,904.26, $61,634.73 
 
-0.11  0.9148 
Marital status  Married: 11 (14.10%) 
Not married: 9 (11.5%) 
Missing: 57 (73%) 
Married: 8,941(14.68%) 
Not married: 9,952 (16.34%) 
Missing: 42,338 (69.55%) 
1.7493  
 
0.7817 
Insurance 
Coverage 
Any private: 58 (74.36%) 
Public only: 19 (24.36%) 
Uninsured: 1 (1.28%)) 
Any private: 35,651(58.57%) 
Public only: 15,619 (25.66%) 
Uninsured: 9,601 (15.77%) 
13.7497 
 
 
0.0010* 
Comorbidities#     
High blood 
pressure 
45 (57.69%) 22,812 (37.48%) 13.6074  0.0087* 
Multiple 
diagnosis of 
high blood 
pressure 
39 (50.00%) 18,541 (30.46%) 15.9239  0.0071* 
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Coronary heart 
disease 
9 (11.54%) 3,802 (6.25%) 3.7601 
 
 
0.4394 
Angina 5 (6.41%) 1,694 (2.78%) 3.8228 
 
 
0.4305 
Heart attack 
(MI) 
5 (6.41%) 2,542 (4.18%) 1.0029 
 
 
0.9094 
Other heart 
disease 
21 (26.92%) 6,805 (11.18%) 19.4358  0.0006* 
Stroke 6 (7.69%) 2,724 (4.48%) 1.9121 
 
 
0.7519 
Emphysema 6 (7.69%)  1,431 (2.35%) 9.6831 
 
 
0.0461* 
High 
cholesterol 
36 (46.15%) 20,144 (33.09%) 6.0526 
 
 
0.1953 
Cancer 12 (15.38%) 5,956 (9.78%) 2.7995 
 
 
0.5919 
Diabetes 12 (15.38%) 7,309 (12.01%) 0.8644 
 
 
0.9296 
Arthritis 32 (41.03%) 16,954 (27.85%) 6.7557 
 
 
0.1494 
Asthma 13 (16.67%) 6,360 (10.45%) 3.2394 
 
 
0.5186 
 
Not married includes divorced, separated, never married, widowed; #: not mutually exclusive; test statistic is chi square value for all 
categorical variables and t value for all continuous variables; p value significance at 0.05  
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p=0.0010*), comorbidities like hypertension (chi-square value: 15.9239, p=0.0071*), 
emphysema (chi-square value: 9.6831, p=0.0461*), and other heart diseases (chi-square value: 
19.4358, p=0.0006*) and occurrence of CF in adults. 
 
Demographics and clinical characteristics of child CF cases and controls 
Demographics and clinical characteristics of child CF cases and controls are presented in Table 
15. The variables included age, gender, race, household income, marital status, insurance 
coverage and comorbidity (asthma). There were 31 child CF cases and 24,650 controls. The ages 
among cases and controls ranged from 0-17 years with the mean age being 4.87 ± 5.75 years in 
cases and 8.35 ± 5.35 years in controls. There was a significant difference in the mean age 
between cases and controls (t statistic: 3.62, p=0.0003*). The average household income was 
similar with $54,718.06 among cases and $55,516.44 among controls (t statistic: 0.08, 
p=0.9356). 
Among cases, the gender distribution was almost equal with males being 15 (48.39%) and 
females being 16 (51.61%), but controls had slightly more males (51.29%) than females. 
Majority of the controls were under 16 years of age (87.55%), however, a minor proportion of 
controls was married (0.56%). It was also observed that none of the cases were uninsured. Half 
of the cases had public insurances and half of them had private insurances. But the uninsured 
proportion was comparatively higher among controls (4.72%). However, 52.95% of controls had 
public insurances and 42.33% had private insurances. 19.35% among cases and 13.62% among 
controls had asthma. Information on other existing comorbid conditions among children was not 
captured by MEPS. Results of the chi-square analyses did not report any association between 
gender, race, insurance coverage, marital status, asthma and occurrence of CF in children. 
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Table 15: Demographic and clinical characteristics of child cystic fibrosis cases and controls  
 
Individual 
characteristics 
Cases (N=31) 
 
Controls (N=24,650) 
 
Test statistic P value 
Age  Mean: 4.87 ± 5.75 years Mean: 8.35 ± 5.35 years 3.62 0.0003* 
Gender Male: 15 (48.39%) 
Female: 16 (51.61%)  
Male: 12,642 (51.29%) 
Female: 12,008 (48.71%) 
0.1041  0.7469 
Race White: 14 (45.16%) 
Black: 1 (3.22%) 
Hispanic: 7 (22.58%) 
Asian: 1 (3.22%) 
Others: 1 (3.22%) 
Missing: 7 (22.58%) 
White: 5,273 (21.39%) 
Black: 3,210 (13.02) 
Hispanic: 6,168 (25.02%) 
Asian: 808 (3.27%) 
Others: 857 (3.47%) 
Missing: 8,334 (33.80%) 
8.5021 
0.0748 
Household income Mean: $54,718.06 ± 55,094.14 
(95% CI: $34,509.37, $74,926.76) 
 
Mean: $55,516.44 ± 54,969.31 
(95% CI: $54,830.20, $56,202.69) 
0.08 
0.9356 
Marital status  Married: 0 
Not married: 0 
Under 16 years: 5 (100%) 
Missing: 26 
Married: 36 (0.56%) 
Not married: 768 (11.88%) 
Under 16 years: 5,655 (87.55%) 
Missing: 18,191 
0.7108 0.9824 
Insurance Coverage Any private: 15 (48.39%) 
Public Only: 16 (51.61%) 
Uninsured: 0 
Any private: 10,435 (42.33%) 
Public Only:  13,052 (52.95%) 
Uninsured: 1,163 (4.72 %) 
1.7411 
0.4187 
Asthma 6 (19.35%) 3,358 (13.62%) 0.9688 0.9145 
 
Not married includes divorced, separated, never married, widowed; test statistic is chi square value for all categorical variables and t 
value for all continuous variables; p value significance at 0.05 
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Resource utilization among cases 
Unweighted total OOP expenditure for all medical events was $31,828.58 of which 57.5% 
($18,328.66) was accounted by prescription medications followed by 23.3% ($7,419.71) by 
office visits. Weighted total OOP expenditure representing OOP payment for the entire US 
population was $615,098,138 (Refer Table 16). 
Unweighted total cumulative expenditure for all medical events was $455,539.70 of which 
33.0% ($150,634.2) was contributed by prescription medications followed by 31.5% 
($143,341.3) by inpatient stays. Weighted total cumulative expenditure representing cumulative 
payment for the entire US population was $6,691,134,764 (Refer Table 17). 
The total OOP and cumulative expenditures were highest in the year 2012 contributing 40.5% 
and 34.4%, respectively (Refer Table 18). Expenditures for different medical services each year 
are presented in Appendices Table 33  
Prescription medicines contributed the highest to total OOP and cumulative expenditure from 
2010-2014. Drug classes attributable to higher cumulative expenditure were pulmonary 
medications ($85,555.33), gastro intestinal agents ($17,255.25), immune modulators 
($14,596.2), antibiotics ($14,186.42) and pain medications ($2,653.53). (Refer Appendices 
Table 35 for complete list and description of drug classes). 
Some medications were more frequently used and some were attributable to high cumulative 
expenditure despite infrequent utilization indicating higher cost of those medications (Refer 
Appendices Table 34 for complete list). The most frequently used medications were metformin 
(9.4%), levocarnitine (7.9%), respiratory agents (7.8%), prednisone (3.8%), Creon® (3.6%), and 
allopurinol (2.5%) (Refer Appendices Table 34 for complete list). 
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Table 16: Out-of-pocket expenditure of medical events (2010-2014) 
 
Medical event Out-of-pocket expenditure from 2010-2014 ($)  
 Unweighted Weighted  
Mean 
 
Total  
 
Mean 
 
Total  
Office visits 87.30 (43.25-131.33) 7,419.71 101.17 (39.38-162.97) 105,795,071 
Home health 24.50 (0-102.46) 98 68.75 (0-160.00) 4,377,427 
Prescription 
medications 
229.11 (23.58-434.64) 18,328.66 371.56 (0-767.00) 433,098,457 
Inpatient stays 65.06 (3.72-126.41) 715.73 46.85 (0-105.50) 6,412,171 
Outpatient visits 226.32 (0-518.35) 4,979.17 186.07 (0-419.90) 63,645,296 
Emergency visits 23.94 (0-62.61) 2,87.31 13.14 (0-40.26) 1,769,716 
Sum - 31,828.58 - 615,098,138 
 
Mean: mean costs for all the observations of a medical event in a year; total: sum of costs for all the observations of a medical event 
in a year; out-of-pocket: expenditure paid directly by an individual 
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Table 17: Cumulative expenditure of medical events (2010-2014) 
 
Medical event 
 
Cumulative expenditure from 2010-2014 ($) 
 Unweighted  Weighted  
 Mean 
 
Total  
 
Mean 
 
Total  
Office visits 769.53 (342.21-1,196.85) 65,410.35 777.49 (194.80-1,360.18) 812,971,988 
Home health 4,362.50 (0-9,681.97) 17,450 5,861.76 (4,221.79-7,501.73) 373,213,579 
Prescription 
medications 
1,882.93 (538.49-3,227.37) 150,634.2 2,046.10 (143.38-3,948.82) 2,385,010,201 
Inpatient stays 13,031.02 (3,450.11-22,611.93) 143,341.3 16,070 (0-32,402.03) 2,199,126,682 
Outpatient visits 3,268.98 (0-7,517.78) 71,917.52 2,481.51 (0-5,893.63) 848,785,772 
Emergency visits 565.53 (157.57-973.49) 6,786.38 535.14 (57.518-1,012.76) 72,026,542 
Sum - 455,539.70 - 6,691,134,764 
 
Mean: mean costs for all the observations of a medical event in a year; total: sum of costs for all the observations of a medical event 
in a year; cumulative: expenditure paid by an individual and payments by private insurance, Medicare, Medicaid and other sources.
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Table 18: Out-of-pocket and cumulative expenditures for all medical events from 2010-
2014 
 
Year Total out-of-pocket expenditure for 
all medical events) ($) 
Total cumulative expenditure for all 
medical events) ($)  
Unweighted Weighted Unweighted Weighted 
2010 1,011.98 15,697,839 16,013.54 195,618,996 
2011 3,835.34 40,815,097 46,368.86 413,793,959 
2012 12,878.75 255,766,819 156,688.8 2,883,703,057 
2013 5,354.42 53,153,619 94,148.59 924,855,899 
2014 8,734.59 249,258,850 141,922.4 2,261,164,451 
Total  31,828.58 615,098,138 455,539.7 6,691,134,764 
 
Out-of-pocket: expenditure paid directly by an individual; cumulative: expenditure paid by an 
individual and payments by private insurance, Medicare, Medicaid and other sources 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 97 
Medications attributable to higher cumulative expenditure were respiratory agents, Creon®, 
aminoglycosides, immunologic agents, Myfortic®, selective immunosuppressants, Xopenex®, 
Spiriva®, Oxycontin®, levocarnitine (Refer Appendices Table 34 for complete list). 
Of the total unweighted cumulative expenditure of $150,634.2 for prescription medications from 
2010-2014, $134,216.86 was due to medications used in CF treatment. Respiratory agents 
accounted for highest cumulative expenditure of $78,316.47 (Refer Table 19). 
 
Incremental cost burden in CF cases 
Table 20 presents the results of regression analysis of incremental expenditure in children with 
CF in comparison to children without CF. After adjusting for covariates such as gender, race, 
insurance and comorbid condition asthma, the mean cumulative expenditure in children with CF 
was 3.67 times of expenditure in children without CF (p=<0.0001*). In general, expenditure in 
males was 1.13 times of that of females (p=<0.0001*). Expenditure in Hispanics, Blacks, Asians 
and others was 0.65, 0.90, 0.64 and 0.70 times of cumulative expenditure in Whites. 
(p=<0.0001*, 0.0024*, <0.0001*, <0.0001*, respectively). Expenditure in children with private 
insurance and public insurance was 1.35 and 1.16 times of that of children without insurance 
(p=<0.0001*, 0.0187*, respectively). Children with asthma had expenditure which was 1.47 
times of that of children without asthma (p=<0.0001*).  
Table 21 presents the results of regression analysis of incremental expenditure of adults with CF 
in comparison to adults without CF. After adjusting for covariates such as gender, race, 
insurance and comorbidity index score, the mean cumulative expenditure in adults with CF was 
1.49 times of expenditure in adults without CF (p=0.0618). In general, expenditure in males was 
0.95 times of that of females (p=0.0207*).  
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Table 19:  Cumulative expenditure of prescription medications used in cystic fibrosis from 
2010-2014 
 
Name of the 
medication 
Drug class Use/category of drug Total cumulative 
expenditure ($)  
Respiratory agents Respiratory agent Drugs or a combination of 
drugs used to prevent, relieve 
or treat respiratory diseases 
78,316.47 
Creon Gastro intestinal 
agent 
Enzyme replacement therapy 
for pancreatic insufficiency 
15,170.16 
Aminoglycosides Antibiotic Antibiotic, to treat pulmonary 
exacerbations of CF/ to treat 
Pseudomonas aeruginosa 
infection 
13,307.2 
Immunologic agents Immune 
modulator 
Modifies immune response 6,176.5 
Myfortic Immune 
modulator 
Immunosupressive, prevents 
organ rejection after 
transplant 
4,392.94 
Selective 
immunosuppressants 
Immune 
modulator 
Suppresses immune system to 
fight infections 
3,824.6 
Xopenex Respiratory agent Bronchodilator 3,281.6 
Spiriva Respiratory agent Bronchodilator 2,223.36 
Prevacid Gastro intestinal 
agent 
To treat stomach ulcers, 
gastro esophageal reflux 
disorder 
1,552.48 
Hormones/hormone 
modifiers 
Hormone 
modifier 
Modifies hormone levels 
inside the body 
769.05 
Singulair Respiratory agent To treat allergies, asthma 642.1 
Azithromycin Antibiotic Antibiotic, to treat CF lung 
disease 
455.5 
Phlexy-10 Dietary 
supplement 
Low protein diet 375 
Epipen-JR Respiratory agent To treat asthma attacks, vaso 
constrictor 
317.33 
Minocycline Antibiotic To treat bacterial infections 
such as urinary tract 
infections, respiratory 
infections, skin infections, 
severe acne, gonorrhea, tick 
fever, chlamydia, and others 
296.92 
Dexamethasone Anti-
inflammatory 
agent 
Steroid, anti-inflammatory 279.88 
Mycophenolate Respiratory agent To treat asthma 275.06 
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Albuterol Respiratory agent Bronchodilator 259.92 
Pancrealipase Gastro intestinal 
agent 
Enzyme replacement therapy 249.78 
Methotrexate Immune 
modulator 
Immunosupressive, 
chemotherapy 
202.16 
Flovent HFA Respiratory agent Steroid and decongestant 188.91 
Pentoxifylline Anti-
inflammatory 
agent 
Anti-inflammatory, vaso 
dilator 
180.54 
Prednisone Anti-
inflammatory 
agent 
Steroid, anti-inflammatory 150.76 
Adipex-p Weight loss 
supplement 
Promotes weight loss 149.97 
Folgard Rx Dietary 
supplement 
Vitamin complex, to treat 
vitamin deficiency 
142.97 
Lansoprazole Gastro intestinal 
agent 
Proton pump inhibitor to treat 
stomach ulcers 
125.82 
Qvar Medical device Aerosol, inhaler 111.55 
Polyethylene glycol Gastro intestinal 
agent 
Laxative 89.14 
Cephalexin Antibiotic Antibiotic, treats pulmonary 
exacerbations of CF 
84.8 
Folbic Dietary 
supplement 
Multivitamin, to treat vitamin 
deficiency 
61.29 
Optichamber Medical device Inhaler 53.98 
Lactulose Gastro intestinal 
agent 
Laxative 53.43 
Cyanocobalamin Dietary 
supplement 
To treat vitamin deficiency 48.44 
Mag-ox 400 Dietary 
supplement 
Antacid to relieve heart burn, 
indigestion, acid indigestion 
43.5 
Amoxicillin Antibiotic Antibiotic 42 
Culturelle Dietary 
supplement 
Probiotic for digestive system 37.38 
Aero chamber Medical device Aerosol 35.03 
Vitamin D Dietary 
supplement 
To treat vitamin deficiency 33.74 
Fluticasone Respiratory agent Steroid, decongestant 31.58 
Phentermine Weight loss 
supplements 
Promotes weight loss 23.39 
Spacer inhaler 
(Optichamber) 
Medical device Inhaler 21.29 
Multivitamin Dietary 
supplement 
To treat vitamin deficiency 19.96 
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Vortex/mask Medical device Helps in inhalation 19.91 
Tri-vitamin Dietary 
supplement 
To treat vitamin deficiency 18.99 
Ibuprofen Anti-
inflammatory 
agent 
Non-steroidal anti-
inflammatory drug 
16 
Vitamin B12 Dietary 
supplement 
To treat vitamin deficiency  16 
Pantoprazole Gastro intestinal 
agent 
Proton pump inhibitor, to treat 
stomach ulcers 
14.45 
Sodium Chloride Respiratory agent Mucolytic, to maintain levels 
of sodium 
10 
Aspirin Anti-
inflammatory 
agent 
Non-steroidal anti-
inflammatory drug, blood 
thinner, prevents heart stroke 
9.75 
Cheratussin AC Respiratory agent Cough suppressant, 
expectorant 
9 
Vitamin B6 Dietary 
supplement 
To treat vitamin deficiency 3.06 
Niacin Dietary 
supplement 
To treat vitamin deficiency 2.23 
Total 134,216.86 
Table 20: Regression analysis to estimate the incremental direct medical expenditure in 
children with cystic fibrosis compared to children without cystic fibrosis 
 
Parameter 
Reference 
category 
Parameter 
estimate  
P value 
CF No CF 3.67 <0.0001* 
Male Female 1.13 <0.0001* 
Hispanic 
White 
0.65 <0.0001* 
Black 0.90 0.0024 
Asian 0.64 <0.0001* 
Others 0.70 <0.0001* 
Any private 
Uninsured 
1.35 <0.0001* 
Public only 1.16 0.0187* 
Asthma No Asthma 1.47 <0.0001* 
 
CI: confidence interval; SE: standard error; p value significant at ≤0.05 
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Table 21: Regression analysis to estimate the incremental direct medical expenditure in 
adults with cystic fibrosis compared to adults without cystic fibrosis 
 
Parameter Reference 
category 
Parameter 
estimate 
P value 
CF No CF 1.49 0.0618 
Male Female 0.95 0.0207* 
Hispanic White 0.77 <0.0001* 
Black 0.91 0.0001* 
Asian 0.82 <0.0001* 
Others 0.91 0.1546 
Any private Uninsured 2.10 <0.0001* 
Public only 2.39 <0.0001* 
Comorbidity index 4-
6 
Comorbidity 
index 1-3 
2.02 <0.0001* 
Comorbidity index 7 
and above 
3.65 <0.0001* 
 
CI: confidence interval; SE: standard error; †: reference category; p value significant at ≤0.05 
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Expenditure in Hispanics, Blacks, Asians and others was 0.77, 0.91, 0.82 and 0.91 times of 
cumulative expenditure in Whites. (p=<0.0001*, 0.0001*, <0.0001*, 0.1546, respectively). 
Expenditure in those with private insurance and public insurance was 2.10 and 2.39 times of 
those without insurance (p=<0.0001*, <0.0001*, respectively). Expenditure in those with 
comorbidity index score 4-6 was 2.02 times and with comorbidity index score 7 and above was 
3.65 times of those with comorbidity index score 1-3 (p=<0.0001*, <0.0001*).  
Table 22 describes the results of incremental expenditure in children with CF compared to 
children without CF. Children with CF had a mean cumulative expenditure of $13,990 where as 
children without CF had a mean cumulative expenditure of $3,231.27. Comparison of means 
between cases and controls using independent sample t test reported significant difference in 
mean cumulative expenditure between the two groups (t value: -4.26, p= <0.0001*).  
Mean cumulative expenditure for all medical events across five years was $16,975.80 in adults 
with CF and $8,859.87 in adults without CF. Comparison of means between cases and controls 
using independent sample t test reported significant difference in mean cumulative expenditure 
between the two groups (t value: -3.12, p=0.0018*). 
The analysis of incremental cost burden in children and adults show that the expenditure in cases 
was higher than in controls and the costs were higher in adults when compared to children. These 
results are different from those obtained in previous studies as they suggested higher expenditure 
in children than in adults. 32 
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Table 22: Comparison of cumulative expenditure among children with and without cystic 
fibrosis 
 N Cumulative expenditure ($) DF t value p value 
 Mean (SE) 95% CI  
24679 -4.26 <0.0001* 
Children 
Without 
CF 
24,650 
3,231.27 (89.43) 3,055.99, 3,406.55 
With CF 
31 
13,990 (3,764.18) 6,302.52, 
21,677.48 
Adults 
Without 
CF 
60,871 
8,859.87 (93.10) 8,677.39, 9,042.36 
60947 -3.12 0.0018* 
With CF 
78 
16,975.80 
(2,735.67) 
11,529.60 -
22,422.00 
 
Cumulative: expenditure paid by an individual and by other sources like insurance; mean: mean 
expenditure in children for all medical events between 2010 and 2014; total: total expenditure in 
children for all medical events between 2010 and 2014; SE: standard error; CI: confidence 
interval; equal variances assumed for t test; p value significant at ≤0.05 
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PART 2: PHARMACOECONOMIC EVALUATION OF 
LUMACAFTOR/IVACATTOR  
 
 
Base-case analysis of cost effectiveness of lumacaftor/ivacaftor 
The cost of therapy per patient in the lumacaftor/ivacaftor was $379,780.11 compared to 
$113,734.54 in the placebo group. The ACER in patients treated by lumacaftor/ivacaftor was 
$151,912.04 indicating a positive change in FEV1% predicted value from baseline. The ACER 
for placebo was -392,188 indicating the amount spent to receive a single unit of negative 
outcome i.e. FEV1% predicted value. The estimated ICER of lumacaftor/ivacaftor over placebo 
was $95,016.28 indicating that one-unit positive change in FEV1% predicted value by 
lumacaftor/ivacaftor was achieved for each additional $95,016.28 
 
Sensitivity analysis of cost effectiveness of lumacaftor/ivacaftor 
The results of one-way sensitivity analyses showed that the ICER of lumacaftor/ivacaftor was 
stable to changes in most input parameters. However, after a ±25% change in the cost of 
lumacaftor/ivacaftor, the drug had an ICER ranging from $70,893.72 to $119,138.87. Similarly, 
lumacaftor/ivacaftor was sensitive to cost of standard therapy with the ICER ranging from 
$87,003.57 to $103,029, followed by change in cost to treat pulmonary exacerbations with the 
ICER ranging from $93,659.88 to $96,372.68, and probability of occurrence of pulmonary 
exacerbations with the ICER ranging from $93,791.14 to $96,241.42. The ICER of 
lumacaftor/ivacaftor was not affected by varying the cost of other variables and probabilities of 
occurrence of medical events. These results suggested that the baseline cost-effectiveness model 
was robust to changes in most of the input parameters except, drug cost, cost of standard therapy 
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and cost to treat, probability of pulmonary exacerbations. Tables 23 and 24 present results of 
sensitivity analysis of placebo. Tables 25 and 26 present results of sensitivity analysis of 
lumacaftor/ivacaftor. Figure 13 presents the tornado plot of one way-sensitivity analysis of cost 
effectiveness of lumacaftor/ivacaftor. Increased (high) and decreased (low) input ranges were 
plotted to determine the effect of different variables on the ICER. The results suggested that even 
after varying the data input ranges, lumacaftor/ivacaftor therapy was stable to most of the 
variables except for the cost of drug, standard therapy and pulmonary exacerbations. Refer 
Appendices Table 36 for impact of variables on ICER value. 
 
Base-case analysis of budget impact of lumacaftor/ivacaftor 
The cost of therapy per patient due to standard therapy alone before the inclusion of 
lumacaftor/ivacaftor was $113,734.52 and after the inclusion of lumacaftor/ivacaftor on the 
formulary was $379,780.11. Hence, the total budget impact due to inclusion of the drug on the 
formulary was $266,045.59. Based on a one million hypothetical plan population, the PMPM 
cost was $0.022 and the PTMPM cost was $6.2067 based on a target population of 3,572. 
 
Sensitivity analysis of budget impact of lumacaftor/ivacaftor 
The results of one-way sensitivity analysis showed that the PTMPM cost of lumacaftor/ivacaftor 
was most likely to be influenced by change in certain input parameters. After a ±25% change in 
cost of lumacaftor/ivacaftor, the drug had PTMPM cost ranging from $4.1076 to $8.3059. 
Similarly, lumacaftor/ivacaftor was slightly sensitive to change in cost to treat pulmonary 
exacerbations with PTMPM cost ranging from $6.1181 to $6.2953 and probability of occurrence 
of pulmonary exacerbations with PTMPM cost ranging from $6.1153 to $6.2868. 
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Sensitivity analysis of placebo 
 
Table 23: Costs 
 
Variable Base case Low High ICER at 
low 
ICER at high 
Drug costs 
Standard 
therapy  
89,742.40 
 
67,306.80 112,178 103,029 
 
87,003.57 
Monitoring costs 
Sputum 
culture 
633.6 475.2 
 
792 
 
95,072.85 
 
94,959.71 
 
PFT’S 73.04 54.78 91.3 95,022.81 
 
95,009.76 
 
Flu shot 24 18 30 95,018.43 
 
95,014.14 
 
Fat soluble 
vitamins 
408 306 510 95,052.71 
 
94,979.86 
 
OGT 34 25.5 42.5 95,019.32 
 
95,013.25 
Clinic visits 1,382.25 1,037.13 
 
1,728.56 
 
95,139.75 94,892.82 
 
Outpatient 
visits 
1,002.53 
 
751.89 1,253.16 
 
95,105.79 
 
94,926.77 
 
Inpatient 
stays  
1,321.96 
 
991.47 1,652.45 
 
95,134.32 
 
94,898.25 
 
Costs to treat adverse events 
PE 19,112.14 14,334.11 
 
23,890.17 
 
96,722.72 
 
93,309.84 
 
 
Sensitivity analysis conducted at low (-25%) and high (+25%); %); PFT: pulmonary lung 
function test; OGT: oral glucose tolerance test; PE: pulmonary exacerbations
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 Table 24: Probabilities of medical events 
 
Variable Probability 
Base case 
Probability 
low 
Probability 
high 
Base case  low  high ICER at 
low 
ICER at 
high 
Clinic visits 0.56 0.42 0.70 1,382.25 1,036.95 1,728.25 95,139.82 
 
94,892.93 
 
Outpatient 
visits 
0.55 0.41 0.69 1,002.53 
 
747.33 1,257.71 95,221.51 
 
95,039.23 
 
Inpatient 
stays 
0.28 0.21 0.35 1,321.96 
 
991.47 1,652.45 95,134.32 
 
94,898.25 
 
PE 0.39 0.30 0.48 19,112.14 14,701.66 23,522.65 96,591.46 
 
93,441.10 
 
 
Sensitivity analysis of probabilities conducted at low (-25%) and high (+25%); PE: pulmonary exacerbations 
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Sensitivity analysis of lumacaftor/ivacaftor 
 
Table 25: Costs 
 
Variable Base case Low High ICER at 
low 
ICER at high 
Drug costs 
Lumacaftor 
/ivacaftor 
270,172.8 
 
202,629.60 
 
337,716 
 
70,893.72 
 
119,138.87 
 
Standard 
therapy  
89,742.40 
 
67,306.80 112,178 87,003.57 
 
103,029 
 
Monitoring costs 
AST 56 42 70 95,011.28 95,021.28 
ALT 56 42 70 95,011.28 95,021.28 
Bilirubin 52 39 65 95,011.64 
 
95,020.93 
 
Sputum 
culture 
633.6 475.20 792 
 
94,959.71 
 
95,072.86 
 
PFT’S 73.04 54.78 91.3 95,009.76 
 
95,022.81 
Flu shot 24 18 30 95,014.14 
 
95,018.43 
 
Fat soluble 
vitamins 
408 306 510 94,979.86 
 
95,052.71 
 
OGT 34 25.5 42.5 95,013.25 
 
95,019.32 
 
Clinic visits* 1,244.56 
 
933.42 1,244.56 
 
94,905.16 
 
95,016.28 
Outpatient 
visits* 
902.27 
 
676.70 902.27 
 
94,935.72 
 
95,016.28 
Inpatient 
stays* 
1,189.764 
 
892.32 1,189.764 
 
94,910.05 
 
95,016.28 
Costs to treat adverse events 
PE 15,191.71 
 
11,393.78 18,989.63 
 
93,659.88 
 
96,372.68 
 
Sensitivity analysis conducted at low (-25%) and high (+25%); * Sensitivity analysis conducted 
at high (-10%) and low (-25%); AST: aspartate aminotransferase tes; ALT: alanine 
aminotransferase test; PFT: pulmonary lung function test; OGT: oral glucose tolerance test; 
PE: pulmonary exacerbations
  
1
0
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Table 26: Probabilities of medical events 
Variable Probability 
base case 
Probability 
low 
Probability 
high 
Base case  
 
Low  High ICER at 
low 
ICER at high 
Clinic visits 0.56 0.42 0.70 1,244.56 
 
933.42 1,555.70 94,905.16 
 
95,127.41 
 
Outpatient 
visits 
0.55 0.41 0.69 902.27 
 
672.57 1,131.89 94,934.25 
 
95,098.29 
 
Inpatient stays  0.28 0.21 0.35 1,189.764 
 
892.32 1,487.21 94,910.05 
 
95,122.51 
 
PE 0.31 0.24 0.38 15,191.71 
 
11,761.32 18,622.10 93,791.14 
 
96,241.42 
 
 
Sensitivity analysis conducted at low (-25%) and high (+25%); PE: pulmonary exacerbations 
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Figure 13: Tornado plot of one-way sensitivity analysis of cost effectiveness of 
lumacaftor/ivacaftor  
 
 
 
Sensitivity analysis conducted at low (-25%) and high (+25%); * Sensitivity analysis conducted 
at high (-10%) and low (-25%); AST: aspartate aminotransferase test; ALT: alanine 
aminotransferase test; PFT: pulmonary lung function test; OGT: oral glucose.  
The PTMPM cost of lumacaftor/ivacaftor was not affected by varying the cost of other variables 
and probabilities of occurrence of medical events. These results suggested that the baseline 
budget impact model was robust to changes in most of the input parameters except, drug cost, 
cost to treat and probability of pulmonary exacerbations.  
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Tables 27 and 28 present results of sensitivity analysis of standard therapy alone. Tables 29 and 
30 present results of sensitivity analysis post inclusion of lumacaftor/ivacaftor on the formulary 
with preexisting standard therapy. Figure 14 presents the tornado plot of one way-sensitivity 
analysis of budget impact of lumacaftor/ivacaftor. Increased (high) and decreased (low) input 
ranges were plotted to determine the effect of different variables on the PTMPM. The results 
suggest that even after varying the data input ranges, lumacaftor/ivacaftor therapy was stable to 
most of the variables except for the cost of drug and pulmonary exacerbation. Refer Appendices 
Table 37 for impact of variables on PTMPM cost.
Sensitivity analysis of standard therapy 
Table 27: Costs 
 
Variable Base case Low  High PTMPM at 
low 
PTMPM at 
high 
Drug costs 
Standard therapy 89,742.40 
 
67,306.80 
 
112,178.00 
 
6.7301 
 
5.6833 
 
 
Monitoring costs 
Sputum culture 633.6 475.2 
 
792 
 
6.2104 
 
6.2030 
 
PFT’S 73.04 54.78 91.3 6.20716 
 
6.2063 
 
Flu shot 24 18 30 6.2069 
 
6.2066 
 
Fat soluble 
vitamins 
408 306 510 6.2091 
 
6.2044 
 
OGT 34 25.5 42.5 6.2069 
 
6.2065 
 
Clinic visits 1,382.25 1,037.13 
 
1,728.56 
 
6.2148 
 
6.1987 
 
Outpatient visits 1,002.53 
 
751.89 1,253.16 
 
6.2126 
 
6.2009 
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Inpatient stays 1,321.96 991.47 1,652.45 
 
6.2144 
 
6.1990 
 
Cost to treat adverse events 
PE 19,112.14 14,334.11 
 
23,890.17 
 
6.3182 
 
6.0953 
 
 
Sensitivity analysis conducted at low (-25%) and high (+25%); PTMPM: per treated member 
per month; OGT: oral glucose tolerance test.
  
1
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Table 28: Probabilities of medical events 
 
Variable Probability 
Base case 
Probability 
low 
Probability 
high 
Base case Low  High PTMPM 
at 
low 
PTMPM 
at 
high 
Clinic visits 0.56 0.42 0.70 1,382.25 1,036.95 1,728.25 6.2148 
 
6.1987 
 
Outpatient 
visits 
0.55 0.41 0.69 1,002.53 
 
747.33 1,257.71 6.2127 
 
6.2008 
 
Inpatient 
stays 
0.28 0.21 0.35 1,321.96 
 
991.47 1,652.45 6.2144 
 
6.1990 
 
PE 0.39 0.30 0.48 19,112.14 14,701.66 23,522.65 6.3096 
 
6.1038 
 
 
Sensitivity analysis conducted at low (-25%) and high (+25%); PTMPM: per treated member per month; PE: pulmonary 
exacerbations 
 
 
 
 
 
 
 114 
Sensitivity analysis of lumacaftor/ivacaftor post inclusion of lumacaftor/ivacaftor on the 
formulary with preexisting standard therapy 
 
Table 29: Cost of medications 
 
Variable 
 
Base case Low  High PTMPM at 
low 
PTMPM at 
high 
Drug costs 
Lumacaftor/ivacaftor 359,915.17 
 
269,936.38 449,893.96 4.1076 
 
8.3059 
 
Monitoring costs 
AST 56 42 70 6.2064 6.2070 
ALT 56 42 70 6.2064 
 
6.2070 
 
Bilirubin 52 39 65 6.2064 
 
6.2070 
 
Sputum culture 633.6 475.2 792 
 
6.2030 
 
6.2104 
 
PFT’S 73.04 54.78 91.3 6.2063 
 
6.2071 
 
Flu shot 24 18 30 6.2066 
 
6.2069 
 
Fat soluble vitamins 408 306 510 6.2043 
 
6.2091 
 
OGT 34 25.5 42.5 6.2065 
 
6.2069 
 
Clinic visits* 1,244.56 933.42 1,244.56 6.1995 
 
6.2067 
 
Outpatient visits* 902.27 676.70 902.27 6.2015 
 
6.2067 
 
Inpatient stays * 1,189.76 892.32 1,189.76 6.1998 
 
6.2067 
 
Cost to treat adverse events 
PE 15,191.71 
 
11,393.79 18,989.63 6.1181 
 
6.2953 
 
 
Sensitivity analysis conducted at low (-25%) and high (+25%), PTMPM: per treated member per 
month; * Sensitivity analysis conducted at high (-10%) and low (-25%); AST: aspartate 
aminotransferase test; ALT: alanine aminotransferase test; PFT: pulmonary lung function test; 
OGT: oral glucose tolerance test; PE: pulmonary exacerbations 
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Table 30: Probabilities of medical events 
 
Variable Probability 
Base case 
Probability 
low 
Probability 
high 
Base case Low  High PTMPM 
at 
low 
PTMPM 
at 
high 
Clinic visits 0.56 0.42 0.70 1,244.56 
 
933.42 1,555.70 6.1995 
 
6.2140 
 
Outpatient visits 0.55 0.41 0.69 902.27 
 
672.57 1,131.89 6.2014 
 
6.2121 
 
Inpatient stays 0.28 0.21 0.35 1,189.76 
 
892.32 1,487.21 6.1998 
 
6.2137 
 
PE 0.31 0.23 0.38 15,191.71 
 
11,271.27 18,622.10 6.1153 
 
6.2868 
 
 
Sensitivity analysis conducted at low (-25%) and high (+25%); PTMPM: per treated member per month; PE: pulmonary 
exacerbations 
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Figure 14: Tornado plot of one-way sensitivity analysis of budget impact of 
lumacaftor/ivacaftor  
 
 
Sensitivity analysis conducted at low (-25%) and high (+25%); * Sensitivity analysis conducted 
at high (-10%) and low (-25%); AST: aspartate aminotransferase test; ALT: alanine 
aminotransferase test; PFT: pulmonary lung function test; OGT: oral glucose tolerance test; 
prob: probability.
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CHAPTER FIVE: DISCUSSION 
 
This chapter provides the study findings, draws conclusions, presents study implications, lists 
limitations of the study and provides recommendations for future research.  
 
PART 1: BURDEN OF ILLNESS IN CYSTIC FIBROSIS 
CF is a rare disease with a prevalence of 0.0089% in the US population. However, the economic 
burden is substantial. Very few studies have reported burden of illness and CF healthcare 
resource utilization. Most of the studies in the literature were conducted in early 2000s. 29,30 The 
results indicate that CF-related medications and hospitalizations account for majority of the total 
CF care costs. Given the lack of recent data on the economic burden of the disease due to 
utilization of various medical services such as outpatient visits, emergency visits, office visits, 
home health, prescription medications and hospital inpatient stays across the time, the present 
burden of illness study was conceptualized to provide estimates of OOP and total economic 
impact of CF. The burden of illness studies not only provide in depth estimates of utilization, 
OOP and cumulative expenditures of various medical services, but quantify the economic impact 
of CF on the entire US population.   The objective of this part of the study was to estimate the 
burden of illness due to CF using MEPS database using weighted estimates from a nationally 
representative sample. 
Specific research questions were to describe the demographics, clinical characteristics, resource 
utilization of CF patients and to estimate the incremental cost burden in CF patients over control 
population.  
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Conclusion for part 1  
Since CF is a rare condition, data was extracted from multiple years of MEPS. To check the 
representativeness of the study sample, the demographics were compared to those identified in a 
2015 Patient Registry Report. The analysis of 2010-2014 MEPS data identified a total of 109 CF 
cases, out of which 78 (71.5%) were adults (≥18 years). However, the proportion of adults in the 
sample was higher than that of CF population reported in Patient Registry which ranged from 
38.7% to 51.6% from 2000 to 2015. The sample identified from the present study was much 
older than that reported in the Patient Registry (Refer Appendices Table 32). The most common 
gender and ethnicities affected by the disease were females, Whites followed by Hispanics. This 
finding was contrary to CF Patient Registry Report as it reported majority of the CF patients to 
be males (51.6%). A study by Harness-Brumley et al., (2014) presented an overview of gender 
differences in outcomes of patients with CF. Using a retrospective cohort analysis of US CF 
Foundation Patient Registry over a 13-year period, the authors reported that males were more 
likely to be affected by CF than females. 134 However, unlike other X-linked disease genetic 
conditions, CF occurs equally in men and women as it is an autosomal recessive disorder and 
hence the genetic mutation for CF is not impacted by gender. 135 The severity of symptoms 
related to CF, however, does vary in men and women. According to an argument made by CF 
researchers, women with CF have more difficulty in growing and face more lung-related 
problems compared to men because of the early-onset of lung infections and difficulty to 
maintain healthy weight after puberty. 135 Due to these more severe symptoms, women with CF 
have shorter life expectancies than men. It is estimated that men with CF live four to five years 
longer than women with CF. Moreover, under the age of 20, girls have a 60% higher chance of 
dying due to CF complications compared to males. Thus, the prevalence of male adults with CF 
 119 
is greater than the prevalence of female adults with CF. 135 A study conducted by Chatterjee et 
al., utilizing 2003-2013 data from National Inpatient Sample (NIS) of HealthCare Cost and 
Utilization Project (HCUP) reported that the percentage of hospital discharges were higher in 
females than in males indicating severity of disease, worsening of symptoms, and need for 
hospitalization in women. 42 This comparison of study sample with real world data highlights 
challenges of using a public health care database for analysis. But, it is important to note that 
Patient Registry does not provide expenditure information. The nature of data collection also 
plays an important role as Patient Registry data is provided by CF foundation by surveying a 
sample population referred by physicians whereas public healthcare databases avoid selection 
bias by surveying a random and a representative sample. Hence, it is still possible to use public 
healthcare databases to conduct analysis using a right methodology which was possible through 
this study. 
Only a minor proportion (around 1%) of the sample in the present study was uninsured 
indicating the importance for insurance to cover and reimburse high expenses due to CF care and 
economic burden of the disease on patients. It was also observed that, majority of the patient 
population were covered under private insurances. This finding was similar to that of Patient 
Registry Report. In 2015, 59.5% of total CF patients reported in the Registry had private 
insurance, 9.6% had Medicare (covered around 20 to 40 percent of adults aged 30 to 65 years. 
Individuals under age 65 who received Medicare met the federal criteria for disability), 44.8% 
had Medicaid (including 57% of children under age 10 years), 2.4% had Tricare or other military 
heath plan and only 0.7% had no insurance. The majority of people with CF who were age 18 to 
25 years received health insurance through their parent’s plan. As insurance coverage reflected 
coverage at any point during the year, these categories were not mutually exclusive. 21 
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The most common comorbid conditions among adults identified from the present study were 
high blood pressure, high cholesterol, and arthritis. A study using 2012 Kid’s Inpatient Database 
(N=10,258 CF-related hospital discharges) and 2012 NIS (N=3,142 CF-related hospital 
discharges) of HCUP data reported chronic obstructive pulmonary disease (30%), weight loss 
and uncomplicated diabetes (20%), depression and electrolyte imbalance (8%) as frequently 
occurring comorbidities among children (<18 years). Among adults (≥ 18 years), the most 
common comorbid conditions were uncomplicated diabetes (31%), chronic obstructive 
pulmonary disease (30%), weight loss (26%), fluid and electrolyte disorder (16%) and 
depression (15%). 136,137 However, recent studies and CF treatment guidelines emphasized the 
need to screen and treat for depression and anxiety, which are the most common comorbid 
conditions occurring with CF resulting in poor quality of life. Evidence also suggests that 
depression has negative effects on treatment adherence, family functioning, and health-related 
quality of life. Since, MEPS data captured information related to specific comorbid conditions, it 
was not possible to identify the prevalence of these comorbidities, which are considered 
significant risk factors in the management of CF. 138 
Analyses of the resource utilization in CF indicated that medical event expenditures were highest 
for prescription medications followed by office visits. Total unweighted cumulative expenditure 
for all the medical events across five years was $455,539.70 of which, total unweighted OOP 
cost was $31,828.58. The estimated average unweighted cumulative expenditure was $770 for 
office visits, $1,882 for prescription medications, $3,269 for outpatient visits, $13,031 for 
inpatient stays and $566 for emergency visits. A study conducted by O’Sullivan et al., utilizing 
claims data from 2002 to 2006 (N=1,064) to assess CF healthcare resource expenditure reported 
mean cumulative expenditure for office visits as $625, prescription medications as $20,054, 
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outpatient visits as $2,153, inpatient stays as $22,102 and emergency visits as $22. 31 Another 
study by Sujit et al., analyzing commercial MarketScan claims database from 2005-2008 
reported average annual cost due to prescription medications as $15,839, outpatient visits as 
$8,397, inpatient stays as $8,885 and emergency room visits as $185. 41 There was a significant 
difference in the prescription medications cost identified in the present study compared to these 
published studies 22, 54 The difference could be attributable to the type of data as MEPS is a self-
reported data, which is subjected to recall bias and result in over- or under-estimation of 
households expenditure, whereas the two published studies was based on retrospective analysis 
of claims databases which are more accurate compared to self-reported data as they are based on 
actual resource utilization data. Secondly, the prescription medication costs may vary with the 
type of existing comorbid conditions. MEPS data is limited to fewer comorbid conditions, which 
may have accounted for lesser prescription medication cost. Third, the study conducted by 
O’Sullivan et al., (2011) considered retrospective data of patients with pulmonary infections 
(severe lung disease) whereas Sujit et al., (2012) study considered data of patients pre- and post- 
pseudomonas aeruginosa infection which might be accountable higher costs due to prescription 
medications.31, 41 
Using estimates from the present study, the national annual direct medical expenditure associated 
with CF care in the US was estimated at $6,691,134,764 across five years of which OOP 
estimates were $615,098,138. Based on these estimates, the average annual cost of CF care in the 
US was around $44,600 which is around $47,276 in 2016 dollars. The study conducted by 
O’Sullivan et al., reported a total annual CF-related healthcare costs of $29,000 (in 2006 dollars) 
which is around $40,600 in 2016 dollars and Sujit et al., reported the cost at $33,305 (in 2006 
dollars) which is around $46,627 in 2016 dollars. The expenditure identified from our study was 
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similar to the other studies when inflated to 2016. But, the difference in expenditure at different 
time points may be due to increasing healthcare costs with advancement of technology and 
increased access to resources and also because of the self-reported nature of MEPS data. 41  
Total cumulative expenditure across five years in the MEPS data was highest for prescription 
medications followed by inpatient stays, whereas total OOP expenditure was highest for 
prescription medications followed by office visits. This could be due to the fact that, the inpatient 
stays are generally covered by insurance making the OOP expenditure minimal. Among the 
prescription medications, drugs used to treat diabetes, metabolic problems, pancreatic 
insufficiency, respiratory agents and immune suppressants were most commonly utilized as they 
are mostly used to treat CF-related complications. Highest cumulative expenditure was 
accounted by antibiotics, respiratory agents, pancreatic agents and immunological agents. 
The results of incremental cost burden analysis, after adjusting for covariates, reported that the 
mean cumulative expenditure was $13,990 in children with CF and $3,231.27 in children without 
CF whereas $16,975.80 in adults with CF it was and $8,859.87 in adults without CF. The 
findings of the present study indicate that there was a significant cost burden of CF on cases 
compared to controls. This cost was still an underestimate of the true cost because secondary 
diagnosis and indirect costs associated with CF were not included in the analysis. These results 
were different from a 2011 study utilizing 2004-2008 US administrative claims data which 
reported an annual healthcare costs of CF to be $30,000, $57,000, and $215,000 for patients with 
mild, moderate, and severe disease, respectively. The study also reported highest expenditure 
among children of age group 10-14 years with CF severe disease with $343,900. Adults of age 
group 40-44 years with mild CF disease had an expenditure of $15,600. 32 The differences in the 
study estimates could be due to latest advances in the treatment including advanced screening 
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techniques, maintenance therapy, novel CFTR modulator therapies, improved resources (>110 
accredited CF care centers nationwide) which account for high treatment costs in CF. 139 Another 
reason attributable to the differences in the study findings is the inability to assess disease 
severity in MEPS database. The estimates obtained are representative of entire CF cases without 
any differentiation of severity in different age groups whereas previous study findings were 
based on disease severity among children and adults.  
 
 
PART 2: PHARMACOECONOMIC EVALUATION OF 
LUMACAFTOR/IVACAFTOR  
 
CFTR modulator therapies have revolutionized the treatment paradigm for CF patients. With 
changing healthcare policies and reimbursement patterns, managing healthcare costs is critical. 
Insurance companies are increasingly demanding for health economic evidence to support their 
formulary decisions. The CFTR modulator therapies have good clinical effectiveness including 
increase in % FEV1 values, improvement in revised CF questionnaire (CFQR) scores, improved 
body mass index (BMI) and reduction in pulmonary exacerbation events. These regimens, 
therefore, have the potential to increase median life expectancy and delay the occurrence of 
death. However, the annual cost of ivacaftor is estimated to be over $300,000 and 
lumacaftor/ivacaftor is estimated to be around $270,000. Ivacaftor targets G551D CFTR 
mutation whose prevalence is just around 4% in total CF population whereas 
lumacaftor/ivacaftor targets F508del mutation, which has a prevalence of around 90% of total CF 
population and around 45% with respect to homozygous F508del mutation. Hence, the market as 
well as coverage for lumacaftor/ivacaftor is bigger compared to ivacaftor alone. Ivacaftor was 
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initially approved in 2012 and has been shown to be cost effective based on published literature. 
33,34 Lumacaftor/ivacaftor was approved in 2015 but was rejected by the Health Technology 
Assessments like UK’s NICE and Ireland’s NCPE, stating poor cost effectiveness and significant 
budget impact. 35,36 Little is known if lumacaftor/ivacaftor is affordable and cost effective in the 
US healthcare system and there is no published economic evaluations reported. Thus, to 
understand its value for money in the US healthcare system, an economic evaluation of 
lumacaftor/ivacaftor is warranted. Specific research questions were to develop a cost 
effectiveness and a budget impact model of lumacaftor/ivacaftor using MS Excel® to understand 
the overall effectiveness and affordability of the drug from a payer perspective. 
 
Conclusion for part 2 
The CEA results reported that the cost of therapy per patient due to lumacaftor/ivacaftor was 
$379,780.11 with an estimated ICER of $95,016.28 per FEV1% predicted. There are no 
published studies which assessed cost effectiveness of lumacaftor/ivacaftor in the US. However, 
a few international studies have been reported that assessed the ICER of lumacaftor/ivacaftor. In 
2015, the NCPE of Ireland conducted the HTA of lumacaftor/ivacaftor and estimated an 
incremental QALY gain of 2.45 with an incremental cost of €903,947 (US $1,017,103.08 in 
2016 dollars) resulting in an ICER of €369,141/QALY (US $415,350.0 in 2016 dollars). The 
model effects were mainly driven by mortality and the incremental life years gained were 
estimated to be 2.47, resulting from a median increase in overall survival of 7.4 years. A one-
way sensitivity analysis highlighted that the cost of lumacaftor/ivacaftor impacted the ICER in 
the analysis. The study concluded that lumacaftor/ivacaftor was not cost effective for the 
treatment of CF in patients 12 years and older who were homozygous for the F508del mutation 
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in the CFTR gene and therefore, it was not recommended for reimbursement in Ireland. 36 The 
major differences between this study and NCPE were the source of data and choice of clinical 
end points. The NCPE HTA was sponsored and the model inputs were provided by the 
manufacturer of lumacaftor/ivacaftor whereas this study was conducted as a part of academic 
research and model inputs were taken from public sources like Physician Fee Schedule of 
Centers for Medicare and Medicaid (CMS), Redbook or published literature. The NCPE HTA 
used QALY as clinical outcome whereas this study utilized FEV1% predicted. QALY is 
preferred in a cost utility analysis (CUA) or a CEA when utilities for each transition state and 
long term clinical effectiveness is known. But this study used a more appropriate measure i.e. 
FEV1% predicted because the long term clinical effectiveness and the transition states possible 
after treatment initiation were not known at the time this study was conducted. 
 In 2016, the NICE in the UK issued a draft guidance against recommending 
lumacaftor/ivacaftor for treating CF. The guidance reported an annual treatment cost of €104,000 
(US $118,560 in 2016 dollars) per patient due to lumacaftor/ivacaftor. In 2016, the Scottish 
Medicines Consortium also issued a guidance which did not recommend lumacaftor/ivacaftor. 35  
In the US, the CEA threshold, traditionally ranged from US $50,000 per QALY gained. This 
threshold has recently been updated to $100,000 or $150,000 per QALY gained to account for 
the increased willingness to pay which was $50,000 to $100,000 per QALY 2 decades ago. 140,141 
Although the ICER of lumacaftor/ivacaftor calculated in the present study was above the initial 
threshold of US $50,000, it is still within the debatable range of formulary consideration given 
the nature of the disease. Ivacaftor and lumacaftor/ivacaftor represent a paradigm shift in the 
treatment of CF and clinical trial data have provided evidence of better outcomes in this 
population. These CFTR modulator therapies are the only available disease modifying therapies 
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which have the potential to increase the median life expectancy in CF patients. The current 
median predicted survival age is close to 40, which is a dramatic improvement from the 1950’s, 
when a child with CF rarely lived long enough to attend elementary school. 3 The possibility of 
increased life expectancy with newer treatments may be a justification for accepting the high 
ICER thresholds. The uncertainty analyses also suggest that this conclusion is relatively modest 
to the model assumptions over a large range of inputs. However, the ICER of 
lumacaftor/ivacaftor was most likely to be influenced by change in cost of lumacaftor/ivacaftor, 
standard therapy and cost to treat pulmonary exacerbations.  
The results of BIA reported an annual cost of $113,734.52 due to standard therapy and 
$379,780.11 after the inclusion of lumacaftor/ivacaftor on the formulary with existing standard 
therapy. Hence, the annual total budget impact due to inclusion of the drug on the formulary was 
$266,045.59 resulting in a PMPM cost of $0.022 (based on a one million hypothetical plan 
population) and a PTMPM cost of $6.2067 based on a target population of 3,572. One-way 
sensitivity analysis showed that the PTMPM cost of lumacaftor/ivacaftor was most likely to be 
influenced by change in cost of lumacaftor/ivacaftor, cost to treat pulmonary exacerbations and 
probability of occurrence of pulmonary exacerbations. The PTMPM cost of lumacaftor/ivacaftor 
was not affected by varying the cost of other variables and probabilities of occurrence of medical 
events. These results suggested that the baseline budget impact model was robust to changes in 
most of the input parameters except drug cost, cost to treat, and probability of pulmonary 
exacerbations. There were no previous studies that assessed the affordability of 
lumacaftor/ivacaftor in the US. However, the BIA study in Ireland, assessed an annual cost of 
lumacaftor/ivacaftor at €158,306 (US $178,122.74 in 2016 dollars) or €159,050 (US 
$178,959.87 in 2016 dollars) including the patient care fee for a target population of 505. The 
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manufacturer (Vertex Pharmaceuticals) estimated the 5-year gross budget impact of 
lumacaftor/ivacaftor at €352,281,736 (US $396,380,363.71 in 2016 dollars). The study estimate 
of the 5-year budget impact was €391,892,681 (US $440,949,806.80 in 2016 dollars). In 
conclusion, they reported that the budget impact due to lumacaftor/ivacaftor was significantly 
higher. 36 The Institute for Clinical and Economic Review published an estimated annual 
potential budget impact threshold of $904 million for each new molecular entity for the year 
2016. 142 But, decisions regarding BIA’s are made purely by the payers and, assessing whether a 
PMPM and a PTMPM cost falls within a US national threshold is difficult. However, based on 
our results, a 5-year gross budget impact of lumacaftor/ivacaftor was estimated at a PMPM cost 
of $1,320,000 and a PTMPM cost of $1,330,219.94.  
 
IMPLICATIONS OF STUDY FINDINGS 
The present study was undertaken to assess the burden of illness due to CF and to evaluate the 
overall effectiveness and affordability of lumacaftor/ivacaftor in the treatment of CF. The present 
study improved upon some previous national estimates of CF and estimated the major domains 
of healthcare utilization. The study findings are important for several reasons. Increased 
coverage for uninsured population in healthcare system coupled with an increase in aging 
population and increase in the prevalence of CF could potentially result in increased healthcare 
recourse utilization. Thus, there is a need to introduce strategies at the primary care level, which 
will not only decrease the burden of CF on the healthcare system but also reduce the overall 
costs associated with the disease. Strategies like disease screening and increased health literacy 
will be helpful in decreasing the overall disease burden by early detection and appropriate 
treatment in rare disease like CF and mucopolysaccharidosis. 143-145 As discussed earlier, 
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screening techniques such as the use of new born screening, prenatal testing and genetic testing 
can be helpful in controlling the increase in disease severity in a timely manner. Currently, there 
are increased cases of CF among individuals less than 18 years of age. Hence, there is a need to 
implement programs like health awareness among children about the risk factors for CF. A study 
on CF patient experiences reported lack of time, forgetfulness and too many medications as 
barriers to treatment. More education, avoiding hospitalization were identified as motivators of 
treatment. 145 For reducing resource utilization among elderly individuals suffering from chronic 
conditions like CF, improved adherence to treatment with home health model could be 
implemented, that will help in decreasing the emergency room and inpatient facility expenses, 
and would also provide better care to the individuals. 145 
 
Implications to the payers 
Although the ICER of lumacaftor/ivacaftor is still debatable for reimbursements, it has the 
potential to delay disease progression and offset costs due to events like lung transplantation 
which occur at later stages of CF disease thus leading to life time cost savings in patients with 
homozygous F508 del mutation. Managed care organizations may not see short-term cost 
savings by covering lumacaftor/ivacaftor, however, the long-term benefit to payers and patients 
must be considered before making formulary and coverage decisions. This study will help the 
managed care organizations and payers such as Medicare/Medicaid in understanding the 
increased burden of CF. The systematic assessment of CF and their associated incremental costs 
to the society is essential in increasing the awareness of decision makers to implement 
intervention strategies that are effective in lowering the disease incidence and in reducing the 
overall cost of disease management. The implementation of disease management programs like 
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home health, screening for early disease detection and the use of cost-effective treatments will 
help payers control the rising costs of CF, including the cost of CF-related prescription 
medications. 
 
Implications to the prescribers 
The current treatment guidelines indicate the use of lumacaftor/ivacaftor for CF patients aged 6 
years and above with homozygous F508 del mutation of CFTR. While the regimen is shown to 
be clinically effective resulting in positive absolute change in FEV1% predicted values from 
baseline values, the results of published clinical trials also reported high rates of treatment 
discontinuation (4.6%) compared to placebo (1.6%) attributable to adverse events (pulmonary 
exacerbations). Therefore, prescribers should value treatment guidelines along with their own 
clinical judgment while making treatment decisions for their patients.  
 
Implications to patients 
The overall discontinuation rates were higher in lumacaftor/ivacaftor group compared to placebo 
group and of the patients that discontinued treatment, the primary reason reported were adverse 
events which was pulmonary exacerbations predominantly. The current formulary matrix 
indicates lumacaftor/ivacaftor to be a specialty tier with many commercial insurance companies 
and pharmacy business managers not including the drug on the formulary (Refer Table 31). Few 
payers cover lumacaftor/ivacaftor for a six month or one-year time frame with a prior 
authorization. 146-148 
Only 35-40% of CF population are covered under Medicaid and lumacaftor/ivacaftor is covered 
under Medicare Part D with a typical copay range of $6,014 - $24,057. 149 
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Table 31: Market access matrix of lumacaftor/ivacaftor 
 
Payer Lumacaftor/ivacaftor* 
Medicare Part D 
UHC Specialty tier (unique and/or very high cost drug) 
Humana Specialty tier 
Cigna Not covered 
Commercial 
UHC Not covered 
Anthem Not covered 
Aetna Specialty drug (very high cost drug) 
PBM 
Express scripts Not covered 
Optum Not covered 
CVS caremark Specialty drug and it requires prior authorization 
 
Top 3 Medicare beneficiaries, commercial insurance companies and pharmacy business 
managements considered (based on 2017 coverage policies). 
*Redbook WAC of lumacaftor/ivacaftor, WAC last updated on July 1st, 2017. 
30 days: $19,923.08 (2015), annual: $270,172.77 (inflated to 2016)  
30 days: $20,919.23 (2017, annual: $272,577.56 (2017) 
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As the prevalence of CF is more in children and young adults, Medicare might not protect a large 
proportion of CF patients except those who are 65 years and above or with end stage renal 
disease and disabilities. However with an average monthly copay of $1,252.94, in those who are 
covered under Medicare, patients reach the donut hole (coverage gap of $3,310 in 2016) in the 
third month which will make the patients responsible for major part of their prescription 
medications costs. Once, the patients reach post donut hole (also called catastrophic coverage, 
$4,850 in 2016) stage, Medicare will cover most of the drug costs. 37 
Another major implication to patients is that the manufacturer cannot provide direct patient 
assistance program when they are covered under Medicare part D. Hence, the manufacturers 
provide indirect assistance by donating to disease foundations. In 2015, 30.9% of a total 28,983 
CF patient population participated in patient assistance program provided by CF Foundation. 21 
However, the Department of Health and Human Services (HHS) keeps a check on these patient 
assistance programs to restrict indirect incentivization of patients by manufacturers for using 
their products. Patients should consider these implications while discussing concerns with their 
payers and seek provider’s regular help for side effects monitoring, education or counseling to 
understand their regimen, possible side effects due to lumacaftor/ivacaftor and make decisions 
accordingly. 
 
LIMITATIONS OF THE STUDY 
Both parts of the study have some limitations and these are discussed in the following section. 
These limitations need to be considered before deriving inferences from the reported results. 
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Limitations of burden of illness study 
The limitations associated with any retrospective database are applicable to this study. Some of 
these limitations include retrospective nature of the data, whose quality may be limited by 
systematic or recorder bias, data coding-recoding errors, incomplete data, data quality, and 
confounding factors. MEPS database provides self-reported information collected from a sample 
of families and individuals in selected communities across the US, drawn from a nationally 
representative subsample of households that participated in the prior year's National Health 
Interview Survey (conducted by the National Center for Health Statistics).  Individuals with CF 
were identified based on the medical conditions they reported. This could potentially over-
estimate or under-estimate disease prevalence. Similarly, there was a possibility of over-
estimating or under estimating the expenditures.  Also, self-reported data can possibly introduce 
recall bias as the data is based on recollecting the time when the event occurred. Second, the 
analysis only included direct medical expenses. Indirect cost such as loss of productivity 
transportation expenses, lost wages among family members, caregiver burden, were not included 
in the estimation of the overall expenditures calculation. Third, the study included only patients 
with the primary diagnosis of CF, since MEPS does not provide secondary diagnosis. Fourth, 
MEPS does not provide any data on disease severity and disease history. These are important 
covariates in predicting the total healthcare expenditures. Since, the CF sample identified from 
MEPS database reported other existing comorbid conditions, it was not possible to identify 
disease severity in CF cases based on expenditures, frequency of medical events. Fifth, MEPS 
captures information on fewer comorbid conditions such as cardiovascular diseases, cancer, 
diabetes, arthritis, and asthma. In children, the only comorbidity that was captured was asthma. 
Information related to other important comorbidities associated with CF such as gastro intestinal 
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disorders, pancreatic disorders, problems related to fertility and reproduction were not reported. 
Finally, as lumacaftor/ivacaftor was approved in 2015 by US FDA and the data used for the 
present study was from 2010-2014, it was not possible to capture information about the impact of 
CFTR modulator therapies on healthcare resource utilization including prescription medications. 
 
 
Limitations of the pharmacoeconomic evaluation study 
Although, the present study is one of the first studies to conduct pharmacoeconomic evaluation 
of lumacaftor/ivacaftor, there were some limitations. First, there were no existing comparator 
drugs as lumacaftor/ivacaftor is indicated to CF patients with homozygous F508 del mutations. 
Hence, the evaluations involved comparisons against placebo or standard therapy. Second, the 
standard therapy available in the market consisted of maintenance therapies and the present study 
was restricted to the use of standard therapy consisting of pulmonary medications mentioned in 
the published clinical trials of lumacaftor/ivacaftor which did not include drugs used to treat CF 
complications. 
Third, cost inputs and probabilities of events used in the models were obtained from multiple 
sources including Medicare reimbursements, healthcare blue book and published literature. 
Although one-way sensitivity analyses were conducted to vary input ranges, the result estimates 
of any modeling study need to be treated with some degree of caution. Fourth, it was not possible 
to develop dynamic models consisting of transition state probabilities as the drug was not 
approved until 2015 and long-term data were unavailable. Lastly, the analyses involved certain 
assumptions such as 100% adherence to treatment and unchanged prevalence of CF in 2015 and 
2016 which may differ from real world scenarios. 
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RECOMMENDATIONS FOR FUTURE RESEARCH 
All the evidence generated from the present study indicate that there is a significant economic 
burden due to CF and lumacaftor/ivacaftor has reasonable value for money. Although the present 
study identified varied prevalence of CF among ethnicities, there are no studies that explain the 
reasons behind this disparity. Future studies should explore reasons behind disparities in 
prevalence associated with demographic characteristics. There is also a need to understand cost 
effectiveness and affordability of the drug over a lifetime period using dynamic Markov models 
in the US. Since the data inputs used in this study were from published clinical trials and 
literature, real-world drug effectiveness should be assessed using data from large- claims 
databases that have a robust sample size. Future research should also capture information on 
indirect costs using societal perspective to get more comprehensive picture of the overall 
effectiveness of the drug, especially on caregivers. Another major area for future research would 
be to include humanistic outcomes by conducting a qualitative research like focus groups, 
interviews with CF patients to understand their health status, quality of life, satisfaction, barriers 
to treatment and other important factors.  
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APPENDICES 
Table 32: Demographics of CF sample identified from MEPS database and Patient 
Registry report  
 
Individual 
characteristics 
Cases (N= 109) 
(Children= 31) 
Controls 
(N= 85,521) 
(Children= 24,650) 
Patient Registry 
(N= 28,983) 
(Children= 14,027) 
Age  Mean: 38.2 ± 25.32 
years  
Median: 39 years 
Range: 0-82 years 
Mean: 35.75 ± 23.31years 
Median: 34 years  
Range: 0- 85 years 
Mean: 20.9 years 
Median: 18.6 years 
 
Gender Male: 39 (35.77%) 
Female: 70 (64.22%) 
Male: 39,433 (46.11%) 
Female: 46,088 (53.89%) 
Males: 
14,955(51.6%) 
Female: 
14,027(48.4%) 
Race White: 71 (65.14%) 
Black: 16 (14.68%)  
Hispanic: 17 (15.60%) 
Asian: 2 (1.83%) 
Others: 3 (2.75%) 
White: 244,96 (28.64%)  
Black: 11,903 (13.92%) 
Hispanic: 16,932 
(19.80%) 
Asian: 3,727 (4.35%) 
Others: 1,971(2.30%) 
Missing: 26,492 (30.98%) 
White: 27,186 
(93.8%) * 
Black: 1,333 (4.6%) * 
Hispanic: 2,463 
(8.5%) * 
Others: 956 (3.3%) * 
 
 
Household 
income 
Mean: $59,903.78  
(95% CI: $49,467.19, 
$70,340.37) 
Mean: $59,549.47  
(95% C.I: 59,171.39, 
59,927.55) 
 
Marital status  Married: 36 (32.03%) 
Not married: 44 
(40.36%) 
Underage (<16 years): 
29 (26.60%) 
Married: 8,977 (10.50%) 
Not married: 10,360 
(12.11%) 
Underage (<16 years): 
5,655 (6.61%) 
Missing: 60,529 (70.77%) 
Married: 12,028 
(41.5%) 
Not married: 16,955 
(58.5%)  
Insurance 
Coverage 
Any private: 73 
(66.97%) 
Public Only: 35 
(32.11%) 
Uninsured: 1 (0.92%) 
Any private: 46,086 
(53.89%) 
Public: 28,671 (33.52%) 
Uninsured: 10,764 
(12.59%) 
Any private: 17,245 
(59.5%) * 
Public: (56.8%) * 
Uninsured: 202 
(0.7%) 
* 
Not mutually exclusive
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Table 33: Resource utilization in cystic fibrosis cases from 2010-2014 
 
Medical 
event 
Type of 
expenditure 
Unweighted ($) Weighted ($) 
Office 
 visit 
 Mean (95% CI)  Total  Mean (95% CI)  Standard 
error 
of mean 
Total  
2010 Cumulative 270.65 (132.28-409.01) 3,518.45 236.00 (104.79-367.21) 60.22 46,727,279 
 OOP 26.76 (0-60.56) 348.00 20.20 (0-46.02) 12.03 3,999,927 
2011 Cumulative 750.63 (0-1,683.13) 9,007.65 866.90 (0-2,215.14) 596.00 96,042,725 
 OOP 97.68 (0-203.58) 1,172.21 64.39 (0-137.64) 32.38 7,134,509 
2012 Cumulative 698.58 (142.64-1,254.53) 16,766.06 615.66 (137.91-1,093.42) 230.94 208,612,877 
 OOP 54.29 (19.36-89.23) 1,303.17 54.36 (25.08-83.63) 14.15 18,419,478 
2013 Cumulative 387.37 (188.77-585.97) 8,134.89 354.30 (180.27-528.33) 83.42 77,593,347 
 OOP 76.0 (0-154.56) 1,596.16 79.49 (4.86-154.12) 35.77 17,409,519 
2014 Cumulative 1,992.26 (0-4,441.19) 27,891.63 2,561.69 (0-6,608.70) 1,873.29 381,228,802 
 OOP 213.58 (0-445.55) 2,990.17 393.29 (73.30-713.28) 148.11 58,529,799 
2010-2014 Cumulative 769.53 (342.21-1,196.85) 65,410.35 777.49 (194.80-1,360.18) 292.90 812,971,988 
 OOP 87.30 (43.25-131.33) 7,419.71 101.17 (39.38-162.97) 31.06 105,795,071 
Home health       
2010 Cumulative 7,800 7,800 7,800 0 91,567,718 
 OOP 0 0 0 0 0 
2013 Cumulative 0 0 0 0 0 
 OOP 0 0 0 0 0 
2014 Cumulative 4,825 (0-18,306.28) 9,650.00 5,673.27 (809.36-10,537.18) 382.79 281,645,861 
 OOP 49.0 (0-671.60) 98.0 68.75 (0-160.00) 28.67 4,377,427 
2010-2014 Cumulative 4,362.50 (0-9,681.97) 17,450.00 5,861.76 (4,221.79-
7,501.73) 
515.31 373,213,579 
 OOP 24.50 (0-102.46) 98.0 68.75 (0-160.00) 28.67 4,377,427 
 
 
Prescription 
medications 
      
2010 Cumulative 239.15 (9.12-469.17) 1,674.03 234.76 (56.76-412.76) 72.75 23,321,143 
 OOP 39.29 (0-84.19) 275.03 49.26 (0-101.58) 21.38 4,893,934 
2011 Cumulative 272.00 (0-589.52) 4,080.14 235.35 (0-512.42) 128.25 49,471,759 
 OOP 45.66 (3.80-87.53) 684.93 49.93 (12.25-87.62) 17.45 10,496,571 
  
1
5
8
 
2012 Cumulative 1,753.14 (0-3,566.72) 38,569.02 1,587.35 (0-3,994.60) 1,157.55 589,327,708 
 OOP 401.99 (0-1,079.77) 8,843.69 550.36 (0-1,550.89) 481.11 204,329,474 
2013 Cumulative 2,323.87 (0-6,091.51) 39,505.82 1,728.50 (0-4,439.82) 1,278.98 369,990,095 
 OOP 197.80 (0-489.56) 3,362.63 150.10 (0-357.42) 97.80 32,129,508 
2014 Cumulative 3,516.06 (0-7,996.85) 66,805.19 4,996.49 (0-12,183.55) 3,420.91 1,352,899,495 
 OOP 271.70 (0-658.58) 5,162.38 669.38 (0-1,751.49) 515.07 181,248,970 
2010-2014 Cumulative 1,882.93 (538.49-
3,227.37) 
150,634.20 2,046.10 (143.38-3,948.82) 955.73 2,385,010,201 
 OOP 229.11(23.58-434.64) 18,328.66 371.56 (0-767.00) 198.63 433,098,457 
Inpatient 
stays 
      
2010 Cumulative 2,138.76 2,138.76 2,138.76 0 22,279,789 
 For facility 1,951.95 1,951.95 1,951.95 0 20,333,761 
 For doctor 186.81 186.81 186.81 0 1,946,028 
 OOP 177.37 177.37 177.37 0 1,847,690 
 For facility 140.0 140.0 140.0 0 1,458,401 
 For doctor 37.37 37.37 37.37 0 389,289 
2011 Cumulative 7,261.97 (0-45,359.80) 14,523.93 10,260 0 90,993,224 
 For facility 6,572.33 (0-35,907.53) 13,144.66 8,881.06 0 78,761,237 
 For doctor 689.63 (0-9,452.28) 1,379.27 1,379.27 0 12,231,987 
 OOP 10.0 (0-137.062) 20.0 20.0 0 177,369 
 For facility 0 0 0 0 0 
 For doctor 10.0 (0-137.062) 20 20.0 0 177,369 
2012 Cumulative 16,809.49 (0-72,631.18) 50,428.46 20,515 (0-80,647.01) 13,976 146,401,438 
 For facility 15,359.32 (0-65,129.10) 46,077.96 18,681 (0-72,136.65) 12,424 1,333,133,494 
 For doctor 1,450.17 (0-7,548.02) 4,350.50 1,834.01 (0-8,541.53) 1,558.92 130,880,887 
 OOP 0 0 0 0 0 
 For facility 0 0 0 0 0 
 For doctor 0 0 0 0 0 
2013 Cumulative 13,915.21 41,745.62 12,308 (0-57,114.65) 10,414 421,740,687 
 For facility 12,695.47 (0-56,559.63) 38,086.40 11,144 (0-52,969.18) 9,720.89 381,828,192 
 For doctor 1,219.74 (0-4,640.38) 3,659.22 1,164.83 (0-4,185.71) 702.09 39,912,495 
 OOP 126.87 (0-442.15) 380.63 100.39 (0-451.58) 81.62 3,439,816 
 For facility 0 0 0 0 0 
 For doctor 126.87 (0-442.15) 380.63 100.39 (0-451.58) 81.62 3,439,816 
2014 Cumulative 17,252.24 (0-53,992.87) 34,504.48 16,773 (0-52,505.56) 2,812.19 200,098,600 
 For facility 15,817.37 (0-43,093.46) 31,634.73 15,462 (0-41,989.29) 2,087.76 188,425 
 For doctor 1,434.88 (0-10,899.41) 2,869.75 1,311.47 (0-10,516.27) 724.43 758,870 
 OOP 68.86 (0-877.42) 137.73 79.40 (0-865.77) 61.88 947,295 
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 For facility 13.55 (0-185.71) 27.10 15.79 (0-183.23) 13.17 184,453,125 
 For doctor 55.31 (0-691.70) 110.63 63.61(0-682.53) 48.71 15,645,475 
2010-2014 Cumulative 13,031.02 (3,450.11-
22,611.93) 
143,341.25 16,070 (0-32,402.03) 7,219.46 2,199,126,682 
 For facility 11,899.61 (3,216.64-
20,582.58) 
130,895.70 14,604 (0-29,252.61) 6,475.32 1,998,509,809 
 For doctor 1,131.41 (188.50-
2,074.33) 
12,445.55 1,466.03 (0-3,179.34) 757.37 200,616,873 
 OOP 65.06 (3.72-126.41) 715.73 46.85 (0-105.50) 25.92 6,412,171 
 For facility 15.19 (0-43.53) 167.10 12.03 (0-37.43) 11.22 1,646,826 
 For doctor 49.87 (0-104.48) 548.63 34.82 (0-83.75) 21.62 4,765,344 
Outpatient 
visits 
      
2010 Cumulative 220.57 (0-625.73) 882.30 188.58 (0-470.43) 88.56 11,723,067 
 For facility 173.02 (0-429.49) 692.10 157.90 (0-334.63) 55.53 9,815,754 
 For doctor 47.55 (0-198.87) 190.20 30.68 (0-142.24) 35.05 1,907,313 
 OOP 52.89 (0-164.20) 211.58 79.72 (0-210.29) 41.02 4,956,288 
 For facility 52.89 (0-164.20) 211.58 79.72 (0-210.29) 41.02 4,956,288 
 For doctor 0 0 0 0 0 
2011 Cumulative 3,243.37 16,216.85 2,722.62 (0-7,796.45) 1,827.45 175,641,035 
 For facility 2,904.30 (0-7,539.34) 14,521.51 2,424.32 (0-6,826.50) 1,585.54 156,396,789 
 For doctor 339.06 (0-1098.05) 1,695.34 298.30 (0-1,054.00) 272.18 19,244,246 
 OOP 391.64 (0-1,441.36) 1,958.20 356.62 (0-1,374.31) 366.54 23,006,648 
 For facility 356.34 (0-1,345.73) 1,781.74 326.78 (0-1,280.82) 343.61 21,081,310 
 For doctor 35.29 (0-102.07) 176.46 29.84 (0-97.30) 24.29 1,925,337 
2012 Cumulative 10,100.60 (0-34,318.27) 50,503.01 11,496 (0-37,895.52) 9,508.31 610,179,280 
 For facility 6,615.53 (0-22,362.89) 33,077.66 7,530.20 (0-24,685.22) 6,178.77 399,677,140 
 For doctor 3,485.07 (0-11,957.40) 17,425.35 3,966.01 (0-13,212.89) 3,330.47 210,502,140 
 OOP 546.37 (0-1,947.20) 2,731.89 622.08 (0-2,156.07) 552.50 33,017,867 
 For facility 424.01 (0-1,485.69) 2,120.09 483.71 (0-1,643.05) 417.56 25,673,913 
 For doctor 122.36 (0-462.08) 611.80 138.36 (0-513.70) 135.18 7,343,955 
2013 Cumulative 798.08 (0-2,738.80) 3,192.34 367.66 (0-1,125.86) 238.24 10,955,329 
 For facility 734.86 (0-2,486.78) 2,939.45 345.78 (0-1,031.52) 215.47 10,303,202 
 For doctor 63.22 (0-252.11) 252.89 21.88 (0-94.69) 22.88 652,128 
 OOP 3.75 (0-15.68) 15.00 5.81 (0-21.29) 4.86 173,206 
 For facility 3.75 (0-15.68) 15.00 5.81 (0-21.29) 4.86 173,206 
 For doctor 0 0 0 0 0 
2014 Cumulative 272.39 (0-790.85) 817.18 303.54 (0-904.73) 139.72 31,055,619 
 For facility 133.53 (0-443.37) 400.60 149.89 (0-513.05) 84.40 15,336,035 
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 For doctor 138.86 (0-351.33) 416.58 153.64 (0-393.59) 55.76 15,719,585 
 OOP 19.66 (0-61.99) 59.00 23.31 (0-55.25) 7.42 2,385,643 
 For facility 9.66 (0-51.25) 29.00 10.22 (0-53.79) 10.12 1,045,615 
 For doctor 10.00 (0-53.02) 30.0 13.09 (0-61.22) 11.18 1,340,029 
2010-2014 Cumulative 3,268.98 (0-7,517.78) 71,917.52 2,481.51 (0-5,893.63) 1,640.74 848,785,772 
 For facility 2,360.78 (0-5,171.07) 51,937.16 1,756.38 (0-4,020.69) 1,088.81 600,760,361 
 For doctor 908.19 (0-2,378.87) 19,980.36 725.12 (0-1,892.13) 561.16 248,025,411 
 OOP 226.32 (0-518.35) 4,979.17 186.07 (0-419.90) 112.44 63,645,296 
 For facility 189.13 (0-430.77) 4,160.91 155.05 (0-349.41) 93.46 53,035,975 
 For doctor 37.19 (0-95.45) 818.26 31.01 (0-77.16) 22.19 10,609,321 
Emergency 
visits 
      
2011 Cumulative 846.76 (0-3,231.29) 2,540.29 174.60 0 1,645,216 
 For facility 755.17 (0-3,065.69) 2,265.53 124.60 0 1,174,077 
 For doctor 91.58 (0-184.66) 274.76 50.00 0 471,139 
 OOP 0 0 0 0 0 
 For facility 0 0 0 0 0 
 For doctor 0 0 0 0 0 
2012 Cumulative 211.13 (0-615.89) 422.27 215.02 (0-613.75) 31.38 11,568,811 
 For facility 180.92 (160.02-201.82) 361.85 181.12 (160.53-201.71) 1.62 9,745,100 
 For doctor 30.21 (0-414.06) 60.42 33.89 (0-412.03) 29.76 1,823,711 
 OOP 0 0 0 0 0 
 For facility 0 0 0 0 0 
 For doctor 0 0 0 0 0 
2013 Cumulative 523.30 (0-1,781.31) 1,569.92 919.96 (0-1,915.10) 231.28 44,576,441 
 For facility 407.07 (0-1,808.16) 1,221.23 847.41 (0-1,958.76) 258.29 41,061,412 
 For doctor 116.23 (0-260.09) 348.69 72.54 (0-188.78) 27.01 3,515,029 
 OOP 0 0 0 0 0 
 For facility 0 0 0 0 0 
 For doctor 0 0 0 0 0 
2014 Cumulative 563.47 (0-1,755.42) 2,253.90 621.32 (0-2,006.53) 435.26 14,236,074 
 For facility 324.13 (0-1,074.67) 1,296.52 359.63 (0-1,220.25) 270.42 8,240,059 
 For doctor 239.34 (0-700.93) 957.38 261.69 (0-798.78) 168.76 5,996,015 
 OOP 71.82 (0-222.74) 287.31 77.23 (0-248.57) 53.83 1,769,716 
 For facility 46.827 (0-133.26) 187.31 46.89 (0-137.41) 28.44 1,074,420 
 For doctor 25.00 (0-104.56) 100.00 30.34 (0-120.40) 28.29 695,296 
2010-2014 Cumulative 565.53 (157.57-973.49) 6,786.38 535.14 (57.518-1,012.76) 211.13 72,026,542 
 For facility 428.76 (69.26-788.25) 5,145.13 447.42 (0-915.91) 207.09 60,220,648 
 For doctor 136.77 (25.72-247.81) 1,641.25 87.71 (1.34-174.08) 38.17 11,805,893 
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 OOP 23.94 (0-62.61) 287.31 13.14 (0-40.26) 11.98 1,769,716 
 For facility 15.60 (0-38.83) 187.31 7.98 (0-23.12) 6.69 1,074,420 
 For doctor 8.33 (0-26.67) 100.0 5.16 (0-17.94) 5.64 695,296 
 
OOP: out-of-pocket; CI: confidence interval; mean: mean costs for all the observations of a medical event in a year; total: sum of 
costs for all the observations of a medical event in a year; out of pocket: expenditure paid directly by an individual; cumulative: 
expenditure paid by an individual and by other sources like insurance; 95% CI was not available for events having only one 
observation or more than one observation with expenditure available only for one observation; some of the events had negative 
confidence intervals because of statistical calculations; for this study, negative values of confidence intervals were converted to 0 to 
avoid misinterpretation of negative values as savings due to occurrence of medical event.  
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Table 34: Cumulative expenditure of prescription medications (2010-2014) 
 
Drug name  Frequency  
N (%) 
Mean cumulative 
expenditure (S.D) $ 
Total cumulative 
expenditure $ 
Respiratory agents 43 (7.80%) 3,213.38 (253.06) 78,316.47 
Creon 20 (3.60%) 758.51 (899.34) 15,170.16 
Aminoglycosides 2 (0.40%) 6,653.6 (0) 13,307.2 
Immunologic agents 5 (0.90%) 1,235.3 (0) 6,176.5 
Myfortic 7 (1.30%) 627.56 (115.62) 4,392.94 
AAA batteries 10 (1.80%) 432.67 (0) 4,326.7 
Selective 
immunosuppressants 
4 (0.70%) 956.15 (0) 3,824.6 
Xopenex 4 (0.70%) 820.4 (0) 3,281.6 
Spiriva 3 (0.50%) 741.12 (0) 2,223.36 
Oxycontin 5 (0.90%) 437.47 (0) 2,187.35 
Levocarnitin 44 (7.90%) 42.21 (12.02) 1,857.02 
Prevacid 8 (1.40%) 194.06 (9.52) 1,552.48 
Deplin 15 7 (1.30%) 115.23 (0) 806.61 
Metformin 52 (9.40%) 15.51 (17.29) 806.33 
Pataday 7 (1.30%) 114.51 (0.42) 801.6 
Hormones/hormone 
modifiers 
13 (2.30%) 59.16 (9.13) 769.05 
Lantus 3 (0.50%) 225.53 (9.95) 676.58 
Singulair 5 (0.90%) 128.42 (0) 642.1 
Bayer contor 5 (0.90%) 110.13 (5.68) 550.66 
Azithromycin 4 (0.70%) 113.88 (73.94) 455.5 
Niaspan 4 (0.70%) 111.42 (3.04) 445.68 
l-methylfola 5 (0.90%) 89 (10.51) 444.95 
Tramadol hcl 6 (1.10%) 71.37 (41.43) 428.2 
Phlexy-10 4 (0.70%) 93.75 (0) 375 
Clonidine 10 (1.80%) 33.92 (39.74) 339.15 
Epipen-jr 1 (0.20%) 317.33 (-) 317.33 
Minocycline 5 (0.90%) 59.38 (57.11) 296.92 
Warfarin 11 (2.00%) 25.81 (7.23) 283.9 
Dexamethason 12 (2.20%) 23.32 (4.12) 279.88 
Mycophenolat 5 (0.90%) 55.01 (5.26) 275.06 
Albuterol 8 (1.40%) 32.49 (12.28) 259.92 
Pot citrate 9 (1.60%) 28.41 (17.46) 255.65 
Pancrelipase 1 (0.20%) 249.78 (-) 249.78 
Precisn xtra 2 (0.40%) 119.37 (0) 238.74 
Apidra 2 (0.40%) 117.26 (150.05) 234.52 
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Gabapentin 4 (0.70%) 54.99 (32.89) 219.95 
Methotrexate 4 (0.70%) 50.54 (0) 202.16 
Flovent HFA 1 (0.20%) 188.91 (-) 188.91 
Pentoxifylli 8 (1.40%) 22.57 (10.36) 180.54 
Neurontin 2 (0.40%) 75.55 (0) 151.1 
Prednisone 21 (3.80%) 
7.18 (8.93) 
150.76 
Adipex-p 3 (0.50%) 49.99 (0) 149.97 
Methocarbam 4 (0.70%) 37.13 (0.89) 148.5 
Folgard RX 3 (0.50%) 47.66 (23.67) 142.97 
Allopurinol 14 (2.50%) 9.28 (2.07) 129.86 
Danazol 12 (2.20%) 10.59 (19.36) 127.05 
Lansoprazole 3 (0.50%) 41.94 (0) 125.82 
Qvar 1 (0.20%) 111.55 (-) 111.55 
Cephalexin 5 (0.90%) 16.96 (0) 84.8 
Hyoscyamine 1 (0.20%) 68.45 (-) 68.45 
Folbic 1 (0.20%) 61.29 (-) 61.29 
Levothyroxin 9 (1.60%) 6.71 (0) 60.39 
Polyeth Glyc 2 (0.40%) 29.69 (0) 59.38 
Pravastatin 5 (0.90%) 10.82 (0) 54.1 
Optichamber 2 (0.40%) 26.99 (0) 53.98 
Cyanocobalam 8 (1.40%) 6.06 (2.62) 48.44 
Cyproheptad 3 (0.50%) 16 (2.68) 47.97 
Omega-3 fatty acids cap 
1000 mg 
4 (0.70%) 11.63 (0) 46.52 
Test strip 3 (0.50%) 15.26 (0) 45.78 
Tricor 1 (0.20%) 45.54 (-) 45.54 
Mag-ox 400 5 (0.90%) 8.7 (0) 43.5 
Amoxicillin 4 (0.70%) 10.5 (6.35) 42 
Contour Strips 1 (0.20%) 40.32 (-) 40.32 
Fludrocort 4 (0.70%) 10 (0) 40 
Lisinopril 2 (0.40%) 20 40 
Metformin ER 8 (1.40%) 4.90 (0.36) 39.18 
Oxycod/apap 2 (0.40%) 18.99 (0) 37.98 
Lactulose 2 (0.40%) 18.96 (0) 37.92 
Culturelle 2 (0.40%) 18.69 (0) 37.38 
Aerochamber 1(0.20%) 35.03 (-) 35.03 
Vitamin D 1(0.20%) 33.74 (-) 33.74 
Clopidogrel 1(0.20%) 32.29 (-) 32.29 
Fluticasone 1(0.20%) 31.58 (-) 31.58 
Polyethylene glycol 3350 
NF powder 
1(0.20%) 29.76 (-) 29.76 
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Truplus lanc 4 (0.70%) 6.5 (0) 26 
Fludricortisone 2 (0.40%) 12 (0) 24 
Phentermine 1(0.20%) 23.39 (-) 23.39 
Spacer inh (optichamber) 1(0.20%) 21.29 (-) 21.29 
Sprintec 28 2 (0.40%) 10.25 (1.77) 20.5 
Trazodone 2 (0.40%) 10 (0) 20 
Multivitamin 4 (0.70%) 4.99 (0) 19.96 
Vortex/mask 1(0.20%) 19.91 (-) 19.91 
Klor-con M20 1(0.20%) 19.69 (-) 19.69 
Tri-vitamin 1(0.20%) 18.99 (-) 18.99 
Bayer micrlt 1(0.20%) 17.83 (-) 17.83 
Ibuprofen 4 (0.70%) 4 (0) 16 
Vit B12 4 (0.70%) 4 (0) 16 
Generlac 1(0.20%) 15.5 (-) 15.5 
Pantoprazole 1(0.20%) 14.45 (-) 14.45 
Toothpaste 3 (0.50%) 4 (0) 12 
Fluoxetine 2 (0.40%) 5.42 (2.01) 10.84 
Atenolol 1(0.20%) 10 (-) 10 
Sod Chloride 1(0.20%) 10 (-) 10 
Aspirin 5 (0.90%) 1.95 (0) 9.75 
Cheratussin AC 1(0.20%) 9 (-) 9 
Insulin syringe 3 (0.50%) 2.73 (0) 8.19 
Citalopram 1(0.20%) 6 (-) 6 
Topical agents 1(0.20%) 5.99 (-) 5.99 
Fish oil 1(0.20%) 4 (-) 4 
Glyburid mcr 1(0.20%) 3.52 (-) 3.52 
Vitamin b-6 6 (1.10%) 0.51 (0) 3.06 
Niacin 1(0.20%) 2.23 (-) 2.23 
 
Mean cumulative expenditure: average expenditure for all the observations of a medication paid 
by an individual and payments by private insurance, Medicare, Medicaid and other sources,  
Total cumulative expenditure: total expenditure for all the observations of a medication paid by 
an individual and payments by private insurance, Medicare, Medicaid and other sources, (-): no 
standard deviation due to a single observation. 
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Table 35: Cumulative expenditure of various drug classes (2010-2014) 
 
Drug class Total cumulative expenditure 
$ (2010-2014) 
Respiratory agents 85,555.33 
Gastro intestinal agents 17,255.25 
Immune modulators 14,596.2 
Antibiotics 14,186.42 
Medical devices 5,495.98 
Pain medications 2,653.53 
Drugs used to treat renal failure  2,242.53 
Anti-diabetics 1,760.13 
Anti-depressants 1,268.4 
Anti-allergic agents 849.57 
Hormone modifiers 829.44 
Dietary supplements 822.25 
Anti-inflammatory agents 636.93 
Anti-hypercholesterolemic agents 595.84 
Anti-convulsants 588 
Anti-hypertensive agents 473.15 
Anti-coagulants 316.19 
Weight loss supplements 173.36 
Drugs used to treat angioedema 127.05 
Contraceptives 20.5 
Tooth paste 12 
Topical agents 5.99 
 
 
Respiratory agents: include bronchodilators, steroids, decongestants, cough suppressants, 
expectorants, mucolytics, vasodilators, drugs used to treat asthma, vasoconstrictors; gastro 
intestinal agents: include enzyme replacement therapies, proton pump inhibitors to treat stomach 
ulcers, laxatives, drugs used to treat gastro esophageal reflux disorders; immune modulators: 
includes drugs suppressing or modifying immune responses or immune system to fight infections; 
antibiotics: includes aminoglycosides, macrolide antibiotics, tetracyclins, penicillin like 
antibiotics, cephalosporins etc.; medical devices: include aerosols, inhalers, glucose monitoring 
kits, diabetes testing kit, syringes; pain medications: narcotics; drugs used to treat renal failure: 
include medications for kidney stones, dialysis, kidney disease; anti-diabetics: includes drugs 
used to treat high blood glucose levels; anti-depressants: drugs used in the treatment of major 
depressive disorders and other conditions including anxiety, obsessive compulsive disorder etc.; 
anti-allergic agents: includes drugs used to treat allergic conjunctivitis, anti histaminics, local 
anesthetics; hormone modifiers: drugs regulating the levels of hormones inside the body; dietary 
supplements: includes vitamins, probiotics, low protein diet, supplements used to correct levels 
of minerals and nutrients inside the body; anti-inflammatory agents: non-steroidal drugs used to 
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treat swelling or inflammation; anti-hypercholesterolemic agents: drugs used to lower 
cholesterol levels inside the body; anti-convulsants: drugs used to treat seizures, spasms, 
epilepsy, anti-tremor agents, muscle relaxants. Anti-hypertensive agents; anti-coagulants: blood 
thinners; weight loss supplements: drugs which promote weight reduction; drugs used to treat 
angioedema: hormones or medications used to reduce the swelling of the lower layers of skin 
and tissue under the skin or mucous membranes; contraceptives: drugs preventing child birth; 
topical agents: creams, ointments or lotions applied externally on skin. 
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Table 36: Sensitivity analysis of cost effectiveness of lumacaftor/ivacaftor 
 
Variable ICER at  
Low 
ICER at 
high 
Difference 
Flu shot 95,014.14 95,018.43 4.29 
OGT 95,013.25 95,019.32 6.07 
Bilirubin 95,011.64 95,020.93 9.29 
AST 95,011.28 95,021.28 10 
ALT 95,011.28 95,021.28 10 
PFT’S 95,009.76 95,022.81 13.04 
Fat soluble vitamins 94,979.86 95,052.71 72.86 
Outpatient visits* 94,935.72 95,016.28 80.56 
Inpatient stays* 94,910.05 95,016.28 106.23 
Clinic visits* 94,905.16 95,016.28 111.12 
Sputum culture 94,959.71 95,072.86 113.14 
Prob of outpatient visits 94,934.25 95,098.29 164.04 
Prob of inpatient stays 94,910.05 95,122.51 212.46 
Prob of clinic visits 94,905.16 95,127.41 222.24 
Prob of pulmonary 
exacerbations 
93,791.14 96,241.42 2,450.28 
Pulmonary exacerbations 93,659.88 96,372.68 2,712.80 
Standard therapy 87,003.57 103,029 16,025.43 
Drug cost 70,893.72 119,138.87 48,245.15 
 
Sensitivity analysis conducted at low (-25%) and high (+25%); * Sensitivity analysis conducted 
at high (-10%) and low (-25%); AST: aspartate aminotransferase test; ALT: alanine 
aminotransferase test; PFT: pulmonary lung function test; OGT: oral glucose tolerance test; 
prob: probability. 
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Table 37: Sensitivity analysis of budget impact of lumacaftor/ivacaftor 
 
Variable PTMPM cost at  
Low 
PTMPM cost at  
high 
Difference 
Flu shot 6.2066 6.2069 0.0003 
OGT 6.2065 6.2069 0.0004 
Bilirubin 6.2064 6.2070 0.0006 
AST 6.2064 6.2071 0.0007 
ALT 6.2064 6.2071 0.0007 
PFT’S 6.2063 6.2072 0.0009 
Fat soluble vitamins 6.2044 6.2091 0.0048 
Outpatient visits* 6.2015 6.2067 0.0053 
Inpatient stays * 6.1998 6.2067 0.0069 
Clinic visits* 6.1995 6.2067 0.0073 
Sputum culture 6.2030 6.2104 0.0074 
Prob of outpatient visits 6.2014 6.2121 0.0107 
Prob of inpatient stays  6.1998 6.2137 0.0139 
Prob of clinic visits 6.1995 6.2140 0.0145 
Prob of pulmonary 
exacerbations 
6.1153 6.2868 0.1715 
Pulmonary exacerbations 6.1181 6.2953 0.1772 
Drug costs 4.1076 8.3059 4.1983 
 
Sensitivity analysis conducted at low (-25%) and high (+25%); * Sensitivity analysis conducted 
at high (-10%) and low (-25%); AST: aspartate aminotransferase test; ALT: alanine 
aminotransferase test; PFT: pulmonary lung function test; OGT: oral glucose tolerance test; 
prob: probability. 
 
 
